Report of the LD 1818 Work Group to Evaluate Options and Actions Available to Improve the Availablity of and Access to Health Care Data and Examine the All-payor Claims Database System in Maine by Working Group on LD 1818
Maine State Library
Digital Maine
Maine Health Data Organization State Documents
2-23-2013
Report of the LD 1818 Work Group to Evaluate
Options and Actions Available to Improve the
Availablity of and Access to Health Care Data and
Examine the All-payor Claims Database System in
Maine
Working Group on LD 1818
Follow this and additional works at: https://digitalmaine.com/mhdo_docs
This Text is brought to you for free and open access by the State Documents at Digital Maine. It has been accepted for inclusion in Maine Health Data
Organization by an authorized administrator of Digital Maine. For more information, please contact statedocs@maine.gov.
Recommended Citation
Working Group on LD 1818, "Report of the LD 1818 Work Group to Evaluate Options and Actions Available to Improve the
Availablity of and Access to Health Care Data and Examine the All-payor Claims Database System in Maine" (2013). Maine Health
Data Organization. 1.
https://digitalmaine.com/mhdo_docs/1
  
 
 
 
 
 
 
 
 
 
 
Report of the LD 1818 Work Group  
 
To Evaluate Options and Actions Available  
to Improve the Availability Of and Access To  
Health Care Data and to Examine  
the All-payor Claims Database system in Maine 
 
 
 
Submitted to: the 126th Maine State Legislature 
 
February 23, 2013 
 
 
 
 
 
  
Working Group on LD 1818 
February 23, 2013 
 
Final Report:  Resolve Chapter 109 (2011), Resolve to Evaluate the All Payer Claims 
Database of the State 
 
Senator Craven, Representative Farnsworth, and members of the Joint Committee on 
Health and Human Services: 
  
As chairs of the working group convened under Resolve Chapter 109 (2011), Resolve to 
Evaluate the All Payer Claims Database of the State, we are pleased to present you with 
the working group’s report on health care data in Maine. The report is the product of a 
diverse multi-stakeholder group in which all sectors of Maine’s health care industry and 
customers were represented.  The Report is a consensus statement of the group which 
consisted of 17 diverse interests and input from more than 90 stakeholders, 
representing individual customers, payers, insurers, providers, businesses, public and 
private entities, health care information organizations, and others.     
 
It is important to note that the term “consensus” reflects what may be called the lowest 
common denominator--the most basic level of opinion among this group of people. 
 Some members viewed the report as a “floor” and wanted the report to be more 
strident in its recommendations, while others a “ceiling.”  (Attached to this report are 
comments on both ends of the spectrum.)    
 
We believe that the report will serve you and future Legislators as a current description 
of Maine’s health data structures and as a summary of the future uses and expectations 
of these data in policy formulation, health system improvement, and public awareness. 
  
It has been a privilege to work on this report.  We look forward to discussing it with you.  
Colin McHugh    
Dr. Josh Cutler 
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I. Executive Summary  
 
The judicious use of health care data collected through our insurance, clinical care, and other 
systems offers the potential for a smarter health care system in Maine’s future: one in which 
doctors know the best practice treatments, patients know the most effective health 
providers, insurers and government know how to create financial incentives for cost-effective 
care. 
 
Maine is ahead of other states in its use of health care data.  But the further we go along this 
road, the more complicated the issues become. This report is the result of a multi-stakeholder 
collaborative effort established by a Legislative Resolve to “improve the availability and 
access to health care data.”  The Resolve identified four areas for evaluation related to:  the 
current structure of the Maine Health Data Organization (MHDO); the current uses of health 
care data; changes needed to increase access to health care data; and the most appropriate 
and cost-effective sources of data.   
 
The multi-stakeholder group worked tirelessly over the past year to produce this consensus 
report.  It provides a comprehensive and thorough review of the current state of health care 
data issues in Maine, as well as the beginnings of a road map for future initiatives.  The report 
concludes with six recommendations: 
  
1. Continue the ongoing work of the MHDO Board to implement its new vision and 
business imperatives; 
 
2. Charge the MHDO to lead an effort to recommend solutions for improved efficiency for 
current data submitters, and to identify standards to link various health care databases;    
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3. Continue the pilot between MHDO and HealthInfoNet to determine the feasibility of 
linking administrative claims and clinical data at an affordable cost;  
 
4. Conduct a collaborative strategic examination on the health care data currently 
collected, and identify sustainable business models that are efficient, avoid 
fragmentation and duplication, provide the best value for data, and identify the best 
uses of data; 
 
5. Have the MHDO and Maine’s Office of the State Coordinator for HIT collaborate to 
leverage funding available for electronic health records, access to health care data, and 
reporting systems in order to improve the efficiency and quality of health care; and  
 
6. Continue the work of the Maine Quality Forum (MQF) within the MHDO (conditioned on 
availability of funding and the identification of administrative efficiencies).  
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II. Introduction from the Chairs 
 
The cost of health care is having a stifling effect on Maine’s workers, families, taxpayers, and 
the economy. Public and private health care costs continue to grow more rapidly than those 
in other sectors. These obligations are crowding out our capacity to invest in other public 
goods, such as education and infrastructure,  and to grow our economy.   
 
The health care system in the United States, and in Maine, is less efficient than those in other 
developed countries.  If we could achieve the efficiency of those health systems – or even in 
the best systems within in the United States – we could eventually lower health costs by 15% 
to 30% in Maine, with no sacrifice in quality. 
 
 In order to accomplish this efficiency, our health system needs the capability to observe and 
measure its value (defined as favorable outcome achieved per dollar spent); to become, as 
the Institute of Medicine has described, a continuously learning health system.  This capability 
can only be achieved through the judicious and widespread use of health data.  
 
Maine is ahead of most states in its ability to analyze the performance of the health care 
system, based on the health data we currently collect.  However, there is considerable room 
for improvement.  This report, the product of a multi-stakeholder workgroup created through 
Resolve Chapter 109 (2011), Resolve to Evaluate the All-Payer Claims Data System for the 
State (Resolve), explores the current state of health data arrangements in Maine and makes 
recommendations for continued improvement.  
 
The State of Maine has been a leader in the collection of health data to facilitate analysis of 
the state health care costs.  The Maine Health Data Organization (MHDO), a state agency, was 
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created in 1995 by the Legislature to maintain the first all-payer claims data base (APCD) in 
the United States.  This database includes claim records from most medical treatments that 
are provided to Maine citizens and that are paid for by private and public insurers.  The Maine 
Health Data Organization also collects inpatient and outpatient encounter information on all 
episodes of care provided by Maine’s hospitals and ambulatory surgical centers, as well as 
summary level financial and quality information provided by Maine hospitals.  These data, 
termed administrative as opposed to clinical data, have proven immensely useful in the 
analysis of provider and health system performance.  
 
The data enable the examination of care patterns and costs in the State.  Maine employers in 
particular, as funders of health care, have used this information to identify high cost 
providers, high cost conditions, and the effects of employer-based wellness interventions on 
the cost of health care for their employee population.  One analysis of the cost of health care 
in Maine, done for the Dirigo Health Agency’s Maine Quality Forum, illuminated the impact of 
avoidable complications of chronic illness on the total costs of care in Maine.  That report has 
led to policies promoting the adoption of “best practices” among primary care providers in 
Maine.  Other analyses have advanced understanding of the use of expensive hospital 
emergency room care by different groups; provided comparative data that have helped 
hospitals to advance value-based purchasing; and shown different patterns in Maine and two 
comparison states in service use and cost through a path breaking tri-state variation study.   
 
The demand for these data from business, government, insurers, health care providers, and 
health analysts, has been high and will only increase in the future.  It is fair to say that the 
MHDO struggled to meet these demands on a timely and convenient basis in the past. There 
were reliability and timeliness issues with the availability of both claims data (particularly 
those from Medicare and Medicaid) and hospital inpatient and outpatient data.  As a result, in 
2011, proposed legislation (LD 1467) was originally submitted to completely revamp the 
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MHDO operations.  The bill was modified and led to Resolve Chapter 109 (2011), which called 
for the establishment of a Work Group led by the Department of Health and Human Services 
to evaluate and report on options to “improve the availability and access to health care data.”  
The Resolve identified four areas for evaluation:  
 
1. Review the current structures of, and relationships among, the Maine Health Data 
Organization, the Maine Health Data Processing Center and Onpoint Health Data in 
order to evaluate the timeliness and effectiveness of the data received; 
 
2. Review the current purposes and uses of the data, and limitations on access to the data, 
and considering additional uses for the data and changes that might be necessary to 
achieve and facilitate additional uses; 
 
3. Consider federal and state privacy and security laws regarding the use and release of 
protected health information, including policy and technical changes needed to allow 
increased access to protected health information, and the feasibility of those changes; 
and 
 
4. Consider the availability of the data, the most appropriate sources of the data, and the 
cost of providing the data. 
 
Resolve Chapter 109 was later amended (LD 1818) to provide the Work Group additional time 
to complete its work.  (See Appendix A for the Resolve; a complete record of committee 
meetings and documents is available at http://www.maine.gov/hit/ld_1818/index.html).  
The Work Group convened in April 2012 and met at least monthly through the remainder of the 
year.  The Group was led by elected Co-Chairs Dr. Josh Cutler and Colin McHugh.  The Group 
accepted the working principle that health system reform and improvement depends upon the 
ability to objectively analyze the system’s performance in terms of cost and quality.  Such 
analysis relies, in turn, on the maintenance of accurate and timely administrative and clinical 
health data that is accessible (with strict safeguards and confidentiality requirements) to 
patients, providers, purchasers, payers, and researchers.   
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The Work Group recognized that the path to the desired state requires broad consumer and 
stakeholder participation, and therefore issued a “Voice of the Customer” (VOC) survey in late 
spring.  The VOC process led to several presentations and thoughtful discussions between the 
Work Group and experts in the health care data and claims field, including health services 
researchers, hospital and health system representatives, physicians, payers, public agencies, 
individual consumers, and employers.  
 
What the Work Group heard above all else is that stakeholders are eager to gain access to 
timely and accurate health care data, including claims and clinical data, in order to move 
forward from the current state of our health care system towards meeting the goals of the 
Triple Aim (improving the individual experience of care; improving the health of populations; 
and reducing the per capita costs of care for populations). 
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The Triple Aim recognizes the necessity to move away from paying providers for the volume of 
services provided and to migrate towards paying for value and quality outcomes.  At the core of 
this payment reform initiative is patient-centered health care and provider accountability.  The 
model requires providers to assume greater accountability for the cost and quality of services 
provided, and rewards improved health outcomes and efficiencies. Payers and providers need 
to have health care data to monitor performance and make educated decisions to strive toward 
meeting the goals of the Triple Aim.   
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III. Voice of the Customer (VOC) 
  
 
Although the LD 1818 Work Group represented a variety of interests, the Group believed that it 
was important to have input from additional stakeholders.  As mentioned above, the Group 
issued an electronic survey in late spring to 140 groups and individuals, requesting that 
stakeholders answer three questions keeping in mind the four issues from the Resolve:   
 
1. Which Needs and Expectations are being met by existing processes, relationships, and 
structures as it relates to the use of health care data? 
2. Which Needs and Expectations are NOT being met by existing processes, relationships, 
and structures as it relates to the use of health care data? 
3. What are the desired future uses of clinical and/or administrative claims data that are 
being considered? 
 
See Appendix B for a summary of the 90+ VOC comments.   The complete record, including 
presentations and papers submitted as part of the process, can be seen at 
http://www.maine.gov/hit/ld_1818/index.html).   
 
Four major themes emerged from the results of the survey.  The Group formed subcommittees, 
chaired by Work Group members, to address the four themes:   
   
 Theme 1:  Establish multi-stakeholder directed Data Governance Structures that 
optimize the collection, processing, and distribution (accessibility) of health care data. 
(Dr. Josh Cutler, Chair)  
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 Theme 2:  Implement technically-sound and scalable Data Processing Structures and 
Protocols that permit the timely, accurate, and cost effective submission and 
dissemination of pertinent health care data (both administrative and clinical). (Karynlee 
Harrington, Chair)  
 
 Theme 3:  Balance Consumer Privacy considerations regarding the safeguarding and 
disclosure of Protected Health Information (PHI) with the societal imperative to drive 
higher quality and more affordable health care. (Colin McHugh and Dawn Gallagher, Co-
Chairs)  
 
 Theme 4:  Establish mechanisms to ensure that multi-stakeholder (including consumer) 
engagement and feedback is solicited and prioritized to ensure value is being derived 
from health care data.  (Christine Torraca, Chair) 
 
Subcommittees were asked to identify barriers to achieving each thematic goal, as well as the 
opportunities and their anticipated benefits.  Recommendations were developed by each 
subcommittee and fed up to the full Work Group.  Full subcommittee minutes and documents 
are available on line at http://www.maine.gov/hit/ld_1818/index.html.  
 
The recommendations of the individual subcommittees are not consensus statements of the 
full Work Group.  The recommendations did, however, help to inform Work Group discussions.  
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IV. The Resolve - Four Evaluation Areas and Summary Findings  
 
 
After the work of the subcommittees concluded, the full Work Group held discussions and 
formulated responses to the four questions raised in the Resolve:   
 
1.  Review the current structures of and relationships among the Maine Health Data 
Organization, the Maine Health Data Processing Center and Onpoint Health Data in 
order to evaluate the timeliness and effectiveness of the data received; 
 
The Maine Health Data Organization (MHDO) maintains administrative, financial, and some 
limited clinical health data for use in policy development; adopts rules governing data 
collection, public access, and sanctions for failure to comply; sets fee schedules and 
assessments on health care facilities, payers, and third party administrators; and responds to 
requests for data. The MHDO furnishes reports on quality of care and price comparisons which 
are publicly accessible on the MHDO website.  The MHDO also maintains the following 
databases: 
 Hospital inpatient 
 Hospital outpatient 
 Hospital emergency department 
 Non-hospital ambulatory services (1990 – 2004) 
 Hospital financial 
 Hospital organizational 
 Quality data 
Question No. 1 was raised to address concerns identified in 2009 and 2010.  By the time the 
Work Group was formed in early 2011, the MHDO Board had already initiated plans and actions 
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to improve organizational effectiveness, produce timely and accurate data, achieve 
performance improvements, and restructure the MHDO board. Between December 2011 and 
December 2012, the MHDO brought its all-payer claims database (APCD) up to date, which 
includes data from the two public payers and commercial insurers.  MHDO has developed a 
comprehensive plan to maintain its current level of performance into the future, which includes 
provisions for upgrading its technical infrastructure.  This LD 1818 report will describe the past 
or “as-is” governance structure, and insight into the improvements made, or under 
consideration by, the MHDO Board. 
 
The following diagram depicts the existing relationships of three key health data organizations: 
Maine Health Data Organization (MHDO), Onpoint (a nonprofit successor to the Maine Health 
Information Center), and the Maine Data Processing Center (“DPC” or “MHDPC”).  It is 
important to note that the diagram reflects a structure that is being eliminated and replaced 
with a new more efficient model.  
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The MHDO and Onpoint were permitted by statute in 2001 to form a non-profit corporation, 
the Data Processing Center (DPC), in order to create a publicly available claims dataset.1  The 
DPC has two funding sources:  MHDO (60%) and Onpoint (40%).  This funding supports the 
DPC’s efforts to collect medical, pharmaceutical, dental, and enrollment records from over 100 
commercial payers and third party administrators (TPA).  The Data Processing Center then 
aggregates these millions of records; implements of several layers of quality checks to ensure 
accuracy and quality; and creates a completed, “ready-to-go” dataset for the MHDO.  This work 
is currently being done by Onpoint staff, under funding from the DPC.  This arrangement 
provides an optimal data set for transmission to the MHDO, and provides technical liaison to 
both parties.  DPC is governed by a board that consists of MHDO board members from various 
constituencies, including payers, providers, consumers, and employers; and MHDO and Onpoint 
administrators.   The DPC Board oversees the organization’s activities related to data 
completeness, data quality, timeliness, and financial oversight.  The table below outlines the 
roles and responsibilities of the MHDO and Onpoint. 
Onpoint Health Data MHDO
Payer communication, on-boarding Rulemaking – data collection, release
Payer registration – initial, ongoing Payer compliance
Secure upload and PHI encryption Submitter role – Medicare (including 
mapping to APCD format), MaineCare
Data collection, validation in 
conformance with state regulations
Loading, warehousing data
Data specs, submission schema, 
reporting systems maintenance
Extracts to approved users
Master Person Index Administrative – fee assessment to 
payers/providers, users; board support
Master Provider Index
Extract preparation – qtrly to MHDO
 
                                                 
1
 The claims dataset is described in MHDO Rule Chapter 243: 
dhttp://www.maine.gov/sos/cec/rules/90/90/590/590c243.doc 
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A detailed analysis of factors impacting all-payer claims data timeliness, as well as 
recommendations for improvement, was provided by Onpoint to the MHDO Board, and is 
included in this report as Appendix C.    
While it is helpful to summarize the historical structure of health care data governance, it is 
important to talk in more detail about the transformation of the MHDO governance and 
structure.  In late 2010, Deloitte, a private consulting firm, was hired to assess MHDO’s current 
claims data processing efforts. The Deloitte report sought to address basic questions about the 
current workings of MHDO, and to identify the barriers to timely provision of claims data to 
stakeholders. The report also provided a set of recommendations for improvement on three 
components -- process, technology, and people. 
The Deloitte report described an organization where most of the staff was focused on day-to-
day maintenance and operations tasks. There were no fully articulated processes related to 
testing and quality assurance that would allow issues to be discovered and resolved in a timely 
manner. The data architecture was not tuned to provide the full range of capabilities to its 
users. Most of its leadership policies were ad hoc and not geared to support data processing 
and growth needs. 
The report recommended that MHDO create a leadership structure with clear roles and 
responsibilities to improve its decision making processes. It advised MHDO to establish 
principles and guidelines for the creation of data models, along with metrics to measure 
performance and adherence to the models.  The Report concluded that these 
recommendations would enable MHDO to better govern and support data management 
practices and policies. The complete Deloitte report can be read at the MHDO website at 
http://mhdo.maine.gov/imhdo/_pdf/MHDO_Assessment%20Final%2012-05-2010.pdf.  
Since the writing of the Deloitte report, and more recently since the Work Group initiated its 
evaluation efforts, the MHDO has embarked on a comprehensive plan to improve its 
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performance and better meet the needs of data requestors and submitters.  The MHDO Board 
adopted a new strategic vision and a set of business imperatives to guide MHDO to the future 
state.  The new strategic vision is stated below, followed by the six business imperatives, and 
the current status of the six imperatives. 
The pillars of the new vision include:   
 Responsive and timely data: clearly communicating to our clients what data are 
available and managing data release to published timeframes.  
 
 Accurate data:  ensuring consistency and conformity of claims submissions 
 
 Accessible data: providing self-service applications where possible and removing 
barriers to data access. 
 
 Streamlined process: building efficient processes for data gathering and release. 
 
 Secure data: protecting the confidentiality of personal health data – electronic threats 
change and systems must adapt to meet these challenges 
 
The six business imperatives are: 
1. Restructuring to significantly reduce number of board members, while retaining 
stakeholder diversity and balance; 
  
2. Recommitting to maintaining the agency’s independent status;  
 
3. Refocusing attention on improvements in the current data transformation process, 
using the State’s RFP process to secure a new data contract; 
 
4. Enhancing communication with partner agencies, stakeholders, and end users;  
 
5. Appointing an interim executive director; and  
 
6. Initiating a search for permanent executive director. 
 
The MHDO Board is now implementing these business imperatives.  The existing MHDO Board 
structure, created by State law in 1995, consists of 21 members from the public and private 
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sectors.  Over the years, the Board’s ability to function and move the MHDO forward was 
hampered by the large size of the Board.   Over the past year, MHDO has informally reduced 
the size of the Board to to help achieve their goal of having a nimble, responsive, and 
appropriately engaged board of directors.   The LD 1818 Work Group supports a formal 
reconstitution of the MHDO Board, with increased emphasis on its public role.   (See Appendix 
D for a summary of planned improvements that MHDO presented to the Work Group.)   
 
In early summer 2012, the MHDO issued a request for proposal for a “highly robust and secure 
data warehouse” built on an architecture that can support: 
 high volumes of multiple data files at rapid speeds;  
 a set of common data structures available for third party use; and 
 web access to data and reports.  
 
MHDO envisions creating a shared utility that will provide value for multiple entities. 
 
The MHDO has selected a vendor and, as of early February 2013, is negotiating final terms with 
that vendor.   As recommended by the Deloitte Report, and affirmed by the MHDO Board, 
MHDO will execute an agreement that specifies the levels of security, performance, and 
operation expected of the vendor, as well as penalties for non-compliance with measurable 
performance targets.  
 
MHDO will require that the vendor:  
 Work collaboratively with MHDO to implement the Board’s priorities; 
 Convert the MHDO data into the new warehouse structure;  
 Provide a “dashboard” view of the warehouse in real time to MHDO staff     
showing compliance, efficiency, load, and query information; 
 Test processes to make changes to the system as needed; and  
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 Maintain documentation and tools to allow MHDO staff to operate the system.  
As part of the reconstituted governance and data warehouse changes, the contract with the 
new vendor will be directly with MHDO.  The Board of Directors of the non-profit Maine Health 
Data Processing Center (DPC) has agreed to dissolve itself in 2013.   
The MHDO’s latest release of claims data contains complete data sets from private payers and 
Medicaid through September 2012, and from Medicare through 2010 (which is the most 
current data available from the Federal government).  It marks the first time that the most 
current Medicare and Medicaid data have both been available in the data set.  This high-quality 
and complete data will prove extremely useful. 
The MHDO members of the LD 1818 Work Group acknowledge that considerable work remains 
to be done.   The Work Group is pleased with the work completed by the MHDO in the past 
year.  The Work Group believes that the MHDO Board should be held accountable for delivering 
on the promise of its new vision and business imperatives through disciplined execution of its 
plans and robust stakeholder involvement.   The Work Group recommends that the MHDO 
include in its annual reports to the Maine Legislature updates on its progress in achieving its 
vision and business imperatives, as well as furthering the goals of this report.    
2.  Review the current purposes and uses of the data and limitations on access to the 
data and considering additional uses for the data and changes that might be necessary 
to achieve and facilitate additional uses; 
 
A.  The Policy Case for Linking Claims and Clinical Data  
Analysis of payments alone are not sufficient for a complete view of the value that the payers 
of health care – who are ultimately the wage earners and taxpayers of the state – are getting 
for their investment.  Although claims analysis is useful for observing the processes of care, it is 
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not adequate for evaluating the outcomes of care.  For this, clinical data in addition to 
administrative data are necessary.   This section briefly reviews the classification and types of 
quality data to understand their use in health system performance analysis.  
Quality measurement is concerned with three domains of measurement: structure, process, 
and outcome.   
 Structural quality measures describe attributes of providers (hospital bed size, number 
of primary care physicians in a geographic area).   
 Process measures describe the components of an encounter between a provider and a 
patient (tests ordered, medication prescribed).   
 Outcome measures describe the effect of care on aspects of patient (or population) 
well-being, such as survival, return to function, or state of control of a chronic illness.    
Administrative data, such as claims data, can provide insights into payments, utilization, and 
care processes.  They are valuable to the extent that adherence to certain processes (timely 
intervention for heart attack treatment, for example) is associated with improved outcomes 
(lower mortality rate in heart attack patients).  However, outcomes data, which is arguably the 
most useful quality information, is not available in administrative data sets. The MHDO and the 
Maine Quality Forum have collected some clinical process and outcome measures from 
hospitals for several years, as have other public and private entities, including the federal 
Centers for Medicare and Medicaid Services (CMS) and Leapfrog (a national employer coalition 
concerned about healthcare safety).  These data have described hospital performance on 
healthcare-associated infection and other aspects of patient safety.  The data have shown a 
relationship between adherence to recommended “best practice” care processes and better 
outcomes.  Reporting on these processes and related outcomes has been done on a hospital 
level; processes (derived from administrative and clinical data bases) and outcomes for 
populations of individual patients (derived from clinical data bases and registries) have not 
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been linked.  When Maine’s all-payer claims database (APCD) was organized, there were no 
good ways to collect large amounts of clinical outcomes data for populations.  Now, however, 
with the development of electronic health records and clinical outcomes registries, it is feasible 
to describe health outcomes in large populations of patients. 
There is considerable evidence and expert opinion that the marriage of cost data with 
outcomes data makes robust analysis of the overall performance of health care providers and 
of the value of health care in Maine possible.   Dr. John E. Wennberg, a noted health services 
researcher and founder of the Dartmouth Atlas of Health Care, which catalogs variations in care 
processes in the United States using Medicare claims analysis, wrote “Claims data need to be 
augmented by critical information extracted from patient records and obtained directly from 
patients.”2   
The limitations of claims data alone to evaluate provider quality was demonstrated in a study 
showing that hospital performance on process measures reported by Medicare in its consumer-
facing Hospital Compare website were only modestly correlated with outcomes (mortality 
rates).3   In a Brookings Institution review of the role of clinical data registries in care 
improvement, the following statement was made: “Registries can play an important role in 
better health care performance measurement.  To achieve this, clinical data from registries 
must be integrated with claims data to create a hybrid database that can be used to improve 
care and, in turn, calculate more valid and comprehensive measures of the quality and cost of 
medical care.”4  
Michael Porter of the Harvard Business School, who has written extensively on value in health 
care, states, “The only way to accurately measure value… is to track patient outcomes and costs 
                                                 
2
 Wennberg JE, Fisher ES, Skinner JS. Geography and the Debate over Medicare Reform. Health Affairs 2002; W96 – 
W114. 
3
 Werner RM, Bradlow ET. Relationship Between Medicare’s Hospital Compare Performance Measures and 
Mortality Rates. JAMA 2006; 296 (22): 2694 – 2702.   
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longitudinally.”5  Similarly, in a critique of Great Britain’s National Health Service approach to 
measuring quality, Mountford and Davie found that quality reports have had: 
[a] focus on process and proxies, not on outcomes that matter to patients. To 
date, the dominant focus of quality measurement and reporting has been on 
processes and inputs to care, not on patient-relevant outcomes. Process 
measures can have advantages. For example, they are often easier to measure 
than outcomes, they require less risk adjustment, and there are many examples 
in which a favorable patient outcome has resulted despite a defective process (or 
in which an unfavorable outcome has followed a faultless process). However, 
undue focus on process and proxy measures can have serious and often 
surprising consequences. Patients may have worse outcomes as a result. For 
example, higher mortality in high-risk patients with type 2 diabetes was 
associated with aggressive intervention to achieve normal glycated hemoglobin 
levels. 6 
A large body of evidence now supports the limitation of administrative data alone to describe 
or even drive improvement in health care.7  
B. The Current State of Claims and Clinical Governance  
Having reviewed the classifications and types of quality data, we now turn to the current 
state of governance structures for claims and clinical data:   
 Claims data are kept in the all-payer claims database (APCD) managed by the MHDO, an 
independent State agency governed by a board of directors, representing both public 
agencies and private entities.  MHDO has the authority to require hospitals and payers 
to submit claims and quality data.  By statute, MHDO also has authority to compel 
                                                                                                                                                             
4
 How Registries Can Help Performance Data Improve Care. Engelberg Center for Health Care Reform at Brookings, 
2010, Accessed at http://www.rwjf.org/content/dam/farm/reports/reports/2010/rwjf61984. 
5
 Porter ME. What is Value in Health Care. N Engl J Med 2010; 363:2477 – 2481. 
6
 Mountford J, Davie C. Toward an Outcomes-based Health Care System. JAMA 2010; 304,(21): 2407-2408. 
7
 See Hammill BG et al.Incremental Value of Claims Data beyond Clinical Data in Predicting 30-day Outcomes after 
Heart Failure Hospitalization.  Circ Cardiovasc Qual Outcomes, 2011 Jan 1;4(1):60-7.  See also Farmer SA, et 
al. Tension Between Quality Measurement, Public Quality Reporting, and Pay for Performance. JAMA 
2013; 309(4):349-350) 
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submission of clinical data from providers, and there are precedents for collecting and 
housing data at MHDO. 
 Clinical data is held in several repositories.  It is owned by, and its use controlled by, the 
providers who generate it.  “Real-time” hospital and provider clinical data are often 
submitted to what is called a “Health Information Exchange” (HIE).  In Maine many 
hospitals and providers participate in an HIE through customer agreements with 
HealthInfoNet, a non-profit company, governed by a board of directors, that operates a 
state-wide Health Information Exchange. Participation in the HIE is voluntary.  Its 
current framework does not provide a mechanism to require providers to submit clinical 
data, or for Health InfoNet to release clinical data, unless permitted under its customer 
agreements.  Over the past year, HealthInfoNet has been working with its data 
submitters, stakeholder committees and board of directors to develop the company’s 
policy on clinical data use, data release, and responses to requests for data.  Health 
InfoNet (HIN) is considering using the framework that the MHDO uses to decide data 
requests (such as the purpose of the request), with decision making authority for 
releasing clinical data from the HIE to reside with the HIN board of directors.  HIN 
anticipates that these policies will be finalized in the spring of 2013.  
 
Electronic health records (EHR) carry with them the potential for reporting massive amounts of 
clinical data, much of which is in the category of outcomes. Population disease registries 
maintained by providers and health information exchanges (HIE) such as Maine’s HealthInfoNet 
have demonstrated the potential of EHR to assemble and analyze clinical information from 
large populations for the purposes of quality analysis and care improvement.  A next logical 
step in creating the toolset necessary for development of a learning health system for Maine is 
building the capability of linking these clinical data with administrative data already in place in 
the MHDO.  
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Considerable pressure already exists for providers to engage in care improvement initiatives, 
supported by the monitoring and analysis of cost and quality data.  The Maine State Employees 
Health Commission has been an innovator in the development of incentives for its members to 
choose higher value providers.  Medicare, through its Shared Savings, Bundled Payment, and 
medical home programs, has offered providers the opportunity to share in the savings 
generated by providing high quality care at a lower cost. MaineCare has established a Patient-
Centered Medical Home Pilot and is also developing a Value-Based Purchasing program.  The 
Maine Health Management Coalition Foundation, a public charity, has developed and shared 
robust health care cost and quality information, and provided it not only to its members, but to 
the public free of charge.  This data has had a major impact on improving health care quality 
and safety in Maine.  
Improvement in the availability of administrative data, broadening the range of clinical quality 
measures, and developing safe and reliable rules governing the linkage of these two types of 
health data would allow the assessment of both quality and cost by all Maine stakeholders. This 
will set the stage for providers to continuously improve, for consumers to make better 
informed decisions, and for payers to derive value from Maine’s health care system.   
The value of integrated claims and clinical data was recognized and emphasized by several 
respondents to the “VOC” survey.  Select survey responses include: 
“ Data needs to be aggressively used by all appropriate parties to improve the delivery 
of health care, and therefore made available by a public entity with appropriate 
governance and safeguards to as many qualified users as possible who will work to 
improve the health and safety of Maine people.” 
 
“A common, shared data source of integrated clinical and claims data for all parties to 
use – with appropriate privacy, security and legal safeguards and role-based access – 
will serve as the foundation to system and payment reform. All approved users should 
have fair, affordable and equitable access to the data for the purposes of care 
improvement. “ 
 
  
 
Chapter 109 (2011) [LD 1818] Work Group Report               February 23, 2013  Page 22 
Although there was consensus on the value of linking the claims and clinical data, the challenge 
for the Work Group was establishing processes and mechanisms that should be used to 
accomplish the linking.     
Throughout the course of stakeholder discussions there was a recurring theme regarding the 
importance of providers and consumers having equal access to data.  One VOC respondent said, 
"A publicly governed and accountable entity should maintain the functions of the MHDO. Public 
governance provides the greatest accountability and protection for data users and could provide 
fair and equal data access to all users."  Another VOC respondent stated, "The age of competing 
for market share by controlling access to data is over. Transparent all-payer data should be 
made widely available and competition should be based solely on performance." 
 
The issue of having access to health data must be balanced with privacy issues.  As one VOC 
respondent pointed out, "While there may be value to expanding uses of the MHDO database 
or to linkage with other databases, these decisions should be made with patient’s rights at the 
fore." Another respondent stated," There are lots of questions about crossing the line between 
de- and identifiable data.   We [health systems] want to maintain control of clinical PHI.  Careful 
assessment of what provider organizations are compelled to do vs. doing it voluntarily [is 
necessary]."8 
Surmising that neither the market nor the government can provide the perfect solution, it is 
suggested that the combined effort of both public and private resources continue.   In fact, 
MHDO has contracted with HealthInfoNet to test the feasibility and costs of linking 
administrative and clinical information.  This pilot should inform next steps concerning the 
technical requirements, cost details, and optimal governance of these potential new 
capabilities. 
                                                 
8
 Brackets added to complete the respondent’s thought. 
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C.  Improve and Facilitate Health Data Uses—Maine Quality Forum  
Question 2 also asks the Group to examine current health data uses and to look at ways to 
facilitate improved and expanded uses.   
Although the MHDO collects a wide array of health care data and has general responsibility for 
its provision, analytical work on the data is conducted in collaboration with State agencies.  For 
example, Maine’s Center for Disease Control and Prevention (CDC) and MaineCare, each within 
the Department of Health and Human Services, perform analytic services unique to their 
authority.  
Recognizing the need for population health analytics, in 2003 Maine established the Maine 
Quality Forum (MQF) as a function under the Dirigo Health Agency.  The MQF’s primary 
purposes, assigned in the enabling legislation, include: 
 Research dissemination on quality, evidence-based medicine, and patient safety to 
promote best practices which MHDO must use as the basis of MHDO rules;  
 Coordinate with the MHDO the collection of health care quality data in the State, to 
minimize duplication and burden on the providers of data;  
 Work collaboratively with the MHDO and providers to report in useable formats health 
care quality information to consumers, purchasers, providers, insurers and policy 
makers;  
 Make available information on quality of services on a publicly accessible website and 
conduct educations campaigns;  
 Conduct technology assessment reviews to guide the use and distribution of new 
technologies; and   
 Promote the adoption of electronic health information technology.  
  
 
Chapter 109 (2011) [LD 1818] Work Group Report               February 23, 2013  Page 24 
Together, MHDO and MQF have developed a data base of clinical measures, including outcome 
and process measures, that has advanced the public’s understanding of care quality in Maine’s 
hospitals.  These measures include process and outcome indicators in areas such as heart 
disease, pneumonia, and healthcare-associated infection.  
 
The MQF has analyzed and reported on health care variation in utilization, quality, and cost, 
using data from MHDO data bases.  It has published an annual report on the incidence (and 
efforts at control) of health care-associated infections since 2008, using MHDO quality data; 
commissioned and supervised a study of health care cost drivers in Maine in 2009, using the all 
payer claims data; and reports on its website on variations in care patterns among Maine’s 
healthcare service areas, using hospital discharge data – see the MQF website at 
http://www.mainequalityforum.gov/.  These and other MQF projects have informed health 
policy development in State government and in the private sector.   
The Maine Quality Forum is a function of the Dirigo Health Agency and governed by the Dirigo 
Board of Directors.   The current funding mechanism for the Dirigo Agency will cease at the end 
of 2013.  The Dirigo Board of Directors anticipates and supports funding the operations of the 
MQF through State Fiscal Year 2015 with existing reserves.  (That proposal is in the current 
budget process in the Legislature.)  
 
The Work Group believes that now is the opportunity to continue the work of the MQF in a 
manner that preserves this important and unduplicated capability within State government.  
The functions that the MQF currently perform, especially those done in collaboration with 
MHDO, will still be needed in the future.  The Group believes that the MQF could be relocated 
within the MHDO (conditioned on funding availability, administrative efficiencies, and staffing 
needs).     In addition to sustaining the ability of the MHDO to perform data analysis on its 
administrative and quality data sets, incorporating MQF would provide guidance to MHDO on 
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choices of indicators collected under MHDO Chapter 270, Uniform Reporting System for Quality 
Data Sets; on the development of reports for the public and consumers regarding health care 
providers; and on the use of linked clinical and administrative data for these reports.   The MQF 
Advisory Council has provided, and could continue to provide, a portal for public input into this 
guidance.  
 
D.  Active Multi-Stakeholder Engagement  
 
One of the four themes emerging from the VOC survey was the need to establish mechanisms 
to ensure that multi-stakeholder engagement and feedback is solicited and prioritized, to 
ensure that value is being derived from health care data. The subcommittee charged with 
addressing this theme made three recommendations to improve on the current state:   
 Clarify the role of government, relative to non-governmental entities, of the respective 
contributions to the creation of health care data bases and reporting; 
 Build on current mechanisms that engage stakeholder groups to gather input and 
feedback, discuss opportunities for engagement and education, and continuously 
improve the current state; and  
 Establish a process of accountability and transparency for the stakeholder input system 
aligned with the data governance structure, with the ultimate goal being multi-
stakeholder collaboration to ensure the greatest value is derived from this work. 
 
The subcommittee concluded that, in order to promote efficiency and meaningful outcomes for 
stakeholders, there needed to be ongoing mechanisms to report activities and coordinate 
efforts.  These mechanisms should include articulated goals against which its effectiveness can 
be evaluated on a regular basis (see Appendix E for an inventory of engagement mechanisms, 
as well as notes on sources of the information provided on the next page). 
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Regarding consumers in particular, the establishment of mechanisms to ensure consumer – 
patient engagement has been recognized nationally as instrumental to meeting the goals of the 
Triple Aim.  The Commonwealth Fund calls consumer engagement “a core driver toward a high 
performance health system.” The value of engaging consumer stakeholders was reinforced by 
one VOC respondent, who succinctly stated,  
“Data users - including consumers - should have input into the structure, design, and 
purpose of the state’s data systems to maximize its use for and by all stakeholders, 
including the public.”  
 
Another provided a compelling rationale for consumer engagement;  
“Without this transparency patients cannot truly be engaged or empowered - because 
we lack available data and information, and with the odds as high as 1 in 3 of 
experiencing medical harm in a hospital9, healthcare consumers are choosing blindly 
every day.. 
 
To support consumer engagement and provide a framework that can change and adapt as the 
heath Information field evolves, a consumer engagement pyramid which illustrates the three 
levels of engagement--patient, organization and policy—was developed by one of our Task 
Members, Poppy Arford, and several of her colleagues:  
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3. Consider federal and state privacy and security laws regarding the use and release of 
protected health information, including policy and technical changes needed to allow 
increased access to protected health information and the feasibility of those changes;  
 
Protected health information (PHI) is defined under federal law as any information about health 
status, provision of health care, or payment for health care that can be linked to a specific 
individual.   The federal HIPAA (Health Insurance Portability and Accountability Act) law 
identifies 18 elements (including name, telephone number, email address, social security 
number, and unique identifying number such as a medical record number) that are considered 
as elements of PHI.  
 
The federal HIPAA law limits the disclosure of identifiable health information to treatment, 
payment and operations of the health care practice, and a few other specific purposes.  There 
are more restrictive federal laws governing personal health information related to substance 
abuse.   The general rule is that, unless allowed under these laws, disclosure is not permitted.  
Clinical data bases, such as the health information exchange operated by HealthInfoNet; claims 
and quality data bases, such as those operated by MHDO; and payer and other data bases, 
contain some protected health information (PHI).  Regardless of where the data resides, utmost 
care for privacy and security must be maintained.    
 
Considerable VOC feedback was provided by various stakeholders as it relates to the 
broadening of access to healthcare data, including the following competing comments: 
“While there may be value to expanding uses of the MHDO database or to linkage with 
other databases, these decisions should be made with patient’s rights at the fore.  Often 
those doing the hard work of providing us with healthcare get so excited about 
increasing efficiency or improving coordination of care that patient notice, privacy and 
consent can get lost.” 
                                                                                                                                                             
9
 See http://www.ama-assn.org/amednews/2011/04/18/prl20418.htm 
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“As patient advocates and defenders of personal privacy, we urge continual focus and 
commitment to privacy, confidentiality and security.   Patient rights must be the highest 
priority in Maine’s electronic health information system, and we hope the State will 
continue to demonstrate meaningful commitments to patient privacy.” 
 
“Patient identified data must be included but identifiable only at the patient/provider 
level to allow providers to effectively improve care for their patients. Identified data 
enables the combining of different data sources to allow a meaningful and longitudinal 
understanding of utilization, care patterns, and outcomes.” 
 
“Health care providers need data with personal health information in a HIPAA compliant 
way so they can use it to improve care for those patients they are treating.  Right now 
we have providers willing to take responsibility for the quality and cost of their patients 
and they don’t have good data readily available.  I hear words like ‘betrayal’ and ‘tying 
our hands behind our backs’ from providers.” 
 
To better understand the nature of protected health information law, the Work Group asked 
the Legal Work Group (attorneys and health information privacy experts who are periodically 
convened by the Office of the State Coordinator Health Information Technology Steering 
Committee) to provide information and guidance on this issue.    
 
As background, the Legal Work Group presented to the Work Group a thorough analysis of 
federal and State laws pertaining to HIPAA, Substance Abuse and Alcohol Abuse, Mental Health, 
HIV and how the MHDO, HealthInfoNet and the Health Information Exchange are affected by 
the laws.  A graph depicting these laws is shown below:   
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A full copy of the LWG report and supporting documents is contained in Appendices F and G.10 
Unless otherwise permitted by federal law, State laws cannot contradict federal laws and rules.  
The federal Substance Abuse laws are very inflexible and would require considerable efforts at 
the federal level to make changes to the laws.  HIPAA, even though it is a federal law, allows 
states some flexibility in how they enforce certain elements.  The Legislature has the ability to 
amend Maine laws on access to protected health information.  The MHDO has the authority 
under Maine law to modify its rules (subject to the Administrative Procedures Act). 
                                                 
10 Many LWG members stated that they viewed the scope of the LWG as providing a factual review of the current 
federal and state laws and rules governing protected health information (PHI).  In that respect, the LWG did not 
make what might be termed “subjective” recommendations. Rather, the LWG provided an analysis that was 
factual in nature.   
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The Resolve asked the Work Group to consider changes needed to “increase access” to 
protected health information.   The Work Group viewed this question in two different contexts:  
improving access to PHI and increasing access to PHI.   
Subject to the federal and State laws described above, existing laws allow payers, Accountable 
Care Organizations, hospital systems and their health care providers, and health care practices 
to have access to, and to exchange/release their patients’ records including protected health 
information.  However, MHDO is precluded by Maine law from releasing PHI.   Currently, 
encrypted data is fed from payers, including Medicare and Medicaid (MaineCare), to the DPC 
which then forwards the encrypted data to the MHDO claims and quality data bases.  MHDO 
provides aggregated claims and quality data reports.  These reports are useful to identify costs 
and quality at a high level, such as the total number of claims that had a certain diagnostic 
code, such as hypertension, but do not report claims and quality data that could help improve 
individual patient outcomes.  Although providers and hospitals could benefit from receiving 
claims and quality data available in the MHDO data bases, the MHDO cannot release protected 
health information, even to providers who have a direct relationship with the patient.  A way to 
improve access to PHI is to allow the MHDO to have the same legal rights and responsibilities to 
exchange/release PHI as federal and State laws allow for other entities.   This may be 
accomplished by the Legislature amending the MHDO statute to allow MHDO to modify its 
existing rule to improve access to PHI for purposes allowed under HIPAA and other federal and 
State laws.  The existing applicable MHDO statute and rules are found in Appendices H and I.  
 
As evidenced by the selected VOC comments above, increasing access to personal health 
information for purposes other than what are currently thought of as “treatment, payment and 
operations of the practice” requires further policy discussions.  There could be legitimate and 
appropriate reasons, including public policy considerations, for increasing access to PHI.  The 
Work Group is not putting forth specific changes to Maine law, yet we do believe that the 
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comprehensive review completed by the LWG will certainly guide future directions relating to 
increasing access to personal health information. 
 
4. Consider the availability of the data, the most appropriate sources of the data and the 
cost of providing the data. 
 
Question No. 4 was not discussed in detail, as the Group did not have sufficient time to gather 
and analyze all of the sources of data and the costs of providing the data at the level necessary 
to make an informed presentation.   
 
Given the relative small size of Maine, competing data and reporting structures may pose 
undue costs to system stakeholders and unnecessary fragmentation of the overall system.  As 
one VOC respondent stated, “Resources should be used effectively and care should be taken to 
avoid unnecessary duplication of data systems and the resources needed to support them.  Data 
is a resource that is only valuable when it is accessible and used effectively.” 
Avoiding fragmentation and duplication of effort, and not paying twice (or more) for the same 
data is critical because whether the submitting or receiving entities are public or private, they 
all face funding challenges.  To that end, the Work Group supports an examination of data sets 
that are currently reported to the various entities to determine whether the data are needed; 
the value of the data; whether the data submissions are efficient and avoid duplication; the 
cost of providing the data; and an analysis of funding sources.   The Work Group believes that 
the following statement should guide efforts to address these issues:    
 
 
Maine needs to think strategically about the data we really need 
compared to the data we now collect and the costs of collecting that data; 
sustainable financial business models that are efficient and avoid 
fragmentation and duplication while providing the best value for the data; 
and how to best use the data to improve quality and health outcomes. 
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V.  Next Steps 
 
 
When the full Work Group reconvened to discuss the four sets of subcommittee 
recommendations, there was not consensus that the LD 1818 Report should contain specific 
recommendations for legislation.   The Group believes that we need to move forward and that 
path requires both short and long term steps.  Some steps should be taken in 2013 to set 
improvements in motion while knowledgeable stakeholders further examine and refine actions 
based on emerging technology and policy developments.  This course ensures that we take 
actions that are needed today, while recognizing that health care data needs and technology 
will continually evolve.    
 
The following steps are already underway or under serious consideration in existing 
organizations.  The Work Group wishes to express its support for:      
 
1) Continuing the work underway by the MHDO Board to implement its new vision 
and business imperatives by a Board that is held publically accountable for a 
disciplined execution of its plans with robust stakeholder involvement.  Over the 
past two years, the MHDO Board has informally transformed itself into a smaller, 
more responsive and accountable board.  The joint Committee for Health and 
Human Services has the authority under Resolve, Chapter 109 (2011) to report 
out legislation amending the MHDO statute (created in 1995) to reflect this 
transformation to a modern-day Board structure that will meet the future needs 
of the State’s health care data organization.    The Work Group understands that 
the MHDO board is preparing a legislative proposal to significantly reduce the 
size of the MHDO Board in order to be more nimble and effective, while still 
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maintaining representation of a broad group of stakeholders including 
employers, providers, insurance plans, state agencies and consumers.  
 
2) Studying viable financial models, protocols, data management, privacy, and 
encryption policies by the reconstituted MHDO Board in 2013.  This will lead to 
improved efficiency for current data submitters, and to standards for the use of 
linked databases (in which MHDO is involved).   
 
3) Determining the feasibility of linking administrative claims and clinical data at an 
affordable cost through the close monitoring of the current terms of the contract 
between MHDO and HealthInfoNet.  The monitoring should be conducted by a 
group of knowledgeable stakeholders who understand the myriad of issues 
posed in this report.  The MHDO should report back to the Legislature on the 
results of this pilot.   
 
4) Conducting a collaborative strategic examination on the health care data we 
really need compared to the data we now collect, and of the costs of collecting 
that data; identifying sustainable financial business models that are efficient, 
avoid fragmentation and duplication, and provide the best value for data; and 
identifying the best ways to use the data to improve quality and health 
outcomes.   
 
5) Leveraging federal dollars to promote the use of electronic health records, 
access to health care data, and the development of reporting systems which 
move toward achieving the Triple Aim.  This can be done through a collaborative 
effort between MHDO and Maine’s Office of the State Coordinator for HIT to 
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leverage public funding under sources such as the federal Health Information 
Technology Act and the Medicaid Meaningful Use Program. 
 
6) Continuing the positions the Maine Quality Forum (MQF) within MHDO in order 
to support ongoing data projects focused on quality improvement across the 
Maine health care delivery system; maximizing the public use of existing and 
future data assets of the MHDO; and providing an opportunity for multi-
stakeholder engagement.  This recommendation is conditioned on the 
availability of funding, and on an analysis of administrative efficiencies and 
staffing needs.   
 
After the completion of these “next step” items, further legislation may need to be considered 
to more fully inform ensuing policy discussions, modify existing laws, as well as implement new 
laws and rules. 
 
Comments from individual committee members on earlier drafts of this report are included in 
Appendix J. 
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VI.   Conclusion 
 
 
The experience of our Work Group has illustrated the importance of health data in Maine, and 
the passion and interest that its collection and use evoke among wide audiences in Maine.  We 
wish to acknowledge and thank all of the groups and individuals who have contributed their 
ideas and time to this effort. 
 
Maine has been in the forefront of the country in its health data collection and use.  But the 
field is changing, as new technologies and practices enabling the linking of claims and clinical 
data become more widespread and practical.  Maine needs to keep its leadership position, and 
to reap the benefits in terms of better and more affordable health care.  This is an issue that 
justifies continued public attention in the coming years. 
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 Appendix A: Resolve Establishing Work Group 
 
 
RESOLVE Chapter 109, LD 1467, 125th Maine State Legislature 
Resolve, To Evaluate the All-payor Claims Database System for the State 
HP1076, on - First Regular Session - 125th Maine Legislature 
 
Sec. 1 Creation of working group. Resolved: That the Department of Health and Human 
Services, referred to in this resolve as "the department," shall establish and convene a working 
group to evaluate options and actions available to improve the availability of and access to 
health care data and to examine the all-payor claims database system in the State; and be it 
further 
 
Sec. 2 Membership. Resolved: That the Commissioner of Health and Human Services shall 
invite 17 persons to participate in the working group, as follows: 
1. Two representatives of health insurance carriers; 
2. Two representatives of health care providers, one member representing hospitals and 
one member 
3. Two representatives of employers, one member representing a statewide health 
management representing physicians; coalition and one member representing a 
statewide chamber of commerce; 
4. One representative of consumers; 
5. One expert in both state and federal privacy laws; 
6. One representative of the Maine Health Data Organization; 
7. One representative of the Maine Health Data Processing Center; 
8. One representative of Onpoint Health Data; 
9. One representative of the Department of Administrative and Financial Services, Office of 
Information Technology 
10. One representative of HealthInfoNet; 
11. One representative of the MaineCare program within the department; 
12. One representative of the federal Medicare program; 
13. One representative of the Office of the Attorney General; and 
14. One representative of the Maine Quality Forum; and be it further 
 
Sec. 3  Cochairs. Resolved: That the members of the working group shall select 2 of the 
members to serve as cochairs; and be it further 
 
Sec. 4 Evaluation. Resolved: That the working group shall consider changes to the State's 
allpayor claims database system to improve the availability of and access to health care data by: 
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1. Reviewing the current structures of and relationships among the Maine Health Data 
Organization, the Maine Health Data Processing Center and Onpoint Health Data in 
order to evaluate the timeliness and effectiveness of the data received;RESOLVE 
Chapter 109, LD 1467, 125th Maine State Legislature Resolve, To Evaluate the All-payor 
Claims Database System for the State HP1076, on - First Regular Session - 125th Maine 
Legislature, page 2 
2. Reviewing the current purposes and uses of the data and limitations on access to the 
data and considering additional uses for the data and changes that might be necessary 
to achieve and facilitate additional uses; 
3. Considering federal and state privacy and security laws regarding the use and release of 
protected health information, including policy and technical changes needed to allow 
increased access to protected health information and the feasibility of those changes; 
and 
4.  Considering the availability of the data, the most appropriate sources of the data and 
the cost of providing the data; and be it further 
 
Sec. 5 Funding and staffing. Resolved: That the department shall provide staffing assistance to 
the working group through contracted professional services and shall seek outside nonstate 
funding to support staffing services and administrative costs for the working group. If adequate 
funding is not obtained, the working group may not convene or incur any expenses; and be it 
further 
 
Sec. 6  Report. Resolved: That, by January 31, 2012, the department shall report the 
recommendations based on the findings and conclusions, determined by vote, of the working 
group, along 
with any recommended implementing legislation, to the Joint Standing Committee on Health 
and Human Services. 
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Appendix B:  Themes from Voice of the Customer Exercise 
 
Theme 1:  Establishing multi-stakeholder directed Data Governance Structures that optimize 
the collection, processing, and distribution (accessibility) of health care data.   
 Resources should be used effectively and care should be taken to avoid unnecessary 
duplication of data systems and the resources needed to support them.  Data is a 
resource that is only valuable when it is accessible and used effectively.   
 Management of the APCD and other data sets by state government through the 
independent agency structure and governed by a multi-stakeholder board. 
 A publicly governed and accountable entity should maintain the functions of the MHDO. 
Public governance provides the greatest accountability and protection for data users 
and could provide fair and equal data access to all users.  
 Data users- including consumers- should have input into the structure, design, and 
purpose of the state’s data systems to maximize its use for and by all stakeholders, 
including the public. 
 A common, shared data source of integrated clinical and claims data for all parties to 
use – with appropriate privacy, security and legal safeguards and role-based access – 
will serve as the foundation to system and payment reform. All approved users should 
have fair, affordable and equitable access to the data for the purposes of care 
improvement.  
 The focus should be on developing a combined data warehouse to which appropriate 
entities have access for approved purposes to improve the health of Maine people 
 Data needs to be aggressively used by all appropriate parties to improve the delivery of 
health care, and therefore made available by a public entity with appropriate 
governance and safeguards to as many qualified users as possible who will work to 
improve the health and safety of Maine people. 
 There is still no “all payer” database available.  We need commercial, Medicaid, and 
Medicare claims data combined in a usable data warehouse 
 Integrated clinical data, claims, health risk, and outcomes data is the optimal source of 
information for care improvement and high value. 
 Information created from healthcare data should be made transparent and publically 
available in aggregate with the appropriate safeguards, processes, and criteria for 
reliability. 
 Lots of questions about crossing the line between de- and id-data.   We want to 
maintain control of clinical PHI.  Careful assessment of what provider organizations are 
compelled vs. doing it voluntary.   
 In theory, we would be interested in seeing the full MHDO data.  When we get data 
from CMS, we get patient identifiable information.  One thing that would need to be 
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considered is the ability to get identifiable data from public DB.  This MHDO is good for 
benchmarking purpose.  You would need to address timeliness and PHI.  Particularly 
timeliness.  We would hope for monthly feed and then turn it around within 24 hours.   
 There must be careful evaluation of the roles of the actors—state has regulatory 
requirements; I think it is the ultimate response of the providers to have and use the 
tools with appropriate regulatory oversight.   There is a public perception and costs 
considerations.  State agencies have tried to keep the people within the regulatory 
boundary but not regulate how you deliver the care.  This can get the state pretty close 
to regulating how you deliver the care. 
 One of our most significant challenges is that HIN does not own the data.  Issue is we 
have privately owned data, and within partnership the question of appropriate data use 
that benefits all and does not threaten anybody.   We are focusing on E H R being the 
source of the clinical data.  By the end of next year we will have over 95% of the Hospital 
(and their providers) data set.  The ambulatory is taking a little longer.   We are focusing 
heavily on FQHCs.   We are the first HIE in the country nearing public health profiles 
(CDC) by running our data through systems including the federal POPHealth.  All data is 
de-Id.  We will be able to send data to Maine CDC. 
 Multiple issues are data warehouses that are cropping up.  And then we have the APCD.  
We need to catalog this and the Legislature is aware of all of these cropping up.  
 
Theme 2:  Implementing technically-sound and scalable Data Processing Structures and 
Protocols that permit timely, accurate, and cost effective submission and dissemination of 
pertinent health care data (administrative and clinical). 
 Timely access to all payer data is necessary to support system transformation.  All payer 
data from commercial and public payers should be available at least quarterly to users. 
Data on a subset of patients is insufficient to facilitate population health management.  
Data that is not current does not allow for effective and timely interventions to change 
care. 
 Medicare data is not available in a timely/usable manner 
 Data available for the patient origin report is often not timely 
 Hospital Cost web-site is not maintained and up to date, 
 Problems with the quality of the Maine Care data made some of it unusable, resulting in 
only getting old data (2006) for other pieces.  Delays in the availability of the discharge 
data are a constant frustration.  The process of resulting the data and getting waivers 
for public use was time-consuming and caused a few other delays. 
 The data is not very useful without Medicare and MaineCare data.  To the extent that 
this is in the control of MHDO, a quicker turnaround time for updates is needed. 
 The procedure for ordering data from the Maine Health Data Organization was fairly 
easy, however after several different runs, the data was still unusable. 
 Data dictionaries are hard to find.  Needed some assistance to find the right reports and 
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files.   
 The complex role of data submitters is not well understood by health data stakeholders. 
There are significant costs and limitations to what can be provided and when. 
 Ensure a feedback mechanism through which submitters can verify their own data, as it 
exists as the output of the APCD. 
 A data submitters working group should be convened to help develop common data 
collection standards and procedures including what should be collected, how often, and 
the best approaches to continuous improvement of data quality. 
 There is substantial cost associated with providing health data.  In Maine, one of our 
Plans estimates the cost of programming a single change to a single data element, and 
there are several thousand across multiple platforms, at $10,000.  These operational 
costs are in addition to the annual assessments paid by carriers and providers that, 
along with modest income from data sales, fund the MHDO. 
 There are systemic limitations to claims data in terms of both accuracy and timing that 
need to be acknowledged and understood.   
 Not real time – only 50% of claims are adjudicated within one month of service 
provided, additional 35% in second month. The current release schedule of 90 days after 
close of quarter already requires monthly submissions from carriers. 
 Limited outcomes data such as labs and radiology results. 
 Lack of costs data at the claims/service level for capitated services or other special 
payment arrangements such as bundled payments or DRG payments. 
 Data accuracy – up-coding, bundling and unbundling number to process a claim.  
Therefore, submitters should only be required to pass through the NPI submitted on the 
claim. 
 NPI issues – NPI not available for all servicing providers on claims, NPI “confusion” 
between individual practitioners and billing practices, inaccurate NPIs on claims. Carriers 
may not need an NPI. 
 Support broad based agreement among the states on a consistent set of data elements 
and formats for collection. Greater harmonization will enable increased automation 
through system programming increasing timeliness and efficiency. From a research and 
data integrity perspective, it also allows better comparisons across states, regions and 
populations. 
 Data submissions from carriers should be limited to those elements utilized by carriers 
for the payment of claims.  Seek out the best access point for additional data.  For 
example, carriers do not typically need the middle initial of a provider’s name in order 
to pay claims. It makes more sense to collect this information directly from providers. 
For non-payment essential fields, submitters should be only required to pass through 
what the provider submits and not be required to interpret, correct or enhance provider 
submitted fields. 
 Health Plans need comprehensive, clear and detailed messaging around which fields are 
  
 
Chapter 109 (2011) [LD 1818] Work Group Report               February 23, 2013  Page 41 
causing their files to fail and why.  The current data submission system is iterative and 
uses a serial editing process causing timely and expensive delays and an enormous 
volume of unnecessary communication.  If problems can be addressed and understood 
simultaneously then increased efficiency could be realized, and the time and expense 
for all could be better managed.    
 Expedite the data submission process by identifying all the issues with a data file at 
once. Upon submission, carriers should quickly receive one report back detailing all the 
errors or problems with their data files.  In this way, multiple issues can be addressed 
simultaneously and much more quickly, reducing resources and time required for the 
DQ Pass to be achieved. Where automated error messages frequently generate 
questions, messages should be revised to better explain the error. 
 Changes to thresholds need to be systematized so that they are set with input from 
submitters and occur on a predictable annual schedule with adequate notice. The 
current approach relies heavily on the subjective views of a few and needs to be 
formalized.  In this way, agreements from previous years can be formally tracked and 
recorded and all parties are saved the unnecessary hassle and additional expense of 
repeating requests and justifications. From a data quality perspective, thresholds of 
100% are not realistic and have no place in the data submission standards. 
 In cases where there are systemic issues that prevent the meeting of particular 
thresholds, then a permanent waiver or twelve month waiver period would be 
appropriate. It is resource intensive to have to reapply for the same waiver repeatedly. 
When a systemic issue will not change, Maine’s approach of allowing adjustments 
month by month, rather than for a longer period should be altered to save time and 
resource expense for all. An example of this could be ancillary coverage, which rarely if 
ever has a billing provider; if the industry practice does not include use of a billing 
provider, why not permanently except this type of file from this requirement instead of 
requiring an annual renewal of a variance? 
 Other efficiencies could be achieved by experimenting with ideas such as advance 
applications for threshold adjustments, so the new standard would already be in place 
when a file is submitted.  Additionally, better files could be maintained about why and 
when different carriers requested adjustments.  This would allow easy renewals without 
a new application process each time.  Our plans report that NH has permitted advance 
threshold adjustments but Maine has not. Further, Maine requires that carriers “prove” 
there’s still a problem each time.  A better balance must be struck between Maine’s 
desire to require carriers to provide the highest standard of data and the cost, use of 
limited IT resources and burden to everyone (not just the plans) associated with doing 
so. 
 Maine should consider whether there are some data elements that are more important 
than others.  Prioritizing data elements would help the parties focus on those that are 
most important. Health information is needed by different constituents and different 
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delivery rates. Patient data most frequent, analytical/financial data less frequently. 
 There are several issues similarly impacting most if not all of member plans.  In these 
cases where there seems to be an industry wide challenge, Maine should seek to 
explore ways of addressing these problems using a centralized approach.  For example, 
several plans are facing challenges around the provision of prescriber identification 
data.  Can a solution be devised where Plans pass through to the MHDO what they 
receive on claims and the MHDO or their vendor crosswalks that information to a 
centralized database they maintain from the PBMs?  This is a far more practical 
approach than asking all submitters to develop separate and expensive solutions to a 
similar problem.  This is not to say that we take the increase in assessments that would 
result from an approach like this lightly, but rather, that we recognize the value of 
having one system funded by all assessment payors collectively. For each submitter to 
fund a “fix” would be impractical, cumbersome, and unnecessarily expensive. 
 Clinical data integrated with claims data to support ongoing care process improvement 
and efficiency efforts 
 Inclusion of Medicare and Medicaid data that are up to date and accurate 
 Pharmacy and BH data is inconsistent across payers. 
 The hardest part of the quarterly reporting process is to line up the charge systems data 
lined up with event of care.  Who, what diagnosis, and which are multiple systems in the 
hospital.    
 Important to have a master provider and patient index (slide 8).  MHDO‘s RFP is around 
master patient and provider index.  So we need to make sure that we don’t duplicate 
efforts and systems.  
 Provider centric data is insufficient to provide the type of data needed to parse into 
episodes.  For example, coronary at hospital; what we didn’t know was who went to 
rehab or nursing home or saw PCP twelve times in the next year. 
 
Theme 3:  Balancing Consumer Privacy considerations regarding the safeguarding and 
disclosure of Protected Health Information (PHI) with the societal imperative to drive higher 
quality and more affordable health care. 
 Expansion raises the potential for poor policy decisions to be made about patient 
privacy, confidentiality, consent, notice, and control.     
 Medical information is arguably the most personal and private source of data about us 
as individuals.  In our work on health information technology, we continue to come back 
to the importance of informed consent.  Fundamentally and consistently, patients 
should be aware of and have an opportunity to decide who has access to their medical 
information.   That includes testing, diagnoses, treatment notes, payment and billing 
information, and anything else that is personally identifiable.  
 Both doctors and patients worry that their medical data will not be adequately 
protected.  They have good reason for concern.  The familial, financial and professional 
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ramifications of inappropriately exposed health information could be devastating.  And 
the larger and more comprehensive these databases become, they not only arguably 
become more valuable to patients, health professionals and administrators, they also 
become more vulnerable to thrill hackers, those seeking to commit medical identity 
theft, unscrupulous employees, and others.  
 Concern about inadequate sharing or protection of health information can also lead 
patients to put off seeking care – leading to potential health consequences for that 
individual and fiscal costs for the rest of us.  Imagine discriminatory review by insurance 
companies or potential employers so they can avoid paying for people who might be 
expensive to insure or employ. 
 While there may be value to expanding uses of the MHDO database or to linkage with 
other databases, these decisions should be made with patient’s rights at the fore.  Often 
those doing the hard work of providing us with healthcare get so excited about 
increasing efficiency or improving coordination of care that patient notice, privacy and 
consent can get lost.   
 As patient advocates and defenders of personal privacy, we urge continual focus and 
commitment to privacy, confidentiality and security.   Patient rights must be the highest 
priority in Maine’s electronic health information system, and we hope the State will 
continue to demonstrate meaningful commitments to patient privacy.  
 We need to be very careful in protecting personal health information.  However, we also 
need to be very vigilant about making sure data is being used to improve the health of 
Maine people. 
 Patient identified data must be included but identifiable only at the patient/provider 
level to allow providers to effectively improve care for their patients. Identified data 
enables the combining of different data sources to allow a meaningful and longitudinal 
understanding of utilization, care patterns, and outcomes. 
 Access to PHI data (by appropriate sources and with appropriate protections) to support 
ongoing projects. 
 Health care providers need data with personal health information in a HIPAA compliant 
way so they can use it to improve care for those patients they are treating.  Right now 
we have providers willing to take responsibility for the quality and cost of their patients 
and they don’t have good data readily available.  I hear words like “betrayal” and “tying 
our hands behind our backs” from providers 
 Within PCPs we may be able to only look at 10-15% of population.  We cannot look at 
population data from a longitudinal basis because of the lack of data.  Though I believe 
we need to be absolutely careful of PHI, the overall public good requires us to identify 
and implement standards so we can have PHI, have it timely, and need access to the PHI 
in the APCD.  We will not be able to do the work that needs to be done if we do not do 
this. 
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Theme 4:  Establishing mechanisms to ensure that consumer/stakeholder engagement and 
feedback is requested and prioritized to ensure value is being derived from the APCD. 
 Simple straight forward information that is important for patients making a choice of 
healthcare providers is important. 
 Make consumers more aware that the data is available, and make it free to healthcare 
consumers. Media attention and/or information given out at facilities would help.  Make 
available data simple to understand and easily accessible.  Consumers do not 
understand terms like “4 infections per 1000 patient days”. Put it in an easily searchable 
format online. 
 My use would be for personal use and to help consumers to make wise choices of 
providers for themselves.  My consumer advocacy groups would also use the data to 
help consumers.  Publication of data is also an incentive to facilities and providers to a 
improve quality and safety in their practices. When public data is available to all, then it 
makes healthcare providers accountable and transparent.  Public pressure is often what 
it takes to motivate improvement.   
 User friendly websites that can be found through key word searches on the internet 
would be useful.  I would like to see those providing health insurance or medical 
services sending people diagnosis specific information and helpful hints.   Also referral 
information should be available for an individual's primary health provider when a new 
diagnosis is given.  For most people where they are first told that they have a medical 
problem is a "teachable moment". 
 Everything!  I want to know who, what, where, when, and why!  Then I want to know 
how much it is going to cost me out of my own pocket.  I am a thorough healthcare 
consumer.  I question what medication I am being given, the pros and cons of this 
medication vs. another and the most effective form of delivery.  When tests are 
ordered, I want to know why and what information is going to be learned.  I will refuse 
anything I do not feel is appropriate and am lucky to have a provider who works with 
me.   
 I am a true fan of online resources, reliable and proven ones.  My provider is also an 
excellent resource.  There are many community resources that I am lucky to know about 
as a result of working in mental health and now a community health center. 
 The process has varied depending on what information I was seeking.  Sometimes I have 
been successful and sometimes I have had to change what I was looking for in order to 
find any success at all.   
 I am, once again, shocked to find that the two hospitals in my area are some of the most 
expensive in the state.  I have had some of the procedures listed on this site.  It makes 
me feel like my insurance company was swindled and, in return, so was I in terms of the 
co-pays I had to pay out of my own pocket! 
 There are too many people who need services and the wait for appointments is too 
long.  Health literacy is a huge factor.  Materials are written far above the level of the 
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education of the people served so they cannot benefit.  Many cannot read at all.  
Creating a health navigation or patient advocacy program within the MaineCare system 
is ESSENTIAL not optional!  The people served by this program, for the most part, are 
not good healthcare consumers but are some of the biggest consumers of healthcare! 
 Knowing there is a physician/clinic available 24/7 if I need care, to include but not 
limited to an E.R.Knowing that person has access to my medical record. 
 Whether my care is covered by my insurance. If I have no insurance, cost of care. If I 
have no insurance, will I receive care 
 Health status measures, rates of hospitalizations, emergency room visits, some interest 
in quality of care related measures, county, public health district and state levels, oral 
health, mental health, physical health. 
 Discharge database (inpatient and outpatient), emergency room visits database, All 
Payor Claims database, Quality of care (HAI) data. 
 Possible analysis of integrated care grantees 
 Possible analysis of payment reform grantees 
 More clinically relevant, real-time data that goes beyond claims 
 Providers are going to need timely access to clinical data going into the future 
 Clinical and Administrative data are going to have to be integrated in the future 
 Consumers need a reliable source of information/data when they are choosing where to 
get their healthcare.   Public reports on healthcare acquired conditions, such as HAIs and 
medical errors, ulcers, falls and other problems are extremely limited in the State of 
Maine.  I was asked recently to provide reports from my state to the NEVER and CU 
groups.  The sentinel events report was outdated and inaccurate, the HAI report was 
mostly process measures and only CLABSI and MRSA screening compliance results were 
available, and there were no detailed reports on other preventable errors or injuries and 
readmissions 
 There is currently no detailed public data available to consumers on specific surgical 
complications for specific procedures.  SSI on only Abdominal Hysterectomies and Colon 
surgery will be required by the Feds this year.  This is extremely limited information.  
Patients should be able to access information on their specific condition, at their 
preferred Hospital, and find out exactly how many SSIs there were in the previous year.  
Patients are expected to trust and rely on their doctor’s or Hospital’s word that “there 
aren’t that many”.  While that may be comforting to some, an educated consumer 
would want to confirm that for their own safety. 
 Data on other preventable medical and surgical errors, adverse events and HAIs should 
also be available to healthcare consumers.  I can get more information on a car service 
business than I can from my local hospital 
 There is no ability to match up claims data with other increasingly available data (e.g. 
clinical, health risk, functional status, etc.) and  
o used by providers for improving care for patients for whom they are responsible 
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o used by purchasers and the public (using de-identified data) to help assess the 
value of the care they are receiving and to help guide people where they can 
receive the best value care 
 Health care providers need to focus on improving the health of people.  This includes 
health risks like smoking, nutrition, exercise, etc. that put people at risk for future 
problems as well as how they are functioning in life (i.e. fulfilling roles and 
responsibilities at home, in the community, at work, and in leisure time).  These will be 
measured in the future and if combined with claims and clinical data can give health 
providers a better picture of how to improve the health and quality of life of the people 
they are responsible for.  By also making this de-identifiable data available, it helps to 
find and publicize best practices, helps providers see how they are doing and could do 
better, and allows people to make choices of which providers they would like to go to. 
 Meaningful cost of care data to support employees and families in the purchasing 
decisions 
 Transparency into hospital costs to allow for assessment of systemic “right sizing” based 
on community capacity and fixed cost analyses 
 Transparency into critical quality measures such as sentinel events by hospital 
 I hope that we address in the 1818 group whether this web information should continue 
to be posted, or is it duplicative of payer info.?  We have approximately 20 more to 
post. 
 In Maine very little done to data set to make it valuable to users.  Other states do that.  
Small health systems would have a hard time putting this together.  What additional 
things could we do to make data set more user friendly.  The MHDO RFP moves us in the 
right direction—it could do value added and save money.  One of the frustrations is that 
different organizations use different approaches and tools which make it more difficult. 
 We should consider financial incentives for the use of the systems.  We do something to 
move that work flow.  Policy is probably what is needed to change. 
 How do you bring the consumer into the equation to give them value? That should be a 
recommendation from this group and that is perhaps another committee. 
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Appendix C:  Factors Influencing All Claims Payer Database Timeliness 
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Appendix D: Maine Health Data Organization Program 
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Appendix E: Inventory of Engagement Mechanisms 
 
 
 
Maine Quality Counts - Consumer/Patient Engagement Framework 
Patient/Consumer Interest Patient/Consumer 
Role 
Options for Involvement Supports Needed Key Characteristics/ Skills 
Level A: 
 Improve one’s own 
health 
 Improve health of 
family member 
Active partner in 
care 
 Engage in self-
management, goal-
setting 
 Participate in shared 
decision making  
 Participate in Living Well 
program 
 Participate in support 
group 
 Participate in health-
related social 
networking site 
 Know how to access 
your medical records 
and make changes if 
required 
 Increasing progression 
on the Behavior 
Engagement Framework 
 Use of personal health 
record or other tracking 
 Evidence-based 
guidelines on 
recommended 
treatments, goals 
(e.g. Pathways) 
 Living Well 
program (group, 
online) 
 Information on 
action steps, 
trusted support 
programs  
 Information on 
how to access 
health records and 
how to make 
changes/edits 
 Self-awareness re: 
personal role in managing 
health 
 Ability to identify, 
communicate treatment 
preferences 
 Willingness to 
communicate with care 
team  
 Ability to track and 
organize personal health 
records and information 
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Patient/Consumer Interest Patient/Consumer 
Role 
Options for Involvement Supports Needed Key Characteristics/ Skills 
tools 
Level B: 
 Get information to 
make informed choices 
about care 
Active partner in 
care 
 Access GetBetterMaine 
website and other info 
on health care quality, 
costs 
 Help others access 
information  
 Understand issues of 
healthcare safety and 
advocate with providers 
to adhere to safety 
guidelines 
 Trusted 
information on 
health care quality 
& costs 
 Resources to 
answer questions 
 Desire to seek out 
information 
 Ability to distinguish 
between valid & 
erroneous information 
sources 
 Ability to discuss choices, 
ask questions 
 Level C: 
 Work with others to 
help improve their 
health 
Peer supporter  Serve as Living Well 
instructor 
 Serve as peer-to-peer 
support, mentor 
 Understand Behavior 
Engagement Framework 
and how you can assist 
others with specific 
behaviors 
 Serve as patient 
navigator in your health 
care system 
 Training programs 
 Peer support 
 Patient navigation 
training 
 
 High degree of empathy 
 Good communicator  
 Ability to maintain 
confidentiality  
Level D: 
 Work directly with 
health care providers 
to help improve the 
Practice Change 
Advisor 
 Work with primary care 
practice redesign team 
(“Practice Partner”) 
 Serve on health care 
 Training programs 
(e.g. mtg 
facilitation, 
leadership, 
 Commitment to improve 
care and value team goals 
over individual interests  
 Ability to maintain 
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Patient/Consumer Interest Patient/Consumer 
Role 
Options for Involvement Supports Needed Key Characteristics/ Skills 
delivery, quality, 
experience of care 
Patient Advisory Council 
(e.g. for primary care 
practice,  hospital) 
 Participate in provider 
committees 
knowledge, QI 
methods) 
 Peer support & 
coaching 
confidentiality  
 Desire to gain knowledge 
re: health care quality 
 Comfortable articulating 
patient insights & bringing 
patient feedback to 
improvement team 
 Receptive to views of 
others 
 Good communicator 
Level E: 
 Work with 
stakeholders to drive 
system, policy, 
payment changes to 
transform care 
Policy advisor, 
champion for 
change 
 Serve on QC Board 
 Serve on QC Consumer 
Advisory Council 
 Serve on HIN Consumer 
Committee 
 Get involved in 
meetings with local 
providers 
 Participate on State 
Workgroups 
 Participate in local 
community forums on 
healthcare quality and 
cost 
 
 Training programs 
(e.g. mtg 
facilitation, 
leadership, 
knowledge, QI 
methods) 
 Peer support & 
coaching 
 Commitment to improve 
care and value team goals 
over individual interests  
 Foundational 
understanding of health 
care quality 
 Ability to seek out & 
synthesize information on 
complex topics 
 Receptive to views of 
others 
 Excellent communicator 
 Ability to problem-solve  
in inclusive manner that 
addresses issues from 
myriad of perspectives 
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CONSUMER ENGAGEMENT NOTES  
 
Citations (pages 25-26) 
 
J. Greene and J. H. Hibbard, "Why Does Patient Activation Matter? An Examination of 
the Relationships Between Patient Activation and Health-Related Outcomes," Journal of 
General Internal Medicine, published online Nov. 30, 2011. 
 
J. H. Hibbard, J. Greene, and V. Overton, "Patients with Lower Activation Associated with 
Higher Costs; Delivery Systems Should Know Their Patients' 'Scores,'" Health Affairs, 
Feb. 2013 32(2): 216–22. http://content.healthaffairs.org/content/current 
 
K. Carman, P. Dardess, M. Maurer, S. Sofaer, K. Christine Bechtel, and J. Sweeney, 
“Patient And Family Engagement: A Framework For Understanding The Elements And 
Developing Interventions And Policies”, Health Affairs, February 2013 32:223-231. 
http://content.healthaffairs.org/content/current 
 
R. Osborn and D. Squires, “International Perspectives on Patient Engagement: Results 
from the 2011 Commonwealth Fund Survey,” Journal of Ambulatory Care Management, 
April/June 2012 35(2):118–28.  
 
“Defining Consumer Representation” Aligning Forces For Quality National Program 
Office.  http://forces4quality.org/search/apachesolr_search/Definng consumer 
representation?filters= 
 
“Flattening the Trajectory of Health Care Spending: Engage and Empower Consumers” 
Rand Corporation. http://www.rand.org/pubs/research_briefs/RB9690z3/index1.html 
 
“1 in 3 patients harmed during hospital stay”. AMEDNEWS.COM 
http://www.ama-assn.org/amednews/2011/04/18/prl20418.htm  
 
Definitions 
 
Consumer engagement:  
Consumer engagement is defined by the actions individuals take to obtain the greatest 
benefit from the health care goods and services available to them.   
http://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CDUQFj
AA&url=http%3A%2F%2Fwww.carecontinuumalliance.org%2Ftheforum11%2FPresentati
ons%2FConsumer_Engagement_Across_the_Health_Care_Spectrum.pdf&ei=ydkaUZm-
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M5Kc8gTw4oDYDw&usg=AFQjCNFUqojl3Q 
 
Healthcare consumer  
Actual or potential recipient and/or purchaser of health related goods and services 
such as a patient in a hospital, member of a health insurance plan, client of a 
behavioral health therapist, person receiving community support services from a 
social worker, etc. 
 
Healthcare Consumer - Patient stakeholder Representative   
Individuals who act, in a mission-oriented manner, to further the interests of 
patients and/or consumers, their primary emphasis being on the needs and interests 
of these patients and/or consumers. .  
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Appendix F: Legal Work Group Report 
 
LEGAL WORK GROUP (LWG) PRESENTATION TO THE L. D. 1818 (CHAPTER 109) 
WORKING GROUP  
August 16, 2012 
INTRODUCTION   
This document summarizes the work of the Legal Work Group (LWG) in response to a 
request by the LD 1818 Working Group about Protected Health Information (PHI).  
Specifically, the LWG was tasked with helping inform the Working Group on one of the 
four issues included in LD 1818:     
 
 
 
 
 
 
 
 
This document is divided into five sections:  I. Background; II. Organization of 
Presentation; III. Hierarchy of Laws; IV. Current Federal and State Laws and Rules; and V. 
Conclusion.     
 
I. Background 
 
Among other provisions, the 2009 HITECH Act created three initiatives:  1) The 
establishment of the federal Office of the National Coordinator for HIT; 2) The Medicare 
HIT Meaningful Use (operated and governed by CMS); and 3) The Medicaid Meaningful 
use Program (governed at the State Medicaid level with 100% federal funds for MU 
payments and 90% federal funds for State administration of the program).     
The ONC required States that wanted to participate in the ONC initiatives, to establish 
an Office of the State Coordinator for HIT to oversee state HIT activities.  In addition to 
the OSC, the ONC signed contracts with an entity within each state and provided 
funding to establish and operate a Regional Extension Center (REC).  The RECs sign-up 
hospitals, and up to 1,000 primary health care professionals and entities, to implement 
an electronic health record ( E H R) and participate in a health information exchange 
(HIE).  In Maine, the ONC contract is with HealthInfoNet that established Maine’s REC. 
HIN also used its exchange which had already been established as part of a pilot 
program in the mid-2000s as the HIE.   
 
3. Considering federal and state privacy and security 
laws regarding the use and release of protected 
health information, including policy and technical 
changes needed to allow increased access to 
protected health information and the feasibility of 
those changes; 
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In 2010, the OSC was established by Executive Order (EO), which also named HIN’s HIE 
the “HIE” under the ONC initiative.   The OSC is now housed in DHHS.  It is advised by a 
HIT Steering Committee (HITSC), an approximately 17 member Committee of 
stakeholders established in EO.  The HITSC first established the Legal Work Group (LWG) 
in 2010 to help inform them on privacy issues. The LWG was again reconvened in 2012 
for two purposes, one of which falls under the purview of the 1818 group--To help 
inform the 1818 Group on the question about Increasing Access to PHI.  (The second 
purpose is to draft definitions and roles and responsibilities of a State Designated HIE 
which will be submitted for HITSC for discussion and a report to the OSC).  The LWG has 
approximately 12 members, comprised of lawyers and other professionals from the 
State, healthcare organizations, consumers, and others.     
 
With this background in mind, the LWG is making its initial report to the 1818 Working 
Group.  Many LWG members believed it was important to state that they view the 
scope of the LWG as providing a factual review of the current federal and state laws and 
rules governing PHI.  Then, if the 1818 Working Group desired to have specific scenarios 
examined, the LWG would provide a legal analysis of the specific scenarios.  In that 
respect, the LWG would not make what might be termed “subjective 
recommendations.” Rather, its analysis would be “objective and factual” in nature.   
 
It is a challenge to inventory, analyze and report on laws and rules that govern PHI. They 
have been developed in a piecemeal fashion, and terms and definitions vary by law and 
rule and even in conversation.  For example, some laws may use the term disclose while 
others use release or use.  For these reasons, the documents being presented are an 
attempt to provide in the least complex way, a very complex subject.    
 
II. Organization of Presentation   
 
This presentation consists of several documents, including this summary document, 
definitions document, and several graphics and spreadsheets.   
Since this presentation revolves around "protected health information” (PHI) it is useful 
to define that term. The term PHI is from HIPAA requirements to protect all "individually 
identifiable health information"  which is demographic data that relates to:  
 
 The individual’s past, present or future physical or mental health or condition;  
 The provision of health care to the individual, or  the past, present, or future 
payment for the provision of health care to the individual; and  
 That identifies the individual or for which there is a reasonable basis to believe 
can be used to identify the individual. 
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Individually identifiable health information includes many common identifiers (e.g., 
name, address, birth date, Social Security Number).  
 
1. Graphic and Detailed Grids (Spreadsheets). The graphic and spreadsheets 
are grouped into four categories of PHI:  General Health (termed non-
sensitive PHI); and Mental Health, Substance and Alcohol Abuse, and HIV 
(these three are termed sensitive PHI).  The reason the LWG chose these 
categories is because for the most part, federal and state laws and rules treat 
PHI differently based on which one of these categories the PHI falls under. 
Then, the four categories of PHI are further delineated by the category of 
use:  Informed Consent, Treatment, Payment and Operations (TPO); Public 
health; Fundraising; Research; and Marketing, because federal and state laws 
and rules treat PHI differently based on use.   
 
2. Inverted Pyramids -- This is a very high level graphic that displays each of 
the four categories of information (columns) and the six basic uses of 
information (rows). “Allowed” disclosure of PHI is at the top of the inverted 
pyramid, moving down to the “restricted” disclosure and finally the bottom 
of the pyramid which is “prohibited” without patient consent.  (Note:  This 
document is intended as the general rule.  It does not depict the exceptions 
to the general rule.)  
 
3. Detailed Grid – This spreadsheet builds on the inverted pyramid 
document.  The spreadsheet has two tabs:   1) Detailed (General Health, SA, 
and HIE) and MHDO and HIN/HIE; and 2) Detailed_MH (Shown under 
separate tab because Maine law differentiates between MH agencies and 
professionals who may provide MH services as part of their practices).  
 
For each of the four pyramids, it “drills down” to show the federal and the State laws 
and rules that govern each categories of information (General Health, Mental Health, 
Substance and Alcohol Abuse, and HIV), and within the category, the laws governing 
each of the six types of information.  It provides a brief summary of the applicability and 
a cite to the law.   In addition, there is a column that is color coded to show “allowed” 
disclosure as green; “restricted disclosure” as yellow; and “prohibited without consent” 
as red. (Note:  The color coding is intended to show the general rule.  There are likely 
exceptions to the rule.)  
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III. Hierarchy of Laws 
 
         
 
This diagram shows the hierarchy of law.   Generally speaking, federal statutes (laws 
passed by Congress) and federal rules (Federal Agencies, under the authority of their 
federal statutes, make rules which generally apply across the board to all states), trump 
state statutes (laws passed by state Legislature) and state rules (state agencies, under 
the authority of their state statutes, make rules which generally apply across the board 
to all citizens/entities within their state).   That is, if a federal rule contradicts a federal 
law, the law supersedes the rule.  If a state law contradicts a federal law or federal rule, 
the federal law/rule supersedes the state law.   If a state rule contradicts a state law (or 
a federal law/rule) the state law (or federal law/rule) supersedes the state rule.  Some 
federal laws and rules permit states to ask federal agencies for a waiver, exemption, or 
federal agency action or permission to depart from the general law or rule.  Absent that, 
it takes “an act of Congress” to change a federal law. To change a federal rule would 
require the federal agency to change the rule.  State laws must be changed by 
Legislatures; state rules must be changed by state agencies.    
 
Some federal laws/rules preempt state laws/rules altogether.  This means that states 
must follow only the federal laws/rules and cannot make their own state laws/rules.  
Some federal laws/rules permit states to layer their own state laws/rules on top of the 
federal laws/rules, as long as the state law/rule is not inconsistent. For example, let’s 
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say that a federal environmental law states that the EPA must make a rule that is 
protective of  shore land development.  The EPA makes a rule in accord with APA 
provisions, that preclude a person from building a factory within say, 50 feet of a large 
river.  The EPA law and rule allow states to provide more protection.  So a state passes a 
law that prohibits development within 75 feet.  The state law is legal because it provides 
more protection.  (A state could not pass a law that only provides a 25 foot protection.)    
Federal rules must be made according to the federal Administrative Procedures Act 
(APA), and state rules according to the Maine APA.  The APA governs the process and 
requires agencies to provide notice, allow comments, and to follow designated 
timelines.  In Maine there are two types of rules: 1) Technical which allows the agency 
head to adopt and implement the rule; and 2) Major Substantive, which allows the 
agency head to provisionally adopt the rule but requires the rule to go to the Maine 
Legislature and follow the legislative bill process where the Legislature may vote to 
adopt, modify or not-adopt the rule.   If the legislative votes to adopt the rule, the rule 
goes into effect.  If the Legislature modifies the rule, the modified rule goes into effect.  
If the Legislature votes not to adopt the rule, the rule is void.  
 
Statutes (laws) and adopted rules may be challenged in court.  Federal rules are 
generally challenged in federal court; state laws and rules challenged in state court.  
In addition to statutes and rules, agencies may make policies and practices outside the 
APA process.  These policies and practices do not have the same force of law as laws 
(statutes) passed by the Legislature or agency rules adopted under the APA.  Agencies 
may also enter into contracts (enforceable under contract law), agreements (somewhat 
similar, but sometimes less formal than contracts) and memorandums of understanding 
(more of agreed upon expectations between the parties).   The diagram above places 
these types or arrangements below that of laws and rules.      
 
Entities that are non-government (private parties), must abide by federal and state laws 
and rules.  In addition, contract and other types of laws provide supplemental legal 
parameters.     
 
IV. Current Federal and State Laws and Rules  
 
1. HIPAA 
 
HIPAA is a federal law, that is supplemented with federal rules.  It is the federal 
umbrella that governs all four categories of PHI. (General Health, Mental Health, HIV, 
SA)  Having said that it only applies to what are called “covered entities.” (health plans 
either individual or group plans that provide or pay medical care costs; health care 
clearinghouses which are entities that standardize formatting which covers billing 
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services, repricing companies, community health management information services, 
value-added networks if they perform the standardizing services; and every health care 
provider regardless of size; AND who electronically transmit data).  When PHI is used or 
disclosed to an entity that processes claims, data analysis, utilization review, and billing 
for covered entities, the entity is a "business associate" (BA) and requires a BA 
agreement (BAA) which requires the BA to comply with HIPAA.   
 
The use or release or disclosure of de-identified data is not restricted under HIPAA 
which basically only covers PHI.  If PHI is encrypted in a manner proscribed under HIPAA, 
or consists of a limited data set, or deemed de-identified by a statistician, it can be 
disclosed without consent.      
 
HIPAA allows states to enact laws and rules that provide more protection than HIPAA.  
In addition, HIPAA permits states to have what is termed “contrary” laws for limited 
purposes such as laws requiring providers to report public health types of info, or a law 
requiring health plan reporting, such as for financial audits and for management.   
Changes to HIPAA statutes require an act of Congress.     
 
2. Substance Abuse and Alcohol Abuse (Part 2)  
 
In addition to HIPAA, the federal Substance Abuse and Alcohol Abuse (SAA) laws and 
rules govern SAA PHI. The federal SAA laws and rules preempt state law and rules.  This 
means that states must follow the federal law and rules for Substance Abuse and 
Alcohol Abuse PHI.  In addition to this federal requirement, Maine has laws and rules 
that state Maine must follow the federal law and rules.  Changing the federal laws or 
rules around SA PHI would be the most difficult of any of the four categories.  State laws 
and rules would also need changing.  
 
3. Mental Health  
 
Other than HIPAA, there are few federal laws and rules on mental health PHI. (Mental 
Health providers who participate in Medicare, are subject to federal Medicare 
Communities of Practice (CoPs) governing the privacy and confidentiality of patient 
information.)  Maine does have state laws and rules, and those laws distinguish mental 
health agencies/professionals licensed by the State as MH providers from health care 
agencies/professionals who may provide MH services as part of their practices.  MH 
providers have more restrictions on MH PHI than health care providers.  Since  MH PHI 
is governed by State laws and rules, from a legal standpoint changing them would be 
easier than attempting to change federal law or rules.  Also note that Maine has had a 
series of consent decrees that would need to be considered.    
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4. HIV  
 
Other than HIPAA, there are very few federal laws and rules on HIV.  Maine state laws 
and rules govern HIV PHI, which are summarized in the HIV grid.   
 
5.  Maine Health Data Organization (MHDO) 
 
HIPAA laws do not apply because MHDO is not a covered entity nor is it a business 
associate.   Maine's Attorney General's office has advised MHDO that they are a Public 
Health Authority (PHA), a term created in HIPAA that allows providers and hospitals to 
submit PHI to the PHA.  
 
MHDO is an independent State agency which means it is not an executive department 
agency (such as Department of Transportation, Taxation, DHHS).  MHDO is governed by 
a board (consisting of representatives of public and private entities) under the auspices 
of being a comprehensive health database to improve the health of Maine people.  
MHDO has rulemaking authority, some of which are technical rules while others major 
substantive.    
 
MHDO collects data on claims and finance (per rule, claims data) and in/outpatient, and 
specific quality indicators (per rule, clinical data). By statute, MHDO, under its vendor 
Onpoint, sends algorithms to payors who run their provider's data through the 
algorithm and then submit it to Onpoint who encrypts further and then sends it to 
MHDO.  In this respect, it may be a double encryption.  
 
MHDO must make some de-identified information available to the public and post it on 
the Web.  In addition, entities may request data (in writing per MHDO rules) and 
requests are approved by Board.  Data provided may be unrestricted (receiver may 
further disclose) or restricted (no further disclosure allowed) depending on the type of 
data.  Most MHDO work is done under provider agreements governed by MHDO rules.  
 
MHDO laws and rules generally do not permit the MHDO to disclose/release PHI.  Unless 
the encryption that MHDO has performed is considered to make the data non-PHI, it is 
most likely that the MHDO law and certainly, MHDO rules would need to be changed, to 
allow the MHDO to release PHI.   
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6.  HealthInfoNet and its Health Information Exchange  
 
There are no specific federal laws on HIEs in terms of releasing PHI.  There are a few 
State laws and rules that discuss the term “State Designated HIE”  (SDHIE). Currently, by 
Executive Order, HIN’s HIE serves this capacity.   
 
HIN is currently a non-profit non-governmental entity governed by a Board of Directors. 
It primarily deals in clinical data, and while neither HIN nor its HIE are covered entities, 
they are considered a Business Associate under HIPAA and enter into BAAs with covered 
entities.  From a practical standpoint, HIN and its HIE are affected by HIPAA law.  They 
also fall under General Health, Mental Health, Substance Abuse and HIV laws and rules.  
 
Since HIN and its HIE are neither federal nor state agencies, they do not have 
rulemaking authority nor governmental enforcement authority.  They have a practice of 
negotiating  private agreements with providers that govern the exchange and release of 
PHI.  
 
A State law enacted in 2011 (arising from work performed by the LWG), allows the 
exchange of PHI data as long as the HIE has an opt-out for general health information 
and an opt-in for sensitive health information (MH, SAA, and HIV).  HIN’s HIE follows this 
opt-out and opt-in practice.     
 
V. Conclusion  
 
The LWG appreciates the opportunity to provide this legal review of PHI laws and rules.  
Should the LD 1818 Working Group decide to consider different scenarios, the LWG is 
prepared to provide further review and reporting on changes that would be required 
based on the scenarios presented.   
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DEFINITIONS AND GLOSSARY OF TERMS 
For LWG Presentation to LD 1818 Working Group 
August 16, 2012 
 
1.  HIPAA definitions: 
Business associate: (1) Except as provided in paragraph (2) of this definition, business 
associate means, with respect to a covered entity, a person who: 
(i) On behalf of such covered entity or of an organized health care arrangement (as defined in 
§164.501 of this subchapter) in which the covered entity participates, but other than in the 
capacity of a member of the workforce of such covered entity or arrangement, performs, or 
assists in the performance of: 
(A) A function or activity involving the use or disclosure of individually identifiable health 
information, including claims processing or administration, data analysis, processing or 
administration, utilization review, quality assurance, billing, benefit management, practice 
management, and repricing; or 
(B) Any other function or activity regulated by this subchapter; or 
(ii) Provides, other than in the capacity of a member of the workforce of such covered entity, 
legal, actuarial, accounting, consulting, data aggregation (as defined in §164.501 of this 
subchapter), management, administrative, accreditation, or financial services to or for such 
covered entity, or to or for an organized health care arrangement in which the covered entity 
participates, where the provision of the service involves the disclosure of individually 
identifiable health information from such covered entity or arrangement, or from another 
business associate of such covered entity or arrangement, to the person. 
(2) A covered entity participating in an organized health care arrangement that performs a 
function or activity as described by paragraph (1)(i) of this definition for or on behalf of such 
organized health care arrangement, or that provides a service as described in paragraph (1)(ii) of 
this definition to or for such organized health care arrangement, does not, simply through the 
performance of such function or activity or the provision of such service, become a business 
associate of other covered entities participating in such organized health care arrangement. 
(3) A covered entity may be a business associate of another covered entity. § 160.103 
Direct treatment relationship means a treatment relationship between an individual and a 
health care provider that is not an indirect treatment relationship. § 164.501 
Disclosure means the release, transfer, provision of, access to, or divulging in any other manner 
of information outside the entity holding the information. § 160.103 
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De-identified health information is health information that does not identify an individual and 
with respect to which there is no reasonable basis to believe that the information can be used to 
identify an individual. Information can be de-identified using statistical methods (45 C.F.R. 
§ 164.514(b)(1) or by removing specific information set in the HIPAA rules (45 C.F.R. 
§ 164.514(b)(2). 
Health care operations means any of the following activities of the covered entity to the extent 
that the activities are related to covered functions: 
(1) Conducting quality assessment and improvement activities, including outcomes evaluation 
and development of clinical guidelines, provided that the obtaining of generalizable knowledge 
is not the primary purpose of any studies resulting from such activities; population-based 
activities relating to improving health or reducing health care costs, protocol development, case 
management and care coordination, contacting of health care providers and patients with 
information about treatment alternatives; and related functions that do not include treatment; 
(2) Reviewing the competence or qualifications of health care professionals, evaluating 
practitioner and provider performance, health plan performance, conducting training programs 
in which students, trainees, or practitioners in areas of health care learn under supervision to 
practice or improve their skills as health care providers, training of non-health care 
professionals, accreditation, certification, licensing, or credentialing activities; 
(3) Underwriting, premium rating, and other activities relating to the creation, renewal or 
replacement of a contract of health insurance or health benefits, and ceding, securing, or 
placing a contract for reinsurance of risk relating to claims for health care (including stop-loss 
insurance and excess of loss insurance), provided that the requirements of §164.514(g) are met, 
if applicable; 
(4) Conducting or arranging for medical review, legal services, and auditing functions, including 
fraud and abuse detection and compliance programs; 
(5) Business planning and development, such as conducting cost-management and planning-
related analyses related to managing and operating the entity, including formulary development 
and administration, development or improvement of methods of payment or coverage policies; 
and 
(6) Business management and general administrative activities of the entity, including, but not 
limited to: 
(i) Management activities relating to implementation of and compliance with the requirements 
of this subchapter; 
(ii) Customer service, including the provision of data analyses for policy holders, plan sponsors, 
or other customers, provided that protected health information is not disclosed to such policy 
holder, plan sponsor, or customer. 
(iii) Resolution of internal grievances; 
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(iv) The sale, transfer, merger, or consolidation of all or part of the covered entity with another 
covered entity, or an entity that following such activity will become a covered entity and due 
diligence related to such activity; and 
(v) Consistent with the applicable requirements of §164.514, creating de-identified health 
information or a limited data set, and fundraising for the benefit of the covered entity. 
§ 164.501 
Health plan means an individual or group plan that provides, or pays the cost of, medical care 
(as defined in section 2791(a)(2) of the PHS Act, 42 U.S.C. 300gg–91(a)(2)). 
(1) Health plan includes the following, singly or in combination: 
(i) A group health plan, as defined in this section. 
(ii) A health insurance issuer, as defined in this section. 
(iii) An HMO, as defined in this section. 
(iv) Part A or Part B of the Medicare program under title XVIII of the Act. 
(v) The Medicaid program under title XIX of the Act, 42 U.S.C. 1396, et seq. 
(vi) An issuer of a Medicare supplemental policy (as defined in section 1882(g)(1) of the Act, 42 
U.S.C. 1395ss(g)(1)). 
(vii) An issuer of a long-term care policy, excluding a nursing home fixed-indemnity policy. 
(viii) An employee welfare benefit plan or any other arrangement that is established or 
maintained for the purpose of offering or providing health benefits to the employees of two or 
more employers. 
(ix) The health care program for active military personnel under title 10 of the United States 
Code. 
(x) The veterans health care program under 38 U.S.C. chapter 17. 
(xi) The Civilian Health and Medical Program of the Uniformed Services (CHAMPUS) (as defined 
in 10 U.S.C. 1072(4)). 
(xii) The Indian Health Service program under the Indian Health Care Improvement Act, 25 U.S.C. 
1601, et seq. 
(xiii) The Federal Employees Health Benefits Program under 5 U.S.C. 8902, et seq. 
(xiv) An approved State child health plan under title XXI of the Act, providing benefits for child 
health assistance that meet the requirements of section 2103 of the Act, 42 U.S.C. 1397, et seq. 
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(xv) The Medicare+Choice program under Part C of title XVIII of the Act, 42 U.S.C. 1395w–21 
through 1395w–28. 
(xvi) A high risk pool that is a mechanism established under State law to provide health 
insurance coverage or comparable coverage to eligible individuals. 
(xvii) Any other individual or group plan, or combination of individual or group plans, that 
provides or pays for the cost of medical care (as defined in section 2791(a)(2) of the PHS Act, 42 
U.S.C. 300gg–91(a)(2)). 
(2) Health plan excludes: 
(i) Any policy, plan, or program to the extent that it provides, or pays for the cost of, excepted 
benefits that are listed in section 2791(c)(1) of the PHS Act, 42 U.S.C. 300gg–91(c)(1); and 
(ii) A government-funded program (other than one listed in paragraph (1)(i)–(xvi) of this 
definition): 
(A) Whose principal purpose is other than providing, or paying the cost of, health care; or 
(B) Whose principal activity is: 
(1) The direct provision of health care to persons; or 
(2) The making of grants to fund the direct provision of health care to persons. § 160.103 
Indirect treatment relationship means a relationship between an individual and a health care 
provider in which: 
(1) The health care provider delivers health care to the individual based on the orders of another 
health care provider; and 
(2) The health care provider typically provides services or products, or reports the diagnosis or 
results associated with the health care, directly to another health care provider, who provides 
the services or products or reports to the individual. § 164.501 
Marketing means: 
(1) To make a communication about a product or service that encourages recipients of the 
communication to purchase or use the product or service, unless the communication is made: 
(i) To describe a health-related product or service (or payment for such product or service) that 
is provided by, or included in a plan of benefits of, the covered entity making the 
communication, including communications about: the entities participating in a health care 
provider network or health plan network; replacement of, or enhancements to, a health plan; 
and health-related products or services available only to a health plan enrollee that add value 
to, but are not part of, a plan of benefits. 
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(ii) For treatment of the individual; or 
(iii) For case management or care coordination for the individual, or to direct or recommend 
alternative treatments, therapies, health care providers, or settings of care to the individual. 
(2) An arrangement between a covered entity and any other entity whereby the covered entity 
discloses protected health information to the other entity, in exchange for direct or indirect 
remuneration, for the other entity or its affiliate to make a communication about its own 
product or service that encourages recipients of the communication to purchase or use that 
product or service. § 164.501 
Payment means: 
(1) The activities undertaken by: 
(i) A health plan to obtain premiums or to determine or fulfill its responsibility for coverage and 
provision of benefits under the health plan; or 
(ii) A health care provider or health plan to obtain or provide reimbursement for the provision of 
health care; and 
(2) The activities in paragraph (1) of this definition relate to the individual to whom health care 
is provided and include, but are not limited to: 
(i) Determinations of eligibility or coverage (including coordination of benefits or the 
determination of cost sharing amounts), and adjudication or subrogation of health benefit 
claims; 
(ii) Risk adjusting amounts due based on enrollee health status and demographic characteristics; 
(iii) Billing, claims management, collection activities, obtaining payment under a contract for 
reinsurance (including stop-loss insurance and excess of loss insurance), and related health care 
data processing; 
(iv) Review of health care services with respect to medical necessity, coverage under a health 
plan, appropriateness of care, or justification of charges; 
(v) Utilization review activities, including precertification and preauthorization of services, 
concurrent and retrospective review of services; and 
(vi) Disclosure to consumer reporting agencies of any of the following protected health 
information relating to collection of premiums or reimbursement: 
(A) Name and address; 
(B) Date of birth 
(C) Social security number; 
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(D) Payment history; 
(E) Account number; and 
(F) Name and address of the health care provider and/or health plan. 
§ 164.501 
Protected health information means individually identifiable health information: 
(1) Except as provided in paragraph (2) of this definition, that is: 
(i) Transmitted by electronic media; 
(ii) Maintained in electronic media; or 
(iii) Transmitted or maintained in any other form or medium. 
(2) Protected health information excludes individually identifiable health information in: 
(i) Education records covered by the Family Educational Rights and Privacy Act, as amended, 20 
U.S.C. 1232g; 
(ii) Records described at 20 U.S.C. 1232g(a)(4)(B)(iv); and 
(iii) Employment records held by a covered entity in its role as employer. 
§ 160.103 
Public health authority means an agency or authority of the United States, a State, a territory, a 
political subdivision of a State or territory, or an Indian tribe, or a person or entity acting under a 
grant of authority from or contract with such public agency, including the employees or agents 
of such public agency or its contractors or persons or entities to whom it has granted authority, 
that is responsible for public health matters as part of its official mandate. § 164.501 
Required by law means a mandate contained in law that compels an entity to make a use or 
disclosure of protected health information and that is enforceable in a court of law.Required by 
law includes, but is not limited to, court orders and court-ordered warrants; subpoenas or 
summons issued by a court, grand jury, a governmental or tribal inspector general, or an 
administrative body authorized to require the production of information; a civil or an authorized 
investigative demand; Medicare conditions of participation with respect to health care providers 
participating in the program; and statutes or regulations that require the production of 
information, including statutes or regulations that require such information if payment is sought 
under a government program providing public benefits. § 164.501 
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Research means a systematic investigation, including research development, testing, and 
evaluation, designed to develop or contribute to generalizable knowledge. § 164.501 
Treatment means the provision, coordination, or management of health care and related 
services by one or more health care providers, including the coordination or management of 
health care by a health care provider with a third party; consultation between health care 
providers relating to a patient; or the referral of a patient for health care from one health care 
provider to another. § 164.501 
Use means, with respect to individually identifiable health information, the sharing, 
employment, application, utilization, examination, or analysis of such information within an 
entity that maintains such information. § 160.103 
 
2. 42 CFR Part 2 definitions: 
Alcohol abuse means the use of an alcoholic beverage which impairs the physical, mental, 
emotional, or social well-being of the user. 42 C.F.R. § 2.11 
Drug abuse means the use of a psychoactive substance for other than medicinal purposes which 
impairs the physical, mental, emotional, or social well-being of the user. 42 C.F.R. § 2.11 
Disclose or disclosure means a communication of patient identifying information, the affirmative 
verification of another person's communication of patient identifying information, or the 
communication of any information from the record of a patient who has been identified. 42 
C.F.R. § 2.11 
Federal assistance. An alcohol abuse or drug abuse program is considered to be federally 
assisted if: 
(1) It is conducted in whole or in part, whether directly or by contract or otherwise by any 
department or agency of the United States (but see paragraphs (c)(1) and (c)(2) of this section 
relating to the Veterans' Administration and the Armed Forces); 
(2) It is being carried out under a license, certification, registration, or other authorization 
granted by any department or agency of the United States including but not limited to: 
(i) Certification of provider status under the Medicare program; 
(ii) Authorization to conduct methadone maintenance treatment (see 21 CFR 291.505); or 
(iii) Registration to dispense a substance under the Controlled Substances Act to the extent the 
controlled substance is used in the treatment of alcohol or drug abuse; 
(3) It is supported by funds provided by any department or agency of the United States by being: 
(i) A recipient of Federal financial assistance in any form, including financial assistance which 
does not directly pay for the alcohol or drug abuse diagnosis, treatment, or referral activities; or 
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(ii) Conducted by a State or local government unit which, through general or special revenue 
sharing or other forms of assistance, receives Federal funds which could be (but are not 
necessarily) spent for the alcohol or drug abuse program; or 
(4) It is assisted by the Internal Revenue Service of the Department of the Treasury through the 
allowance of income tax deductions for contributions to the program or through the granting of 
tax exempt status to the program. 42 C.F.R. § 2.12(a) 
Patient identifying information means the name, address, social security number, fingerprints, 
photograph, or similar information by which the identity of a patient can be determined with 
reasonable accuracy and speed either directly or by reference to other publicly available 
information. The term does not include a number assigned to a patient by a program, if that 
number does not consist of, or contain numbers (such as a social security, or driver's license 
number) which could be used to identify a patient with reasonable accuracy and speed from 
sources external to the program. 42 C.F.R. § 2.11 
Program director means: 
 
(a) In the case of a program which is an individual, that individual: 
 
(b) In the case of a program which is an organization, the individual designated as director, 
managing director, or otherwise vested with authority to act as chief executive of the 
organization. 42 C.F.R. § 2.11 
Records means any information, whether recorded or not, relating to a patient received or 
acquired by a federally assisted alcohol or drug program. 42 C.F.R. § 2.11 
Treatment means the management and care of a patient suffering from alcohol or drug abuse, a 
condition which is identified as having been caused by that abuse, or both, in order to reduce or 
eliminate the adverse effects upon the patient. 42 C.F.R. § 2.11 
 
3. 22 M.R.S. §1711-C definitions: 
Disclosure means the release, transfer of or provision of access to health care information in any 
manner obtained as a result of a professional health care relationship between the individual 
and the health care practitioner or facility to a person or entity other than the individual. 22 
M.R.S. §1711-C(1)(B). 
 
Health care information means information that directly identifies the individual and that 
relates to an individual's physical, mental or behavioral condition, personal or family medical 
history or medical treatment or the health care provided to that individual. "Health care 
information" does not include information that protects the anonymity of the individual by 
means of encryption or encoding of individual identifiers or information pertaining to or derived 
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from federally sponsored, authorized or regulated research governed by 21 Code of Federal 
Regulations, Parts 50 and 56 and 45 Code of Federal Regulations, Part 46, to the extent that 
such information is used in a manner that protects the identification of individuals. The Board of 
Directors of the Maine Health Data Organization shall adopt rules to define health care 
information that directly identifies an individual. Rules adopted pursuant to this paragraph are 
routine technical rules as defined in Title 5, chapter 375, subchapter II-A. 
"Health care information" does not include information that is created or received by a member 
of the clergy or other person using spiritual means alone for healing as provided in Title 32, 
sections 2103 and 3270. 22 M.R.S. §1711-C(1)(E). 
 
Health care practitioner means a person licensed by this State to provide or otherwise lawfully 
providing health care or a partnership or corporation made up of those persons or an officer, 
employee, agent or contractor of that person acting in the course and scope of employment, 
agency or contract related to or supportive of the provision of health care to individuals. 22 
M.R.S. §1711-C(1)(F). 
 
4. MHDO 
22 MRSASection 8702. DEFINITIONS 
 
2.  Clinical data. "Clinical data" includes but is not limited to the data required to be submitted 
by providers and payors pursuant to sections 8708 and 8711. 
4. Health care facility. "Health care facility" means a public or private, proprietary or not-for-
profit entity or institution providing health services … licensed by DHHS, but not pharmacies. 
. 
4-A. Health care practitioner. "Health care practitioner" has the meaning provided in Title 24, 
section 2502, subsection 1-A. 
 
90-590 Chap 120: release of data 
2.  Definitions:  
B.  Clinical Data. “Clinical data” mean health care claims, hospital, non-hospital health care 
facility data, quality data, and all other data as described in 22 M.R.S.A. Secs. 8708, 8708-A, and 
8711. 
 
E.  Disclosure. "Disclosure," with respect to clinical, financial, or restructuring data, means to 
communicate information to a person not already in possession of that information or to use 
information for a purpose not originally authorized. For example, to inform a person of the 
identity of a previously unnamed patient is to "disclose" clinical data not already in that person's 
possession with respect to the patient. 
 
G.  Financial Data. “Financial data” means information collected from data providers pursuant 
to Chapter 300 of the MHDO rules, Uniform Reporting System for Hospital Financial Data, that 
include, but are not limited to, costs of operation, revenues, assets, liabilities, fund balances, 
other income, rates, charges and units of services. 
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H. Health Care Claims Data. “Health care claims data” means information consisting of or 
derived directly from member eligibility, medical claims, pharmacy claims, and/or dental claims 
files submitted by health care claims processors pursuant to Chapter 243 of the MHDO’s rules, 
Uniform Reporting System for Health Care Claims Data Sets. “Health care claims data” do not 
include analysis, reports, or studies containing information from health care claims data sets, if 
those analyses, reports, or studies have already been released in response to another request 
for information or as part of a general distribution of public information 
 
J.  Health Care Facility. “Health care facility” means a public or private, proprietary or not-for-
profit entity or institution providing health services and which is licensed by State.  
 
K.  Health Care Practitioner. "Health care practitioner" means physicians and all others certified, 
registered or licensed in the healing arts, including but not limited to, nurses, podiatrists, 
optometrists, pharmacists, chiropractors, physical therapists, dentists, psychologists and 
physicians’ assistants as defined in 24 M.R.S.A., chapter 21. "Health care practitioner" also 
includes licensed clinical social workers as defined in 32 M.R.S.A., chapter 83 and marriage and 
family therapists and professional counselors as defined in 32 M.R.S.A., chapter 119. 
 
L.  Hospital Data. "Hospital data" means information consisting of or derived directly from 
hospital inpatient, outpatient, emergency department, or any other derived data sets filed or 
maintained pursuant to Chapter 241 of the MHDO’s rules, Uniform Reporting System for 
Hospital Inpatient and Hospital Outpatient Data Sets. "Hospital data" do not include analysis, 
reports, or studies containing information from hospital data sets, if those analyses, reports, or 
studies have already been released in response to another request for information or as part of 
a general distribution of public information by the MHDO. 
 
N. MHDO Records. 
 
1. "MHDO record" means any item of data stored in written, printed, graphic, or electronic 
form that is either: 
 
(b) filed with the MHDO or its designee by a data provider in accordance with a 
requirement of statute, rule or MHDO order; 
 
 (d) contained in a final MHDO report, analysis, study, data compilation, decision, 
rule, or order; 
 
2. "MHDO record" does not include any of the following: 
 
 (b) draft documents of any kind, including unsigned or incomplete memoranda, 
decisions, rules or other papers; nor 
 
(c) reports studies, analyses, or data compilations that have not yet been reviewed 
for public release pursuant to section 9 or 10. 
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 R.  Privileged Medical Information. "Privileged medical information" means information 
other than hospital, non-hospital health care facility, or health care claims data that identify 
individual patients and that are derived from communications that: 
 
1. were made for the purpose of diagnosis or treatment among a provider of 
health care, persons assisting the provider or patient, and a patient; 
 
2. were made for the purpose of payment of health care services among a 
provider of health care, a health care claims processor, and a patient; 
 
3. were not intended to be disclosed except to persons necessary to transmit or 
record the communication and persons participating in the diagnosis, treatment, or 
payment; and 
 
4. have not been previously disclosed to the general public. 
 
 U.  Release. To "release" data is to make it available for inspection and copying to 
persons other than the data provider. 
 
90-590  MAINE HEALTH DATA ORGANIZATION, Chapter 125: HEALTH CARE 
INFORMATION THAT DIRECTLY IDENTIFIES AN INDIVIDUAL 
 
C. Direct Identifier. “Direct identifier” means any information that discloses the identity of 
an individual. A case or code number used to create anonymous or encrypted medical data for 
research purposes is not a direct identifier 
 
3. Identifying Information 
 
 Data elements determined to be direct identifiers of individuals include the following: 
 
 A. Patient’s Name; 
 B. Names of Patient’s Family Members; 
 C. Insured’s Name; 
 D. Patient’s or Insured’s Address; 
 E. Patient’s or Insured’s Telephone or FAX Numbers. Includes both home  and 
work numbers; 
 F. Patient Control Number. A unique alphanumeric number assigned by a  health 
care provider to facilitate retrieval of individual financial records and posting of 
payment; 
 G. Medical Record Number. A number assigned to the patient’s medical/health 
record by the provider; 
 H. Patient’s Account Number. A unique number used by a health care provider or 
supplier to identify an individual’s case records and for posting payment; 
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 I. Patient’s or Insured’s Social Security Number; 
 J. Insured’s Unique Health Insurance Identification Number; 
 K. Insured’s Unique Health Insurance Certificate Number; 
 L. Patient’s Medicare/Medicaid Health Insurance Identification Number; 
 M. Patient’s Federal Employees Compensation Act Number; 
 N. Patient’s or Insured’s Credit Card Number; 
 O. Patient’s or Insured’s Bank Account Number; 
 P. Patient’s or Insured’s Operator’s License Number; 
 Q. Patient’s or Insured’s Vehicle Registration Number; 
 R. Patient’s or Insured’s Vehicle License Plate Number; 
 S. Patient’s or Insured’s Vehicle Identification Number; 
 T. Patient’s or Insured’s Finger or Voice Prints; 
 U. Patient’s or Insured’s Photographic Images; 
 V. Patient’s Pilot Medical Certificate Number; 
 W. Patient’s Maine Department of Corrections Inmate Identification Number; 
 X. Patient’s or Insured’s Medical Device Identifiers and Serial Numbers; and 
 Y. Any other unique number, characteristic, code or information that is a direct 
identifier. 
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Appendix G: Matrix of Laws for Protected Health Information 
 
 
MATRIX OF LAWS FOR PHI  
  GENERAL HEALTH  
CATEGORY OF INFO. 
Allowed Restricted 
Prohibited 
Federal Law Maine Law 
Applicability    
HIPAA rules include a security rule and a privacy rule for "covered 
entity (CE)."  (45 C.F.R. § 164.302);  (45 C.F.R. §§ 164.n104, 164.500).  
CE is a "health plan" (individual or group plans that provide or pay 
medical care costs), health care clearinghouse (entities that 
standardize formatting (covers billing services, repricing companies, 
community health management information services, value-added 
networks if they perform the standardizing services), and every health 
care provider regardless of size AND who electronically transmits 
data). Covered entity is permitted, but not required to use and 
disclose PHI w/o consent to 1) individual; 2) TPO; 3) Opportunity to 
agree or object; 4) incident to otherwise permitted use and disclosure; 
5) public interest and benefit activities; and 6) limited data set for 
research, public health or operations.  When PHI is used or disclosed 
to entity that processes claims, data analysis, utilization review, and 
billing, the receiving entity is a "business associate" and requires a BA 
agreement (BAA).  Expanded under ARRA/HITECH Act, to a BA with 
access to covered entity's PHI is bound by same HIPAA provisions as 
covered entity.  (42 U.S.C. §17931(a)) Generally, whenever using, 
disclosing, or requesting PHI, a covered entity must make reasonable 
efforts to limit PHI to the minimum necessary to accomplish the 
intended use. (45 C.F.R. §164.502(b).  
Health Care Facilities (22 M.R.S. §1711-
C(1)(D)); Health Care Practitioners (22 
M.R.S. §1711-C(1)(F).   Note:  Maine's 
Privacy laws were written before 
federal privacy laws. Terms such as use 
or disclosure and release add ambiguity 
when trying to compare federal and 
state law.                                                                                                                                                
HIPAA law preempts state law, but 
allows states to have laws that provide 
more protection or laws that are 
termed "contrary" such as laws 
requiring  provider to report public 
health types of info, or a law requiring 
health plans to report info for financial 
audits and for management.   
Treatment, Payment, 
Operations  
A 
Entity with PHI can disclose to a receiving entity with a direct 
treatment relationship to patient; an entity with a direct treatment 
relationship can use PHI for treatment, payment, and operations 
purposes. (HIPAA / 45 CFR 164.502(a)(1)(ii)). 
Health Care Facilities and Health Care 
Practitioners can disclose PHI to 
another Health Care Facility or 
Practitioner for diagnosis, treatment, or 
care of individuals (22 M.R.S.A. §1711-
C(6)(A)); can disclose for payment (22 
M.R.S.A. §1711-C(6)(L). 
Public Health R 
Can disclose minimum amount of PHI necessary to Public Health 
Authority authorized by law to collect PHI for the purpose of 
preventing or controlling disease, injury, disability (HIPAA / 45 CFR 
164.512(b)(1)(i)); can rely on PHA's finding of minimum amount 
necessary (45 CFR 164.514(d)(3)(iii) (A)); no patient authorization is 
needed.  
Can be disclosed to gov't in order to 
protect the public health and welfare 
when reporting is required or 
authorized by law (22 M.R.S. §1711-
C(6)(E)) 
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Research R 
Can disclose with IRB approval (45 CFR 164.512(i)(1)(i)) to prepare for 
research if PHI is not removed from covered entity (45 CFR 
164.512(i)(1)(ii));  Limited data sets may be disclosed under data use 
agreements (45 CFR 164.514(e)). 
Can disclose PHI to IRB-approved 
researchers, FDA clinical trials without 
patient authorization; researchers may 
not redisclose identifiable PHI (22 
M.R.S. §1711-C(6)(G). Other research 
requires patient authorization (22 
M.R.S. §1711-C(3),(3-A), (3-B)); max 
duration of authorization: 30 months 
Fundraising R 
45 CFR 164.501(6)(v) includes fundraising for benefit of covered entity 
as "operations" use; disclosure of demographic info & dates of care is 
allowed to BA or institutionally related foundation for fundraising 
purposes (45 CFR §164.514(f)). 
Law does not expressly address; 
therefore disclosure to persons other 
than patient for fundraising is 
prohibited; practitioners interpreted 
law to allow internal use for fundraising 
and for provider entities to directly 
solicit donations from patients but not 
from other persons; LWG opinion is 
that internal fundraising use doesn't 
constitute a disclosure. 
Marketing P 
Covered entities can't use PHI for marketing without patient 
authorization (45 CFR 164.501, 508(a)3  
Requires patient authorization (22 
M.R.S. §1711-C(8)) 
SUBSTANCE ABUSE  (Providers receiving federal assistance) 
CATEGORY OF 
INFORMATION  
A, R, P Federal Law Maine Law 
Applicability    
In addition to HIPAA, SA laws apply only to drug or alcohol abuse 
(DAA) info obtained by "federally assisted" DAA  for 
diagnosis/treating/making referral DAA. 42 C.F.R. § 2.12(a)(ii); 
Federally assisted means:  (1) conducted in whole or in part, directly 
or by contract or otherwise, by any dept/agency of US; (2) carried out 
under a license, certification, registration, or other authorization  
under Medicare; (3) methadone treatment;  (4) dispense a controlled 
substance for DAA; (5) supported by US agency  (i) by federal financial 
assistance not used directly pay for SAA diagnosis, treatment, or 
referral activities; or (ii) by State/local gov through general or special 
revenue sharing or other forms of assistance, receives Federal funds 
which could be (but are not necessarily) spent for the alcohol or drug 
abuse program; or (iii.) IRS allowing income tax deductions for 
contributions/ tax exempt status .  42 C.F.R. § 2.12(b) 
Federal law governs (22 M.R.S.A. 1711-
C(11)), but State licensing rules also 
apply; 14-118 CMR Chap 5, Section 
15.2.2 and 18.4 (SA licensing rules)  
Treatment, Payment, 
Operations  
R 
Only with patient consent (allowed: § 2.33; specific form of consent 
required: § 2.31) or for medical emergencies (42 CFR § 2.51) 
22 M.R.S.A. §1711-C(11) states if there 
is another law, that law governs.  So 
federal rule controls.  
Public Health R 
Disclosure and use are allowed for gov't audit & evaluation of the 
program (42 C.F.R. § 2.53(a)); Auditors can disclose only that PHI 
necessary for audit or evaluation purposes (42 C.F.R. § 2.53(c)(4)). 
22 M.R.S.A. §1711-C(11) states if there 
is another law, that law governs.  So 
federal rule controls.  
Research R 
Allowed if "required determination" (complex and lengthy process) is 
made under 42 C.F.R. § 2.52 by the substance abuse program director.  
Researchers may only disclose PHI back to program where PHI 
originated (42 C.F.R. § 2.52(b)).  
22 M.R.S.A. §1711-C(11) states if there 
is another law, that law governs.  So 
federal rule controls.  
Fundraising P 
Rules are silent, given that  intent of law is to prohibit use & disclosure 
except when specified (42 C.F.R. § 2.3(b)); LWG opinion is that 
fundraising use or disclosure would require patient consent.  
22 M.R.S.A. §1711-C(11) states if there 
is another law, that law governs.  So 
federal rule controls.  
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Marketing P 
Prohibited without patient authorization (42 U.S.C. §290ee-3, 42 
U.S.C. §290dd-3; 42 C.F.R. Part 2)). 
22 M.R.S.A. §1711-C(11) states if there 
is another law, that law governs.  So 
federal rule controls.  
HIV  
CATEGORY OF 
INFORMATION  
A, R, P Federal Law Maine Law 
Applicability    
There is no specific federal HIV law. HIPAA rules for General Health 
apply.  
Applies to any person or entity with HIV 
PHI (5 M.R.S. §19203) 
Treatment, Payment, 
Operations  
R 
Entity with PHI can disclose to a receiving entity with a direct 
treatment relationship to patient; an entity with a direct treatment 
relationship can use PHI for treatment, payment, and operations 
purposes. (HIPAA / 45 CFR 164.502(a)(1)(ii)). 
HIV test results can only be disclosed to 
entities designated by patient (5 M.R.S. 
§19203); health care providers may not 
disclose HIV PHI without patient 
authorization (statute 5 M.R.S. §19203-
D(1)); doesn't preclude disclosure of 
other PHI (5 M.R.S. §19203-D(1)(B)).  
(Note:  There are a few exceptions that 
permit disclosure in very limited 
situations)  
Public Health R 
Can disclose minimum amount of PHI necessary to Public Health 
Authority authorized by law to collect PHI for the purpose of 
preventing or controlling disease, injury, disability (HIPAA / 45 CFR 
164.512(b)(1)(i)); can rely on PHA's finding of minimum amount 
necessary (45 CFR 164.514(d)(3)(iii) (A)); no patient authorization is 
needed.  
Notifiable diseases, which includes HIV, 
must be reported to DHHS  (statute 22 
M.R.S.A §822); and DHHS rule 10-144 
C.M.R. Chapter 258(2)(I)) and some 
very limited exceptions that would 
permit disclosure such as abuse, organ 
& tissue donation, etc.  
Research R 
Can disclose with IRB approval (45 CFR 164.512(i)(1)(i)) to prepare for 
research if PHI is not removed from covered entity (45 CFR 
164.512(i)(1)(ii));  Limited data sets may be disclosed under data use 
agreements (45 CFR 164.514(e)). 
Can disclose to researchers; researchers 
can't subsequently disclose (statute 5 
M.R.S.A.  §19203-D(3);  
Fundraising R 
45 CFR 164.501(6)(v) includes fundraising for benefit of covered entity 
as "operations" use; disclosure of demographic info & dates of care is 
allowed to BA or institutionally related foundation for fundraising 
purposes (45 CFR §164.514(f)). 
5 M.R.S. §§ 19203 - 19203-D prohibit 
fundraising use & disclosure without 
patient authorization. 
Marketing P 
Covered entities can't use PHI for marketing without patient 
authorization (45 CFR 164.501, 164.508(a)(3)). 
Prohibited without patient 
authorization (Statute 5 M.R.S. §19203; 
5 M.R.S.A. § 19203-D)  
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  MHDO  
CATEGORY OF 
INFORMATION  
A, R, P  Federal Law  State Law  
Applicability    
HIPAA laws do not apply because MHDO is not a covered entity.   
Maine's Attorney General's office has advised MHDO that they are a 
Public Health Authority, a term created in HIPAA that allows providers 
and hospitals to submit PHI  to the PHA. (45 CFR 164.512(b) and 
160.103).     
MHDO is independent State agency (22 
M.R.S. §8707(3))  governed by board; 
has rulemaking authority; most MHDO 
work done under provider agreements 
governed by MHDO rules. (90-590 CMR 
Chapter 120, §9 (D)).  General notion is 
comprehensive health database to 
improve health of Maine people.  
Collects data on claims and  finance 
(per rule, claims data) and 
in/outpatient, and specific quality 
indicators (per rule, clinical data). By 
statute, MHDO, under its vendor 
Onpoint, sends algorithm to payors 
who run their provider's data through 
algorithm and submit to Onpoint who 
encrypts further and sends to MHDO. 
(Rule, Chapter 243)  In effect, double 
encryption. Must make info available to 
the public.  In addition, entities must 
request data in writing per MHDO rules, 
and requests are approved by Board.  
Data provided may be unrestricted 
(receiver may further disclose) or 
restricted (no further disclosure 
allowed) depending on the type of data.   
Treatment, Payment, 
Operations  
    
Under Public Access (22 M.R.S.A.) Board 
must release information upon request 
and on web (quality measures) except 
privileged medical information and 
confidential information which can only 
be released if individual patients are 
not directly or indirectly identified 
through a reidentification process; 
additional protective protocols apply.   
Public Health     
There is an exception to the 
confidentiality law for Public Health 
Studies (including research) or when 
data is used only for verification  or 
comparison of health data and Board 
finds that adequate protections  exist.   
Research     
There is an exception to the 
confidentiality law for Public Health 
Studies (including research) or when 
data is used only for verification  or 
comparison of health data and Board 
finds that adequate protections  exist.   
Fundraising     Not allowed  
Marketing     Not allowed  
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  HIN's HIE   
  A, R, P  Federal Law  State Law  
CATEGORY OF 
INFORMATION  
      
Applicability    
No specific federal law on HIEs.  HIN / HIE is not a covered entity--it is 
a Business Associate under HIPAA and enters into BAAs, so from 
practical standpoint, is affected by HIPAA law.    
SDHIE created by Executive Order.  
Confidentiality Statute covers SDHIE 
even though SDHIE not defined in law. 
(22 §1711-C.) No rulemaking authority. 
Practice is private agreements with 
providers govern exchange/release.  
Treatment, Payment, 
Operations  
    
May disclose w/o authorization if HIE 
has opt-out for general health 
information (HIE does have opt-out); 
based on this opt-out, may disclose for 
quality assurance, utilization review,  
billing and collection, regulatory or 
licensing authority; For MH and SA, HIE 
is opt-in.  Only patients who opt-in for 
MH have their MH PHI disclosed. 
Currently, even if patient has opt-in for 
SA, HIN blocks SA PHI. 
Public Health     
May disclose to protect the public 
health and welfare when required or 
authorized by law 
Research     
By practice, they do not disclose for 
research  
Fundraising     
By practice, they do not disclose for 
fundraising.  
Marketing     
By practice, they do not disclose for 
marketing  
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Appendix H.  MHDO State Statute on public access to data  
Title 22 M.R.S. §8707. PUBLIC ACCESS TO DATA 
 
The board shall adopt rules to provide for public access to data and to implement the requirements 
of this section. [1995, c. 653, Pt. A, §2 (NEW);  1995, c. 653, Pt. A, §7 (AFF).] 
1. Public access; confidentiality.  The board shall adopt rules making available to any person, upon 
request, information, except privileged medical information and confidential information, provided to the 
organization under this chapter as long as individual patients are not directly or indirectly identified 
through a reidentification process. The board shall adopt rules to protect the identity of certain health 
care practitioners, as it determines appropriate, except that the identity of practitioners performing 
abortions as defined in section 1596 must be designated as confidential and must be protected. Rules 
adopted pursuant to this subsection are major substantive rules as defined in Title 5, chapter 375, 
subchapter II-A. 
[ 2001, c. 457, §14 (AMD) .] 
2. Notice and comment period.  The rules must establish criteria for determining whether 
information is confidential clinical data, confidential financial data or privileged medical information and 
adopt procedures to give affected health care providers and payors notice and opportunity to comment in 
response to requests for information that may be considered confidential or privileged. 
[ 2003, c. 469, Pt. C, §27 (AMD) .] 
3. Public health studies.  The rules may allow exceptions to the confidentiality requirements only to 
the extent authorized in this subsection. 
A. The board may approve access to identifying information for patients to the department and other 
researchers with established protocols that have been approved by the board for safeguarding 
confidential or privileged information. [2001, c. 457, §15 (AMD).] 
B. The rules must ensure that: 
(1) Identifying information is used only to gain access to medical records and other medical 
information pertaining to public health; 
(2) Medical information about any patient identified by name is not obtained without the 
consent of that patient except when the information sought pertains only to verification or 
comparison of health data and the board finds that confidentiality can be adequately protected 
without patient consent; 
(3) Those persons conducting the research or investigation do not disclose medical information 
about any patient identified by name to any other person without that patient's consent; 
(4) Those persons gaining access to medical information about an identified patient use that 
information to the minimum extent necessary to accomplish the purposes of the research for 
which approval was granted; and 
(5) The protocol for any research is designed to preserve the confidentiality of all health care 
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information that can be associated with identified patients, to specify the manner in which 
contact is made with patients and to maintain public confidence in the protection of 
confidential information. [2001, c. 457, §15 (AMD).] 
C. The board may not grant approval under this subsection if the board finds that the proposed 
identification of or contact with patients would violate any state or federal law or diminish the 
confidentiality of health care information or the public's confidence in the protection of that 
information in a manner that outweighs the expected benefit to the public of the proposed 
investigation. [2001, c. 457, §15 (AMD).] 
[ 2001, c. 457, §15 (AMD) .] 
4. Certain confidential information.  The board may determine financial data submitted to the 
organization under section 8709 to be confidential information if the public disclosure of the data will 
directly result in the provider of the data being placed in a competitive economic disadvantage. This 
section may not be construed to relieve the provider of the data of the requirement to disclose such 
information to the organization in accordance with this chapter and rules adopted by the board. 
[ 2011, c. 524, §4 (AMD) .] 
5. Rules for release, publication and use of data.  The rules must govern the release, publication and 
use of analyses, reports or compilations derived from the health data made available by the organization. 
[ 1995, c. 653, Pt. A, §2 (NEW);  1995, c. 653, Pt. A, §7 (AFF) .] 
SECTION HISTORY 
1995, c. 653, §A2 (NEW).  1995, c. 653, §A7 (AFF).  1999, c. 353, §§12,13 (AMD).  2001, c. 457, §§14,15 
(AMD).  2003, c. 469, §C27 (AMD).  2007, c. 466, Pt. A, §44 (AMD).  2011, c. 524, §4 (AMD). 
22 §8708. CLINICAL DATA 
 
Clinical data must be filed, stored and managed as follows. [1995, c. 653, Pt. A, §2 (NEW);  1995, c. 
653, Pt. A, §7 (AFF).] 
1. Information required.  Pursuant to rules adopted by the board for form, medium, content and 
time for filing, each health care facility shall file with the organization the following information: 
A.  [1999, c. 353, §14 (RP).] 
B. A completed uniform hospital discharge data set, or comparable information, for each patient 
discharged from the facility after June 30, 1983 and for each hospital outpatient service occurring 
after June 30, 1996; and [1999, c. 353, §14 (AMD).] 
C. In addition to any other requirements applicable to specific categories of health care facilities, the 
organization may require the filing of data as set forth in this chapter or in rules adopted pursuant to 
this chapter. [1999, c. 353, §14 (AMD).] 
[ 1999, c. 353, §14 (AMD) .] 
2. Additional information on ambulatory services and surgery.  Pursuant to rules adopted by the 
board for form, medium, content and time for filing, each provider shall file with the organization a 
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completed data set, comparable to data filed by health care facilities under subsection 1, paragraph B. 
This subsection may not be construed to require duplication of information required to be filed under 
subsection 1. 
[ 2001, c. 457, §16 (AMD) .] 
3. More than one licensed health care facility or location.  When more than one licensed health care 
facility is operated by the reporting organization, the information required by this chapter must be 
reported for each health care facility separately. When a provider of health care operates in more than 
one location, the organization may require that information be reported separately for each location. 
[ 1995, c. 653, Pt. A, §2 (NEW);  1995, c. 653, Pt. A, §7 (AFF) .] 
4. Data lists.  
[ 2001, c. 457, §17 (RP) .] 
5. Medical record abstract data.  In addition to the information required to be filed under 
subsections 1 and 2 and pursuant to rules adopted by the organization for form, medium, content and 
time of filing, each health care facility shall file with the organization such medical record abstract data as 
the organization may require. 
[ 1995, c. 653, Pt. A, §2 (NEW);  1995, c. 653, Pt. A, §7 (AFF) .] 
6. Merged data.  The board may require the discharge data submitted pursuant to subsection 1 and 
any medical record abstract data required pursuant to subsection 5 to be merged with associated billing 
data. 
[ 1995, c. 653, Pt. A, §2 (NEW);  1995, c. 653, Pt. A, §7 (AFF) .] 
6-A. Additional data.  Subject to the limitations of section 8704, subsection 1, the board may adopt 
rules requiring the filing of additional clinical data from other providers and payors as long as the 
submission of data to the organization is consistent with federal law. Data filed by payors must be 
provided in a format that does not directly identify the patient. 
[ 2007, c. 136, §6 (AMD) .] 
7. Authority to obtain information.  Nothing in this section may be construed to limit the board's 
authority to obtain information that it considers necessary to carry out its duties. 
[ 1995, c. 653, Pt. A, §2 (NEW);  1995, c. 653, Pt. A, §7 (AFF) .] 
SECTION HISTORY 
1995, c. 653, §A2 (NEW).  1995, c. 653, §A7 (AFF).  1997, c. 525, §4 (AMD).  1999, c. 353, §14 (AMD).  
2001, c. 457, §§16-18 (AMD).  2007, c. 136, §6 (AMD). 
22 §8708-A. QUALITY DATA 
 
The board shall adopt rules regarding the collection of quality data. The board shall work with the 
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Maine Quality Forum and the Maine Quality Forum Advisory Council established in Title 24-A, chapter 87, 
subchapter 2 to develop the rules. The rules must be based on the quality measures adopted by the 
Maine Quality Forum pursuant to Title 24-A, section 6951, subsection 2. The rules must specify the 
content, form, medium and frequency of quality data to be submitted to the organization. In the 
collection of quality data, the organization must minimize duplication of effort, minimize the burden on 
those required to provide data and focus on data that may be retrieved in electronic format from within a 
health care practitioner's office or health care facility. As specified by the rules, health care practitioners 
and health care facilities shall submit quality data to the organization. Rules adopted pursuant to this 
section are major substantive rules as defined in Title 5, chapter 375, subchapter 2-A. [2003, c. 469, Pt. C, 
§28 (NEW).] 
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Appendix I.  MHDO rule on release of data  
 
90-590  MAINE HEALTH DATA ORGANIZATION 
 
Chapter 120: RELEASE OF DATA TO THE PUBLIC 
 
 
SUMMARY: This chapter provides for the manner and extent to which data submitted to or 
assembled by the MHDO or its predecessor agencies will be made available to the public. The 
rule defines the scope of the exceptions to the Freedom of Access Law that is provided in the 
Maine Health Data Organization statute. The rule also establishes procedures for determining 
whether data are confidential or privileged and for protecting filed data until that decision is 
made. 
 
 
 
1. Applicability 
 
 This rule governs disclosure to the public of data in the possession of the Maine Health 
Data Organization or its designee. Only data that are physically recorded or stored in 
written, printed, graphic, or electronic form, as opposed to the individual knowledge of 
Board or staff members, are covered by this rule. The coverage of all such data in this 
rule shall not be construed as an MHDO determination that all recorded or stored data 
within its offices or those of its designee are "public records" within the meaning of 1 
M.R.S.A. Sec. 402(3) (1996). 
 
2. Definitions 
 
A. Carrier. "Carrier" means an insurance company licensed in accordance with 24-
A M.RS.A., including a health maintenance organization, a multiple employer 
welfare arrangement licensed pursuant to Title 24-A, chapter 81, a preferred 
provider organization, a fraternal benefit society, or a nonprofit hospital or 
medical service organization or health plan licensed pursuant to 24 M.R.S.A. An 
employer exempted from the applicability of 24-A M.R.S.A., chapter 56-A under 
the federal Employee Retirement Income Security Act of 1974, 29 United States 
Code, Sections 1001 to 1461 (1988) is not considered a carrier. 
 
B. Clinical Data. “Clinical data” mean health care claims, hospital, non-hospital 
health care facility data, quality data, and all other data as described in 22 
M.R.S.A. Secs. 8708, 8708-A, and 8711. 
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C. Confidential Data. "Confidential data" mean "Confidential Restructuring Data," 
"Confidential Agency Data", "Confidential Clinical Data,” or “Confidential 
Financial Data," as defined below: 
 
1. "Confidential Restructuring Data" mean any information filed by a data 
provider in connection with its corporate plan or reorganization that 
contains either a trade secret or contract information: 
 
(a) that have not yet been revealed to persons other than: 
 
(i) employees, agents, or attorneys of the data provider; 
 
(ii) other persons or entities with which the data provider is 
engaged in a joint venture or other commercial action 
in concert; 
 
(iii) other persons or entities with which the data provider is 
actively negotiating for the purchase or sale of goods or 
services; 
 
(iv) other persons or entities with which the data provider is 
jointly participating in an effort to obtain financing; and 
 
(v) other persons or entities to which the data provider has 
applied for financing; 
 
(b) that would, if revealed, substantially and adversely affect the 
ability of the data provider, its affiliated interests or the other 
persons or entities with which the data provider is engaging in a 
joint venture or commercial action to compete with other 
entities offering or proposing to offer the same goods and 
services in the same market; or, that would, if revealed, 
substantially and adversely affect the ability of the data 
provider or its affiliated interest to obtain financing on 
reasonable terms in competition with others seeking similar 
types of capital; or 
 
(c) that could lawfully be concealed under applicable laws 
governing financial transactions. 
 
2. "Confidential Agency Data" are data collected or produced by the 
MHDO that: 
 
(a) have not been revealed to the general public; 
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(b) can be withheld from public access without violation of the 
Freedom of Access Law, 1 M.R.S.A. Sec. 400 et seq.; and 
 
(c) should not, in the opinion of the Executive Director, be 
released. 
 
3. "Confidential Clinical Data" or “Confidential Financial Data” are data 
provided to the MHDO that: 
 
(a) have not been revealed to the general public; and 
 
(b) will directly result in the data provider being placed in a 
competitive economic disadvantage. 
 
D. Data Provider. A “data provider” provides data to the MHDO pursuant to 22 
M.R.S.A. Secs. 8708, 8708-A, 8709, 8710 or 8711 and is a health care facility, 
health care practitioner, or health care claims processor. 
 
E. Disclosure. "Disclosure," with respect to clinical, financial, or restructuring data, 
means to communicate information to a person not already in possession of 
that information or to use information for a purpose not originally authorized. 
For example, to inform a person of the identity of a previously unnamed patient 
is to "disclose" clinical data not already in that person's possession with respect 
to the patient. 
 
F. Executive Director. “Executive Director” means the Executive Director of the 
MHDO or his/her successors. 
 
G. Financial Data. “Financial data” means information collected from data 
providers pursuant to Chapter 300 of the MHDO rules, Uniform Reporting 
System for Hospital Financial Data, that include, but are not limited to, costs of 
operation, revenues, assets, liabilities, fund balances, other income, rates, 
charges and units of services. 
 
H. Health Care Claims Data. “Health care claims data” means information 
consisting of or derived directly from member eligibility, medical claims, 
pharmacy claims, and/or dental claims files submitted by health care claims 
processors pursuant to Chapter 243 of the MHDO’s rules, Uniform Reporting 
System for Health Care Claims Data Sets. “Health care claims data” do not 
include analysis, reports, or studies containing information from health care 
claims data sets, if those analyses, reports, or studies have already been 
released in response to another request for information or as part of a general 
distribution of public information by the MHDO. 
  
 
Chapter 109 (2011) [LD 1818] Work Group Report               February 23, 2013  Page 103 
 
I. Health Care Claims Processor. “Health care claims processor” means a third-
party payer, third-party administrator, Medicare health plan sponsor, or 
pharmacy benefits manager. 
 
J. Health Care Facility. “Health care facility” means a public or private, proprietary 
or not-for-profit entity or institution providing health services including, but not 
limited to a radiological facility licensed under 22 M.R.S.A., chapter 160, a health 
care facility licensed under 22 M.R.S.A., chapter 405 or certified, an 
independent radiological service center, a federally qualified health center 
certified by the United states Department of Health and Human Services, Health 
Resources and Services Administration, a rural health clinic, or a rehabilitation 
agency certified, or otherwise approved by the Division of Licensing and 
Regulatory Services within the Department of Health and Human Services, a 
home health care provider licensed under 22 M.R.S.A., chapter 419, a 
residential care facility licensed under 22 M.R.S.A., chapter 1663, a hospice 
provider licensed under 22 M.R.S.A., chapter 1681, a retail store drug outlet 
licensed under 32 M.R.S.A., chapter 117, a state institution as defined under 34-
B M.R.S.A., chapter 1 and a mental health facility licensed under 34-B M.R.S.A., 
chapter 1. 
 
K. Health Care Practitioner. "Health care practitioner" means physicians and all 
others certified, registered or licensed in the healing arts, including but not 
limited to, nurses, podiatrists, optometrists, pharmacists, chiropractors, physical 
therapists, dentists, psychologists and physicians’ assistants as defined in 24 
M.R.S.A., chapter 21. "Health care practitioner" also includes licensed clinical 
social workers as defined in 32 M.R.S.A., chapter 83 and marriage and family 
therapists and professional counselors as defined in 32 M.R.S.A., chapter 119. 
 
L. Hospital Data. "Hospital data" means information consisting of or derived directly 
from hospital inpatient, outpatient, emergency department, or any other derived 
data sets filed or maintained pursuant to Chapter 241 of the MHDO’s rules, 
Uniform Reporting System for Hospital Inpatient and Hospital Outpatient Data 
Sets. "Hospital data" do not include analysis, reports, or studies containing 
information from hospital data sets, if those analyses, reports, or studies have 
already been released in response to another request for information or as part of 
a general distribution of public information by the MHDO. 
 
L-1. Medicare Health Plan Sponsor. "Medicare health plan sponsor" means a health 
insurance carrier or other private company authorized by the United States 
Department of Health and Human Services, Centers for Medicare and Medicaid 
Services to administer Medicare Part C and Part D benefits under a health plan or 
prescription drug plan. 
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M. MHDO. “MHDO” means the Maine Health Data Organization or its predecessor 
agencies. 
 
N. MHDO Records. 
 
1. "MHDO record" means any item of data stored in written, printed, 
graphic, or electronic form that is either: 
 
(a) contained within the official agency record of an MHDO 
rulemaking proceeding; 
 
(b) filed with the MHDO or its designee by a data provider in 
accordance with a requirement of statute, rule or MHDO order; 
 
(c) contained in the minutes of MHDO meetings; or 
 
(d) contained in a final MHDO report, analysis, study, data 
compilation, decision, rule, or order; 
 
2. "MHDO record" does not include any of the following: 
 
(a) the contents of files maintained by the MHDO's lawyers, or any 
material prepared in anticipation of litigation; 
 
(b) draft documents of any kind, including unsigned or incomplete 
memoranda, decisions, rules or other papers; nor 
 
(c) reports studies, analyses, or data compilations that have not yet 
been reviewed for public release pursuant to section 9 or 10. 
 
O. M.R.S.A. “M.R.S.A.” means Maine Revised Statutes Annotated. 
 
P. Non-Hospital Health Care Facility Data. “Non-hospital health care facility data” 
means information or data consisting of or derived directly from data sets filed 
or maintained pursuant to Chapter 245 of the MHDO’s rules, Uniform Reporting 
System for Non-Hospital Ambulatory Service Data Sets. “Non-hospital health 
care facility data” do not include analysis, reports, or studies containing 
information from non-hospital health care facility data sets, if those analyses, 
reports, or studies have already been released in response to another request 
for information or as part of a general distribution of public information by the 
MHDO. 
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P-1. Pharmacy Benefits Manager. "Pharmacy benefits manager" means an entity 
that performs pharmacy benefits management as defined by 22 M.R.S.A., § 
2699. 
 
Q. Plan Sponsor. “Plan sponsor” means any person, other than an insurer, who 
establishes or maintains a plan covering residents of the State of Maine, 
including, but not limited to, plans established or maintained by two or more 
employers or jointly by one or more employers and one or more employee 
organizations, or the association, committee, joint board of trustees or other 
similar group of representatives of the parties that establish or maintain the 
plan. 
 
Q-1. Prescriber Data. "Prescriber data" means information or data collected from 
data providers pursuant to Chapter 280 of the MHDO's rules, Filing 
Requirements for Prescribers Seeking Confidentiality Requirements, that include, 
but are not limited to, prescriber names, addresses, Maine license or certificate 
numbers, Drug Enforcement Authority registration numbers, and National 
Provider Identification numbers. 
 
R. Privileged Medical Information. "Privileged medical information" means 
information other than hospital, non-hospital health care facility, or health care 
claims data that identify individual patients and that are derived from 
communications that: 
 
1. were made for the purpose of diagnosis or treatment among a provider 
of health care, persons assisting the provider or patient, and a patient; 
 
2. were made for the purpose of payment of health care services among a 
provider of health care, a health care claims processor, and a patient; 
 
3. were not intended to be disclosed except to persons necessary to 
transmit or record the communication and persons participating in the 
diagnosis, treatment, or payment; and 
 
4. have not been previously disclosed to the general public. 
 
S. Protected Information. "Protected information" means information that is 
subject to a protective order that was issued by a court and is binding on the 
MHDO or that was issued by the MHDO, either as part of an adjudicatory 
proceeding or as a general order pursuant to section 12 of this Chapter. 
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T. Quality Data. “Quality data” means information consisting of or derived directly 
from data providers pursuant to Chapter 270 of the MHDO’s rules, Uniform 
Reporting System for Quality Data Sets. "Quality data" do not include analysis, 
reports, or studies if those analyses, reports, or studies have already been 
released as part of a general distribution of public information by the MHDO. 
 
U. Release. To "release" data is to make it available for inspection and copying to 
persons other than the data provider. 
 
V. Restructuring Data. “Restructuring data” means information collected from 
data providers pursuant to Chapter 630 of the MHDO rules, Uniform System for 
Reporting Baseline Information and Restructuring Occurrences for Maine 
Hospitals and Parent Entities, that include, but are not limited to, organizational 
structure, location of separate health service delivery sites or treatment centers, 
acquisitions, consolidations, or mergers. 
 
W. Staff Delegate. “Staff delegate” means a member of the MHDO staff to whom 
the Executive Director delegates specific responsibilities under this Chapter. 
 
X. Third-Party Administrator. “Third-party administrator” means any person 
licensed by the Maine Bureau of Insurance under 24-A M.R.S.A., chapter 18 
who, on behalf of a plan sponsor, health care service plan, nonprofit hospital or 
medical service organization, health maintenance organization or insurer, 
receives or collects charges, contributions or premiums for, or adjusts or settles 
claims on residents of this State. 
 
Y. Third-Party Payer. "Third-party payer" means a state agency that pays for 
health care services or a health insurer, carrier, including a carrier that provides 
only administrative services for plan sponsors, nonprofit hospital, medical 
services organization, or managed care organization licensed in the State. 
“Third-party payer” does not include carriers licensed to issue limited benefit 
health policies or accident, specified disease, vision, disability, long-term care or 
nursing home care policies. 
 
3. Public Access to Data 
 
A. MHDO Records Not Otherwise Restricted. Except as otherwise provided in this 
section, all MHDO records shall be released to any person, in accordance with 
sections 4 and 5, below. 
 
B. Clinical Data. MHDO records, files, reports, tables or any other information 
consisting of or compiled from clinical data shall be released, but only after the 
review and modification procedures set forth in section 9 have been 
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undertaken. Computations, reports, or tables containing clinical data may be 
released without review, if the data have previously been designated as public. 
 
C. Financial or Restructuring Data. MHDO files, reports, tables or any other 
information consisting of or compiled from financial or restructuring data shall 
be released in accordance with the provisions set forth in section 10. 
Computations, reports, or tables containing financial or restructuring data may 
be released without review, if the data have previously been designated as 
public. 
 
D. Data Claimed to be Confidential or Privileged. Those parts of MHDO records 
that have been properly claimed to contain confidential data or privileged 
medical information pursuant to section 6 shall not be released unless the 
Executive Director or a staff delegate determines, pursuant to section 7 or 
section 8, that the requested data or medical information are not confidential or 
privileged. 
 
E. MHDO Documents Containing Confidential, Privileged, or Protected Data. 
MHDO documents labeled in accordance with subsection 11(A), shall not be 
released, until the confidential, privileged, or protected data have been 
removed or obliterated. 
 
F. Data Subject to Protective Order. Those parts of MHDO records that are subject 
to a protective order and are properly labeled as protected shall not be released 
except to the extent that the order may allow. 
 
G. Information Other than MHDO Records. Information in the MHDO's possession 
that does not constitute or form part of a MHDO record may be released after a 
request made in accordance with section 4, only if the Executive Director or a 
staff delegate finds that review under subsection 11(C) is not required and 
either: 
 
1. that the information is a "public record" within the meaning of 1 
M.R.S.A. Sec. 402 (3); or 
 
2. that the information is not a "public record" but that its disclosure: 
 
(a) will not infringe upon confidential, privileged, or protected 
status provided elsewhere in this Chapter; and 
 
(b) will be appropriate and reasonable as determined by the 
Executive Director or staff delegate. 
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H. Prescriber Data. MHDO files, reports, tables, or any other information consisting 
of or compiled from prescriber data shall be released, but must not contain any 
data as identified in section 9(A)(4). 
 
4. Request for Data 
 
A. Request for Data. Each request for data shall be in writing and shall state with 
specificity: the MHDO data or other information sought; the identity, including 
ownership, of the requesting party; whether or not an internal review board is 
to be utilized; the purpose(s) for which it will be used; and the media on which 
the data are to be delivered. If the requesting party intends to display on the 
Internet any of the data sought, the request for such data must so specify. Any 
request that does not contain sufficient detail to enable the MHDO's staff to 
locate the desired data with a reasonable expenditure of time and effort may be 
rejected without being granted or denied. When clinical data requests contain 
data elements as set forth in subsections 9(A)(2), (3), and (4) of this Chapter, the 
request shall also set forth: 
 
1. the ultimate recipient or user of the data; 
 
2. any facts bearing on the willingness and ability of the requesting party 
and ultimate recipient or user of the data to comply with subsection 9 
(B)(2)(b) of this Chapter; and 
 
3. the term during which the research will be conducted or the data will be 
utilized. 
 
In order to ensure that the standards and conditions set forth in section 9 and 
10 are met, the Executive Director or staff delegate may request additional 
information from the requesting party. 
 
B. Initial Action on Request. Upon the filing of a request, the Executive Director or 
a staff delegate shall determine whether any portions of the information 
requested must be reviewed under sections 7, 8, 9, or 10 below, or must be 
modified under subsection 3(E), above. Within thirty business days of the filing 
of the request, the Executive Director or a staff delegate shall: 
 
1. release to the requesting party pursuant to section 5 all information not 
subject to review under sections 7, 8, 9, and 10, and not withheld from 
release pursuant to subsections 3(E), (F), and (G); 
 
2. issue a written denial with respect to any information withheld 
pursuant to subsections 3(E), (F), or (G); and 
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3. issue a written, temporary denial with respect to any requested 
information subject to sections 7, 8, 9, or 10, including an explanation to 
the requesting party that further steps are required to comply with 
statutory restrictions on the release of the information or to seek 
review of an agency determination of confidentiality. 
 
C. Reconsideration of Initial Action. Any requesting party who has not been 
provided an opportunity to be heard on the reasons stated in a written denial 
may request reconsideration within 5 days of the service of the denial. All facts 
and arguments in support of the motion shall be recited therein. If the Executive 
Director determines the written submissions do not provide a sufficient basis for 
a decision, the Executive Director may convene a hearing pursuant to the Maine 
Administrative Procedures Act. 
 
5. Release of Information and Data 
 
A. Inspection and Copying of Existing Documents. Inspection and copying shall be 
conducted: 
 
1. at the offices in which the information released is made available; and 
 
2. in a manner that assures that the copied material is not damaged. 
 
The Executive Director or a staff delegate may require that copying be 
conducted by MHDO staff. 
 
B. Copying Costs. Reasonable costs of copying shall be paid by the requesting 
party. Upon request, MHDO staff shall provide estimates of cost in advance of 
copying. The estimates shall be based upon the applicable fees listed in Chapter 
50 of the MHDO’s rules. 
 
C. Translation, Compilation, Reconfiguration, and Modification 
 
1. When information must be translated from one medium to another, 
compiled from several sources, reconfigured, or modified to avoid 
disclosure of information that must under this Chapter be withheld, the 
costs of all such operations shall be charged to the requesting party. 
Such charges must be paid before the requested information is 
delivered. 
 
2. Notwithstanding the thirty business day period provided in subsection 
4(B), when the operations described above in subsection 5(C)(1) are 
required to fulfill a request, such operations and subsequent inspection 
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may be scheduled to occur at such time as will not delay or 
inconvenience the regular activities of the MHDO staff. 
 
D. Notice of Release 
 
Whenever financial or restructuring data pertaining to a specific data provider 
are released, the MHDO shall notify the filing party. 
 
6. Claims of Confidentiality or Privilege 
 
A. Responsibility of Data Provider 
 
1. At Time of Submission. Whenever a data provider claims that data are 
confidential or privileged within the meanings established in section 2, it 
shall clearly label each page (or, in the case of electronically stored data, 
each subdivision of similar size) to which the claim applies as 
"Confidential" or "Privileged," before submitting the data to MHDO. Each 
submission that includes portions labeled as confidential or privileged 
shall be accompanied by a covering letter or report that sets forth the 
basis for each claim of confidentiality or privilege. 
 
2. Subsequent to Submission. When a data provider discovers or 
concludes, after the submission of data, that they are confidential or 
privileged and should have been so labeled, it may submit a request 
that such data be labeled by the MHDO or that the MHDO substitute a 
labeled copy of the data for the original submission. Any such request 
shall be accompanied by a letter or report of the basis for the claim of 
confidentiality or privilege. If the data provider agrees to assume all 
costs associated with any processing or other data filing, tabulation, 
recording, or management activities that must be repeated in order to 
accomplish, or as a consequence of, the subsequent labeling of data, 
the MHDO will cause the data designated in the request to be labeled as 
confidential or privileged, or will substitute labeled duplicates and 
return the original materials. Thereafter, such subsequently labeled 
material will be treated in the same manner as data claimed to be 
confidential or privileged pursuant to subsection 6(A)(1), above. 
Nothing in the subsection, however, shall require the MHDO to retrieve 
copies of unlabeled data that have been distributed prior to completion 
of the process of subsequent labeling set forth in this paragraph. The 
MHDO shall conduct such labeling activities within such time and in 
such manner as will not disrupt or delay the completion of its other 
administrative responsibilities. 
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B. MHDO Claims. Whenever the Executive Director or a staff delegate considers 
data that is an MHDO record to be confidential agency data, such data shall be 
labeled in the same manner provided for data providers in subsection 6(A). This 
section shall not be construed to require the MHDO or the staff to comply with 
subsection 6(A) with respect to confidential agency information that is not an 
MHDO record. 
 
C. Disclosure Prohibited. No data that are properly claimed to be privileged or 
confidential as provided in this section shall be released, unless the claim is 
denied after a review under section 7 or 8. 
 
7. Review of Data Claimed by a Data Provider to be Confidential or Privileged 
 
When a request for data includes material labeled by a data provider under section 6, 
the procedures set forth in this section shall apply. 
 
A. Notification. The data provider or providers that submitted the labeled data 
shall be notified of the request. 
 
B. Written Support for Confidential or Privileged Designation. Within ten (10) days 
of notification, the data provider(s) may submit written memoranda of all facts 
and arguments that support the claim that the data requested should be found 
to be confidential or privileged. Copies of such memoranda shall be served on 
the requesting party. 
 
 NOTE: For purposes of computing this ten-day period, MHDO will consider 
notification to mean service of the notification, in a manner and with 
the same effect as service under the Maine Rules of Civil Procedure. 
 
C. Written Opposition from Requesting Party. Within ten (10) days of the service 
of the memoranda provided for in subsection 7(B), any opposing memorandum 
from the requesting party shall be filed. 
 
D. Burden of Proof. In reviews under this section, the burden of proof shall rest on 
the data provider(s) contending that information should not be released. 
Therefore, if the submissions under subsection 7(B) fail to establish that the 
data under review are privileged or confidential, the Executive Director or a staff 
delegate may issue a decision releasing the data without further hearing, 
subject to the restriction of subsection 7(G). 
 
E. Requirements for Hearing. No hearing will be held under this section unless, 
after review of the memoranda, the Executive Director determines that the 
memoranda filed do not provide a sufficient basis for a decision, in which case 
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the Executive Director may convene a hearing pursuant to the Maine 
Administrative Procedure Act. 
 
F. Review Period for Release. A decision on whether to release data shall be made 
within thirty days (30) of the notification given under subsection 7(A). 
 
G. Effective Release Date. No decision to release data that have been labeled 
under section 6 shall take effect less than five days after service of the decision 
on the data provider. 
 
H. Modification of Time Periods. The time periods provided in this section may be 
modified in particular instances to accommodate the needs of the requesting 
party or to assure that decisions under this section do not interfere with the 
MHDO's performance of its primary statutory duties. 
 
I. Labeling of Data Deemed to be Public. Once particular items of data have been 
found not to be privileged or confidential pursuant to this section, a notation to 
that effect may be made on the affected documents. Thereafter, such items will 
be treated for purposes of this Chapter as if they were not labeled confidential 
or privileged. The necessary notation may be accomplished by labeling such 
items as "public." 
 
8. Review of Data Claimed to be Confidential Agency Data 
 
When a request for data includes material labeled as confidential agency data by the 
Executive Director or a staff delegate under subsection 6 (B), the procedures set forth in 
this section shall apply. 
 
A. Notification. The requesting party shall be notified that portions of its request 
are claimed to be confidential by the MHDO, and of the basis for that claim. 
 
B. Written Support. The requesting party may submit written memoranda of all 
facts and arguments that support the claim that the data requested should not 
be treated as confidential, within five days of the notification given pursuant to 
subsection (A). 
 
C. Response to Requesting Party. If the Executive Director or a staff delegate 
requests further comment or a response to the requesting party's memoranda 
from members of the MHDO staff, such comment or response shall be served 
on the requesting party. 
 
D. Requirements for Hearing. No hearing will be held under this section unless, 
after review of the memoranda, the Executive Director determines that the 
memoranda filed does not provide a sufficient basis for a decision. 
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E. Review Period for Release. A decision on whether to release information shall 
be made within twenty (20) days of the notification given under subsection 7(A). 
 
F. Modification of Time Periods. The time periods provided in this section may be 
modified in particular instances to accommodate the needs of the requesting 
party or to assure that decisions under this section do not interfere with the 
MHDO's performance of its primary statutory duties. 
 
G. Labeling of Data Deemed to be Public. Once particular items of data have been 
found not to be privileged or confidential pursuant to this section, a notation to 
that effect may be made on the affected documents. Thereafter, such items will 
be treated for purposes of this Chapter as if they were not labeled confidential 
or privileged. The necessary notation may be accomplished by labeling such 
items as "public." 
 
9. Review of Requests for Clinical Data 
 
Clinical data will be released after they have been reviewed in accordance with this 
section. 
 
A. The Executive Director or a staff delegate shall compare the clinical data request 
with the following standards to establish the scope and extent of the request. 
 
1. In accordance with section 3 of Chapter 125 of the MHDO’s rules data 
that directly identify patients, shall not be included in data that are 
released, unless an exception has been specifically authorized in 
accordance with subsection 9(D). Data elements that are direct 
identifiers of individuals under section 3 of Chapter 125 shall be 
released only in an encrypted form that cannot be used to identify 
individuals, although it may permit distinctions to be made among 
unidentifiable individuals. Any data element that is listed under section 
3 of Chapter 125 must also be listed in subsection 9(A)(2)(g) to be 
released in an encrypted format. 
 
2. The following data elements shall be considered to have a possibility of 
indirectly identifying patients if they show for any individual health 
record any of the following information and may only be released in 
accordance with subsection 9(B)(2), unless an exception has been 
specifically authorized in accordance with section 9(D): 
 
(a) date of birth, unless converted to age; 
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(b) hospital inpatient admission date or hospital inpatient discharge 
date, unless each is converted to length of stay plus calendar 
quarter and year; 
 
(c) hospital inpatient procedure date, unless converted to the 
number of elapsed days between admission and procedure 
date; 
 
(d) date of procedure or service, unless converted to calendar 
quarter and year; 
 
(e) race; 
 
(f) when the place of residence is coded at a level that includes 
populations of 20,000 persons or less, except to the extent that 
the MHDO may, by order, approve the use of health planning, 
regulatory, or research areas containing smaller populations; 
 
(g) medical record number, patient control number, plan specific 
contract number, member identification code, or patient social 
security number, in an encrypted form that cannot be used to 
identify individuals; or 
 
(h) insured group or policy number if the total number of 
individuals in the group is 50 or greater, or, if less, data 
associated with other elements listed in this sub-section have 
been removed prior to release to prevent indirect identification. 
 
3. Data elements related to health care facility or practitioner charges 
(total charges, line item charges, charge amount) for services rendered 
shall only be released at an aggregate level that will not allow a 
charge/paid ratio to be computed for each type of service rendered for 
any individual health care claims processor, health care facility, or 
health care practitioner. Requesting parties are prohibited from 
simultaneously arraying and/or displaying data elements related to 
payments for specific health care services by individual health care 
claims processors and health care facilities or practitioners. The MHDO 
may create public reports or tables arrayed in this manner when all 
applicable health care facility and practitioner claims for a specific 
service have been aggregated to produce the total price paid. 
 
4. Any data that directly identifies or would lead to the indirect 
identification of practitioners performing abortions as defined by 22 
M.R.S.A. § 1596, a practitioner's tax identification number, or a 
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practitioner's Drug Enforcement Administration registration number are 
deemed to be confidential and shall not be released. 
 
B. Release of Clinical Data 
 
1. Upon completion of the review requirements of Section 12, data that 
meet the standards of subsection 9(A)(1) and contain none of the 
combinations of data described in subsections 9(A)(2)(3) and (4) shall be 
released without further review. 
 
2. Except to the extent the data are modified by subsection 9(D), when 
clinical data meet the standards of subsection 9(A)(1) but contain data 
elements as described in subsections 9(A)(2), (3), and (4), the following 
procedure will be employed: 
 
(a) If the Executive Director or a staff delegate finds, on the basis of 
information received pursuant to section 4: 
 
(i) that the requesting party is seeking the requested 
clinical data solely for research or statistical purposes; 
 
(ii) that the requesting party is seeking only the clinical 
data that is necessary to fulfill the specific requirements 
of the data request; 
 
(iii) that the requesting party has agreed in a writing filed 
with the MHDO to adhere to the conditions set forth in 
subsection 9(B)(2)(b); and 
 
(iv) that the requesting party has demonstrated that it can 
and will faithfully adhere to such conditions and has 
established procedures to insure such adherence by both 
it and its employees; 
 
then the MHDO shall initiate the process to release the data 
that fall within the scope of subsections 9(A)(2), (3), and (4), 
upon the conditions specified in subsection 9(B)(2)(b). The 
release of the clinical data shall conform to the external review 
provisions described in section 12. 
 
(b) Any person to whom clinical data containing elements as set 
forth in subsections 9(A)(2), (3), and (4) are released shall 
comply with the conditions in this subsection and shall agree to 
so comply in writing before receiving any such data. 
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(i) The data provided will be used by the requesting party 
and its employees only for research and statistical 
purposes and only for those purposes specified in the 
data request, as approved by the MHDO. 
 
(ii) The MHDO shall retain all ownership rights to the data. 
The requesting party shall have no right, title, or 
interest to any of the data provided by the MHDO. 
 
(iii) The requesting party shall name an individual as 
custodian of the data to be responsible for the 
observance of all conditions of use and for 
establishment and maintenance of security 
arrangements to prevent unauthorized use. 
 
(iv) The requesting party shall not release, furnish, disclose, 
publish or otherwise disseminate the data released to it 
by the MHDO under this subsection, to any person, 
except an employee of the requesting party who has 
agreed in writing to comply with all of the conditions of 
this paragraph and is subject to such supervision by the 
requesting party as is necessary to insure such 
compliance. Nothing in this subsection, however, shall 
prevent the requesting party from releasing or disclosing 
those portions of the data that do not include any of the 
data elements found in subsections 9(A)(2)(3) and (4). 
 
(v) The requesting party shall make only such additional 
copies of the data as are required in the conduct of the 
research and shall retain only one copy of the data after 
the term of the research as specified in the request, or 
as modified by the MHDO in approving the request, 
concludes. All other copies shall be destroyed or 
returned to the MHDO at the conclusion of the term of 
the research. 
 
(vi) The requesting party shall not use the data provided in 
any way, or allow such data to be used in any way, for 
purposes of identifying individuals or taking legal, 
administrative or other actions against individuals, nor 
shall the requesting party make contact with, or assist 
others in making contact with, any individuals who may 
be indirectly identified in the data provided. 
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(vii) The requesting party agrees that the data may be 
retained only for the period of time necessary to fulfill 
the requirements of the data request. The requesting 
party shall return the data within 30 days of the 
scheduled completion date of the project or shall 
destroy the data, so certifying by submitting a written 
notice to the MHDO. 
 
(viii) Except as provided in subsection 9 (B)(2)(b)(ix) the 
requesting party shall provide the MHDO with a copy of 
any manuscript, report, or web site universal resource 
locator (URL) intended for public dissemination that 
contain data provided under subsection 9(A) at least 
twenty days prior to their release unless the 
manuscript, report, or web site is being furnished only 
to: 
 
a. the requesting party's employees or its other 
investigators who have agreed with the 
provisions of this paragraph; or 
 
b. the MHDO. 
 
In the event the MHDO determines that the report may 
lead to direct or indirect identification of individuals or 
the determination of a charge/paid ratio, the requesting 
party shall modify the report prior to its release to 
protect against such occurrence. 
 
When multiple reports of a similar nature will be 
created from the data, the MHDO may, in its discretion, 
upon request, waive the requirement that any 
subsequent report or reports be provided to the MHDO 
prior to release by the requesting party. In making such 
a request, the requesting party shall provide the MHDO 
with sufficient information to determine whether the 
subsequent report(s) will create a risk of direct or 
indirect identification of individuals or place an 
individual health care claims processor, health care 
facility, or health care practitioner at an economic 
disadvantage. 
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Reports provided to the MHDO under this subsection 
shall be considered confidential agency data. 
 
(ix) Subsection 9(B)(2)(b)(viii) shall not apply to a requesting party that: 
 
a. is an agency of the federal or a state 
government in the United States or the federal 
or a provincial government in Canada; 
 
b. is subject to a statute, or a rule adopted 
pursuant to statutory authority, that prohibits 
the agency from releasing those portions of the 
data in its custody that would have a possibility 
of indirectly identifying patients within the 
meaning of paragraph 9(A)(2); and 
 
c. has responsibility, assigned by statute, for the 
collection, custody, and release of clinical data. 
 
The exemption established by this subsection shall 
terminate, and subsection 9(B)(2)(b)(v) shall apply, in 
the event that the statute or rule described in b. 
immediately above shall be repealed without being 
replaced by an equivalent provision. 
 
C. Modification of Data. When requested clinical data do not meet the standards 
set forth in subsection 9(A)(1), the MHDO will inform the requesting party. If the 
requesting party is willing to pay the reasonable cost of modification, the 
Executive Director or a staff delegate shall modify the requested data to meet 
the subsection 9(A)(1) standards. 
 
D. Public Health Exception. Notwithstanding subsections A (2) and (4) above, the 
MHDO may release identifying data to the Department of Health and Human 
Services (“Department”) for the purpose of gaining access to medical records 
and other medical information pertaining to an investigation or research project 
of substantial public health importance, in accordance with the procedures set 
forth below. 
 
1. Prior to requesting the release of data under this subsection, the 
Department will prepare a written protocol, describing the public health 
investigation or research to be undertaken, including the legal authority 
under which the investigation or research is being undertaken, the 
qualifications and affiliations of the staff, the background of the study, 
the research questions, the research design, case definition and 
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selection, control definition and selection, if any, study resources, study 
operational description and data analysis methodology. 
 
(a) The protocol must ensure that medical information about patients 
identified by name is not sought from any person without the 
consent of that patient, except that, if supported by the specific 
finding set forth in subsection 9(D)(8)(g), the protocol may 
provide that information pertaining only to the verification or 
comparison of health data that the agency is otherwise 
authorized by law to collect may be obtained without patient 
consent. 
 
(b) The protocol prepared by the agency shall also describe the 
procedure for obtaining patient consent to examine medical 
information, including the manner in which contact will be 
made with patients and the practices that will be followed to 
preserve the confidentiality of any medical information that can 
be associated with an identified patient. 
 
(c) The protocol will be designed to ensure that identifying 
information released by the MHDO will be used only to gain 
access to medical records and other medical information for 
public health purposes identified in the document. 
 
(d) The protocol will be designed to ensure that any identifying 
information released, with or without consent, shall be subject 
to all confidentiality requirements established in this section. 
 
2. Each person who seeks access to data released under this subsection 
must agree in writing to comply with the conditions set forth below 
before receiving any such data, and thereafter shall comply with the 
conditions set forth below as well as the conditions set forth in 
subsections 9 (B)(2)(b)(ii) and 9 (B)(2)(b)(v). 
 
(a) The data released will be used by the Department and its 
employees only for the specific purposes described in the 
protocol approved by the MHDO in accordance with this 
subsection. 
 
(b) Medical information about any patient identified by name shall 
not be disclosed to any other person, other than another 
investigator who has agreed to the conditions set forth in this 
paragraph and is subject to such supervision by the Department 
as is necessary to ensure compliance with these conditions, 
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without the patient's consent, unless the protocol specifically 
authorizes verification and comparison without consent in 
accordance with subsections 9(D)(1)(a) and (8)(g). 
 
(c) Medical information about an identified patient will be used to 
the minimum extent necessary to accomplish the purposes of the 
investigation. 
 
(d) The identifying information released will not be used as a basis 
for legal, administrative, or other actions that may directly 
affect identified patients as a result of their identification in the 
investigation, except with the express consent of the identified 
patient. 
 
(e) Unless specified in the original protocol, no follow back 
investigations to obtain additional information from patients 
will be undertaken without obtaining additional authorization 
under this subsection 9(D). 
 
3. Each protocol prepared in accordance with subsection 9(D)(1) must be 
submitted to the MHDO with a request for approval of the release of 
the data required to undertake the proposed study. The request shall be 
accompanied by written agreement to all of the conditions set forth in 
subsection 9(D)(2), signed by each person who will be given access to 
the released information. 
 
4. After receipt of a request filed pursuant to subsection 9(D)(3), the 
MHDO shall notify each affected data provider that identifying data has 
been requested and may be used by the Department for purposes of 
identifying individual patients. The notice will include a copy of the 
proposed protocol and will describe the procedures set forth in this 
subsection and summarize the nature of the proposed investigation or 
research. Each affected data provider may file written comments within 
twenty (20) days after service of the notice, with respect to: 
 
(a) the adequacy of the protection provided to patient 
confidentiality; 
 
(b) the purposes for which the information will be used; and 
 
(c) the extent to which public confidence in the protection of 
medical information is adequately ensured. 
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If necessary to address concerns regarding public confidence in the 
confidentiality of clinical data, comments from the general public or 
persons known or expected to be interested in the investigation, 
research or the requested data may also be sought. 
 
5. The Department submit the protocol prepared in accordance with 
subsection 9(D)(1) for review and approval by an independent advisory 
body that has been charged with responsibility for approving the 
protocol, overseeing the investigation to ensure consistency with the 
protocol and this Chapter, and assessing the scientific validity of the 
investigation and its effects upon patients. The composition and 
organization of the advisory body shall be approved by the MHDO. At a 
minimum, the advisory body must include two consumer 
representatives and two health care practitioners in the field related to 
the investigation or research. The Department may submit the 
proposed protocol to the advisory body at the same time that it files the 
protocol and its data request with the MHDO under subsection 9(D)(3), 
or at any time thereafter. 
 
6. Comments filed with the MHDO in response to the notice issued under 
subsection 9(D)(4) will be forwarded promptly to the advisory body 
charged with review of the protocol. The advisory body, after review of 
the protocol, any comments filed, and any issues or concerns raised by 
its own members or by the MHDO may recommend revisions of the 
protocol and may require such revisions as a condition of its approval. 
 
7. If necessary to ensure that the standards and conditions set forth in this 
subsection will be met, the MHDO may request that additional 
information or comments be provided by the requesting party and any 
other persons interested in the proposed investigation, research or the 
requested data. An informal, oral hearing may be held, if necessary to 
resolve issues raised by the comments and other information 
submitted. 
 
8. The MHDO shall authorize the release of identifying data not otherwise 
permitted under subsection 9(A)(1), and the use of information that 
may be released under subsections 9(A)(2) and (4) for the additional 
purposes specified in this subsection, upon the conditions specified in 
subsection 9(D)(3), if, upon review of the information received, the 
MHDO finds the following: 
 
(a) that the protocol required under subsection 9(D)(1) has been 
prepared, reviewed, and approved by an advisory body in 
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accordance with this subsection and that the protocol conforms 
with all applicable requirements of this subsection 9(D); 
 
(b) that the proposed identification of or contact with patients does 
not violate state or federal law nor diminish the confidentiality 
of medical information; 
 
(c) that the public's confidence in the protection of medical 
information will not be diminished in a manner that outweighs 
the expected benefit to the public of the proposed 
investigation; 
 
(d) that the sole purpose for which information released under this 
subsection will be used is to obtain medical records and other 
medical information necessary to the performance of an 
investigation that is designed to accomplish public health 
research of substantial public importance where failure to 
conduct such research may result in serious harm to patients or 
other individuals; 
 
(e) that the Department and each person who will have access to 
the data under the auspices of the applicable Maine state 
agency have agreed in a writing filed with the MHDO to adhere 
to the conditions set forth in subsection 9(D)(3); 
 
(f) that the Department has demonstrated that it can and will 
faithfully adhere to the conditions established in this subsection 
and has in place procedures to ensure such adherence by the 
agency and its employees; and 
 
(g) that medical information about any patient identified by name 
will not be sought from any person without consent of that 
patient, unless: 
 
(i) the information sought pertains solely to verification or 
comparison of health data that the Department is 
otherwise authorized by law to collect; 
 
(ii) the manner in which such verification and comparison is 
carried out is consistent with all applicable 
requirements of this subsection 9(D); and 
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(iii) the confidentiality of medical information and the 
public's confidence in the protection of that information 
will be adequately protected without patient consent. 
 
10. Review of Requests for Financial or Restructuring Data 
 
Financial or restructuring data shall be released after it has been reviewed in 
accordance with the provisions of this section. 
 
A. Review by the MHDO. The Executive Director or a staff delegate will review the 
financial or restructuring data request to determine whether it meets the 
following standards: 
 
1. Confidential financial data, confidential restructuring data, or protected 
information are not included in the data to be released; and 
 
2. The data to be released shall not in combination with data in the 
possession of the requesting party result in the data provider being 
placed in a competitive economic disadvantage. 
 
B. Release of Financial or Restructuring Data. Data that meets the provisions of 
subsection 10(A) shall be prepared for release to the requesting party. The 
release of the financial or restructuring data shall conform to the external 
review provisions described in section 12. 
 
 
11. Review of MHDO Reports and Compilations that May Contain Confidential, Privileged, 
or Protected Data 
 
A. All Reports and Compilations. The Executive Director or a staff delegate shall 
review every report or data compilation prepared by the MHDO from information 
in its possession or control, to determine whether any portions of the document 
contain confidential, privileged, or protected data, or data claimed to fall into 
those categories. Any such portions will be clearly labeled before the document is 
deemed final, and the cover of such documents shall state that confidential, 
privileged, or protected data will be found therein. 
 
B. Determination of Privilege or Confidentiality. Should the MHDO or its staff 
question any claim of confidentiality or privilege with respect to data used in 
any compilation or report, the Executive Director or a staff delegate may initiate 
the review process set forth in section 7. 
 
C. Studies, Analyses, and Reports. In addition to the review described in subsection 
11(A), the MHDO shall provide notification of studies, analyses or reports 
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prepared under 22 M.R.S.A. Sec. 8704(1)(D) to every affected data provider, at 
least twenty (20) days before such documents are deemed final or made a part of 
the MHDO's records. Where such documents are to be disseminated to the public, 
the MHDO's notification shall include: 
 
1. the date that the study, analysis, or report is expected to be made 
public; 
 
2. the places at which a copy of the study will be available for review on 
the MHDO web site (http://www.maine.gov/mhdo); 
 
3. the price (not to exceed actual cost of reproducing and mailing the 
study) and means of obtaining a copy of the study; and 
 
4. the affected data provider's right to file comments on the document 
with the MHDO before that date. Any such comments that are filed 
shall be stored by the MHDO with the original or master copy of the 
study, analysis, or report to which they are directed and shall be 
released upon request. 
 
12. External Review of Data Recipients/Requests 
 
A. Data Recipient/Request List. The MHDO shall create a page on its web site 
(http://www.maine.gov/mhdo) that lists the identity and address of all parties 
requesting clinical, financial, restructuring, or prescriber data with a summary of 
each data request. The MHDO shall update the list on the first business day of 
every week. In addition, through a written request to the MHDO that must 
include a valid electronic mail address, a data provider or other interested party 
shall be automatically notified of any new data requests via electronic mail. 
 
B. Comments. Data providers or other interested parties may submit to the 
Executive Director comments related to the requesting party and/or the 
proposed use of the data. To be considered, comments must be received by the 
Executive Director in writing or via electronic mail no later than ten business 
days after the identity of the requesting party first appears on the MHDO web 
site. For all data requests that include identifiable practitioner data elements, 
with the exception of those for prescriber data, or the insured group or policy 
number, data providers or other interested parties shall have thirty business 
days to submit comments. 
 
C. MHDO Determination. If the Executive Director determines that: 
 
1. The comments are of significant importance to delay the release of the 
data;  
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2. Additional information is required from the requesting party to address 
the comments;  
 
3. The data request includes identifiable practitioner data elements; or 
 
4. The data request includes identifiable group or policy numbers; 
 
then the data shall not be released until the additional information has been 
received from the requesting party and an additional review is conducted by the 
MHDO to ensure that the requesting party conforms to all applicable 
requirements of this chapter. The Executive Director may establish a data 
advisory committee composed of two members of the MHDO Board, two 
members of the Maine Health Data Processing Board, and such other 
individuals, as determined by the Executive Director, with relevant expertise to 
assist with the additional review of the data request. If the data request includes 
identifiable practitioner data elements, the Executive Director shall establish a 
data advisory committee composed of two members of the MHDO Board, two 
members of the Maine Health Data Processing Board, a representative from the 
Maine Quality Forum, and representatives from the Maine based practitioner 
professional associations and/or affiliated medical specialty organizations 
associated with the potentially impacted practitioners. If the data request 
includes identifiable group or policy numbers, the Executive Director shall 
establish a data advisory committee composed of two members of the MHDO 
Board, two members of the Maine Health Data Processing Center Board, a 
representative of an employer or a business organization potentially impacted 
by the request, a Maine based representative of consumers, a representative of 
a Maine based third-party payer organization, and a representative of the third 
party payer potentially impacted by the request. The requirements of this 
subsection shall not apply to the release of prescriber data. 
 
13. Protective Orders 
 
On its own motion or that of its staff or a data provider, the MHDO may enter a general 
protective order governing specified items of data. Such an order shall be granted 
whenever a similar order would be permissible in the course of formal MHDO 
proceedings or under the Maine Rules of Civil Procedure and Maine Rules of Evidence. 
Any data that are subject to such an order shall be labeled by the moving party with the 
words "protected data" or an equally clear indication that it is subject to a protective 
order. When general protective orders are requested outside of the context of either 
discovery proceedings or particular requests for data under this rule, the MHDO may 
issue them ex parte, subject to subsequent reconsideration on motion of any party 
aggrieved thereby. 
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14. Compliance 
 
A. False Claims or Labels. It shall be a violation of this rule to claim and label, in 
accordance with subsection 6(A), data that do not fall within the scope of the 
definitions in subsections 2(C), (N) and (R), unless the contention of the data 
provider that data which fell within these subsections were, although incorrect, 
substantially justified. 
 
B. Advanced Protective Order. Any data provider that violates this rule in the 
manner described in subsection 14(A) shall be required, in all submissions made 
with the MHDO for one year following an order finding a violation, to obtain a 
protective order in advance of the date of submission for any data claimed to be 
confidential or privileged. All data submitted without such an order shall be 
released on request. Any motion for such an order shall be made at least thirty 
days in advance of the required submission date. 
 
C. Second Offense. The penalties provided in 22 M.R.S.A Sec. 8705-A shall apply to 
a second offense under subsection 14(A), and to any other violations of the 
requirements of this Chapter. 
 
15. Relationship to Discovery 
 
A. Request for Data. Inquiries that purport to be requests filed pursuant to this 
Chapter but actually seek data in the form and character of discovery in a 
pending proceeding before the MHDO or a court or administrative proceeding 
to which the MHDO is a party shall not be deemed to be requests for data. Such 
inquiries will be processed in accordance with the rules of practice applicable to 
the case to which the discovery would apply. 
 
B. Confidential, Privileged, or Protected Data. Nothing in this Chapter shall limit or 
modify the right of a directly interested person to seek discovery from a data 
provider of data that may not be released by the MHDO under this Chapter. The 
MHDO may order such discovery with any protective restrictions that may 
appear necessary, pursuant to such rules of practice as the MHDO may adopt. 
 
16. Final Agency Action 
 
A party aggrieved by a final action of the MHDO under these rules has the right to 
judicial review pursuant to 5 M.R.S.A., chapter 375, subchapter VII and M.R.Civ.P. 80(C). 
For purposes of this rule, the term "final agency action" means an action, or the failure 
or refusal to take a requested action, of or by the MHDO. Unless otherwise provided for 
by statute, an aggrieved party shall file a petition for judicial review of final agency 
action of the MHDO no later than thirty (30) business days after receipt of notice of 
MHDO action, or the failure or refusal of the MHDO to undertake a particular action. 
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STATUTORY AUTHORITY: 22 M.R.S.A. §8704, sub-§4 and §8707 
 
EFFECTIVE DATE: 
 June 27, 1984 
 
AMENDED: 
 October 5, 1987 
 April 24, 1991 
 November 5, 1991 
 July 6, 1994 
 January 1, 1995 
 February 17, 1998 
 
NON-SUBSTANTIVE CORRECTION: 
 April 8, 1998 - insertion of “and” at the end of §2(C)(2)(b). 
 
AMENDED: 
 February 13, 2000 
 
NON-SUBSTANTIVE CORRECTIONS: 
 March 13, 2000 
 
AMENDED: 
 August 9, 2003 - filing 2003-244, major substantive 
 
NON-SUBSTANTIVE CORRECTIONS: 
 September 8, 2003 - removal of stray spaces 
 
AMENDED: 
 August 6, 2005 – filing 2005-278 
 January 1, 2007 – filing 2006-209, major substantive 
 June 22, 2008 – filing 2008-227, major substantive 
 August 15, 2009 – filing 2009-366, major substantive 
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Appendix J.  Comments received on earlier draft reports  
 
 
Comment #1 on the February 8 draft report from Elizabeth Mitchell of the Maine 
Health Management Coalition on February 12, 2013 
  
The narrative and policy case are greatly improved in this draft and reflect broader needs and 
uses of the data beyond quality improvement including evaluation, measurement, consumer 
choice and payment. To ignore these uses would put Maine significantly behind the national 
debate and direction and their inclusion strengthens the report.  
  
Despite improvements in the narrative, the recommendations are wholly inadequate to meet 
the stated aims. Though the 'Voice of the Customer' process was appropriate and is well 
documented, what the customer requested has seemingly been ignored. 
 
 The report acknowledges that it will not make any recommendations regarding access 
to PHI though this was a primary purpose of the workgroup. 
 
 The MHDO Board notes the process it is undertaking to improve its responsiveness yet 
fails to acknowledge that an overall lack of accountability generated the need for the 
original legislation and the workgroup. We are asked to defer future action to the 
Board and presume we will have a different outcome than past experience. While we 
support the steps MHDO is taking and we are hopeful that it will lead to 
improvement, there are no recommendations on what to do if improvements are not 
achieved other than 'continued public attention'. 
 
 Also of concern is the tautological argument that resources should follow historical 
investments- that because we have invested in a service, organization or 
infrastructure in the past, we must continue to invest in that same service, 
organization or infrastructure regardless of its effectiveness or relevance to the future 
state. A key purpose of the original bill and the workgroup was to identify more 
efficient and effective uses of resources to provide data. The conclusion of the group 
seems to be that no current roles or relationships should change regardless of cost, 
effectiveness or efficiency. 
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Comment #2 on the January 4 draft  report from HealthInfoNetmail on January 11, 
2013  
 
Overarching Public Policy Case for the Increased Use of health Care Data for Improvement in 
Health Care 
Administrative data (claims data) is not by itself sufficient to evaluate quality and costs of the 
health care system at the individual consumer, provider, practice, hospital or payer levels.   
Similarly, clinical data is not by itself sufficient to evaluate quality and costs of the health care 
system at the individual consumer, provider, practice, hospital or payer levels.  Accurate, 
available administrative and clinical health data that is accessible (with strict safeguards and 
confidentiality requirements) to patients, providers, purchasers, payers, and researchers is 
necessary to analyze our current health care system and guide future development for overall 
improvement in population health and efforts toward a sustainable health care system.  
Comment: No details are provided on why administrative data is not sufficient for providing a 
fairly robust basis for data and analytics on utilization, episodes of care and quality indicators. 
Significant studies have been done in these areas using administrative data. MHDO, MQF and 
others have not provided timely data and/or analysis of the administrative data to date. The 
performance of MHDO in processing, managing, and providing data does not present a 
convincing argument for expanding their data collection efforts by adding a much more complex 
and high volume database to the MHDO databases that appear to have limited requests from 
users (42 requests in 2012 – 13 requests for claims data, 20 requests for IP/OP, 9 requests for 
other data).  More work is needed to improve the operations of MHDO and expand the use of the 
existing data before any additional statewide databases should be added. Adding more data 
doesn’t solve the problem of limited use of existing databases. Also, throughout the LD1818 
report and in these recommendations, statements are made on the value of the linked claims 
and clinical data. While this is broadly viewed by policy makers and others as true, no reference 
to published studies, other states’ experience or private sector experiences in this area or any 
empirical evidence is provided to support these statements. Just because someone says it, 
doesn’t make it true. As such, prior to any requests made to the Maine State Legislature, an 
objective third-party factual/empirical review should be recommended to provide a projection of 
value relative to what we are trying to accomplish by bringing forward specific proposed 
changes in structure and statute.  This type of work (conducted by an accounting firm and 
subsequently by a University) was essential to engendering support and demonstrating the 
potential value of a Statewide Health Information Exchange in Maine. These studies were 
provided to the legislature as background information for requested changes to Maine State Law 
and appropriations for HIE efforts, that were critical to the success of HealthInfoNet over the last 
five years.  Without this type of information the legislature has very little evidence to support the 
changes to legislation and rule making discussed in this report and little justification for financial 
support.  
Four general themes related to governance, data protocol, consumer engagement and 
protected private health information emerged. 
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Comment: There is no effort to connect these themes with the intent of the Resolve and the four 
specific questions asked in the Resolve. 
Theme 1 Recommendations: Governance 
1) There is consensus that there is significant value in linking clinical and claims 
and other data.  This may be achieved through one or more databases.  Action: 
Examine the current relationship and contrasting roles of MHDO and HIN to 
determine and build the framework needed to serve the public’s interest in 
improving quality, accuracy, and timeliness and access to, clinical, claims and 
other health care data.  Linking claims and clinical information shall meet a set of 
security and technical capabilities established by current industry standards. 
 
Comment: What are the contrasting roles of MHDO and HIN? HIN has been built on a multi-
stakeholder governance model with strong participation by the State in providing funding and 
collaborative support for the development and implementation of a statewide HIE. HIN has been 
working closely with MHDO on a project to test the feasibility of linking claims and clinical data. 
Who has determined that the public’s interest isn’t currently being met? Why is there any need 
for additional legislative action at this time to develop a working relationship between these two 
organizations as they work toward determining options for optimizing a structured relationship 
between the clinical and claims databases? Many sweeping statements are made throughout 
the LD1818 Workgroup report and in these recommendations without background or supporting 
details. 
2) We desire a single point of accountability and oversight that would be 
conducted by a government agency.   The MHDO is the steward and setter of 
policies on claims and quality data and an existing governmental structure that 
could provide this single point.  To better carry out public interest functions, the 
MHDO Board needs to be reconstituted to be held accountable and to carry out 
the public oversight (promulgate rules) of clinical, claims and other sources of 
data.  Action: Amend State law which currently gives MHDO general oversight of 
health care claims and quality and data, to include oversight of clinical health care 
data.  Amend State law to reconstitute MHDO Board to be accountable and to 
carry out the increased role of public interest by having 8 Directors--a 
representative of a hospital, healthcare professional, consumer, payer, 
MaineCare, CDC, OSC, and PFR. Amend State law to continue the Office of the 
State Coordinator for Health Information Technology in the Department of Health 
and Human Services and to serve as a co-chair of the reconstituted MHDO Board. 
Amend State law to move the existing Maine Quality Forum responsibilities to the 
MHDO.    
Comment: Who is “we” and what is the need for and advantage of a single point of 
accountability? HIN is one of the most successful statewide HIE’s in the country with a high 
volume of participation. The statement that MHDO needs to become accountable for “oversight 
of clinical health care data” is too vague in its intent.  This will be point of departure and political 
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opposition to these recommendations from multiple stakeholders. Why is accountability needed 
for the clinical data when a successful system for collecting the data is up and running and the 
construction of a data warehouse with plans for making data available is underway? How does 
the proposed approach “better carry out public interest functions”?   Amending the current 
regulations to require the filing of the clinical data by the providers will cause the providers to 
fight against that requirement and threaten the existence of the statewide HIE. Once the public 
knows a governmental agency (MHDO) will have oversight authority of their clinical data and 
will have full access to the personal identification in the clinical data, there is a high probability 
of the opt-out rates increasing significantly. With each opt out, gaps in the statewide data are 
created and puts into question the value of the data for linking and for analytic use. Many of the 
recommendations appear to be building a larger and more robust government agency at a time 
when there is no state funding to support these efforts. How will this new combined agency be 
funded and what additional resources will be needed to support this operation? Has there been 
any evaluation of the Maine Quality Forum’s (MQF’s) value and the need for its continuation? 
The data on its website is very old and the tables provided are not user friendly. Prior to merging 
and/or continuing the existence of the state agencies identified, will any performance evaluation 
be conducted? Given the state budget situation and limited funding from other sources, is this 
the right time to build bigger?  
3) There needs to be a mechanism for the submission, release, disclosure, use of 
clinical, claims and other data that is as comprehensive as possible, recognizing 
that improvements in technology will allow ever increasing data flow possibilities.  
ACTION: Enact legislation requiring MHDO to conduct major substantive 
rulemakings consistent with legislative guidance to develop mechanisms and 
processes for the appropriate submission, use, and release of health care data and 
to establish proposed rates, fees, subscription, or other financial models. The rules 
should address the submission of data and reporting requirements, to include 
clinical, claims and other data, and reporting by various sources such as providers, 
and payers and other sources currently reporting to the APCD and MHDO.  The 
rules should determine the appropriate use (disclosure or exchanges, etc.) of 
clinical, claims, and other data (raw data, not analytics) and include descriptions 
and definitions of 1) appropriate requesters (i.e. payers, ACOs, Value-Based 
Purchasers, Consumers, Researchers, etc.); 2) appropriate release of a) de-
identified or aggregated data; b) "minimally necessary" PHI for treatment, 
payment, and operations as those terms are defined under the HIPAA, and other 
federal or State laws or rules, and CDC laws and rules; and 3) the specific review, 
approval, and appeals process for the request of clinical, claims, and other data.   
MHDO should use existing accepted MHDO rule formats where practical and 
should consider reduced burdens for submission requirements similar to 
exemptions under State rules for small businesses.   Focused stakeholder 
discussions with hospitals and key providers should be convened to clearly 
document issues and concerns associated with mandatory requirement to submit 
clinical data to a SDSW HIE.  As part of this effort, the MHDO needs to identify 
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what data elements and metrics should be requested without duplicating what is 
already collected under current rules.    
Comment: MHDO already has a set of regulations that cover all of the above for all of the data 
mandated by them. The only data that is not addressed in MHDO rules is the clinical data as 
collected by HealthInfoNet. The report and recommendations never define exactly what new 
data MHDO would govern if they were to mandate the HIE data. It might be worthwhile to 
identify the specific data elements that would be involved, e.g. problem list, allergies, lab results, 
radiology test results, etc. and most importantly the patient identifying information including 
name, social security #, full address, etc. No other database currently governed by MHDO has 
that level of identifying information. HIN has drafted policies and procedures for providing access 
to the clinical data. It has not been proven that the current system is not working for 
management and use of the data but this set of recommendations seems to ignore any work by 
HIN in this area. Nowhere in the LD1818 Workgroup report or in these recommendations, is a 
financial estimate provided for how much it will cost for MHDO to take on this added database, 
which would be the largest and most complex database MHDO would manage. There is also no 
discussion about how a “statewide file” would be created. It is one thing for a single provider to 
file mandated clinical data but how is the data going to be normalized and mapped to create a 
comparative statewide file? Last, “mandating” the filing of clinical data and introducing 
oversight authority by a governmental authority will jeopardize the trust between HIN and the 
health care providers participating in the exchange and HIN and Maine health care consumers. 
The HIN exchange is fairly new and the building of trust has been a challenge, which has been 
met, but it is new and could be easily destroyed by this type of intrusion on work that is 
underway successfully in Maine. 
4) Recommend that the highest regard must be taken concerning the “Trust” 
model associated with individual privacy rights, informed consent and personal 
ability to safeguard protected health information.  Except as otherwise provided 
by law, the decision whether personal medical records are included in a HIE or a 
claims system if the claims data is "identifiable" should be made by the patient.  
All patients should have the ability to have (or not have) their personal medical 
records in a health care data HIE.  ACTION: State law should continue to allow the 
current opt-out and opt-in mechanisms for clinical data.  If claims data is 
maintained in a manner that does not protect a patient's PHI from being viewed, 
the MHDO rules should determine the feasibility of creating similar opt-out and 
opt-in methods for claims data, or a mechanism whereby protected health 
information is not released.  
Comment: As stated, patients currently have the option to opt-out of the HIN exchange. The 
HealthInfoNet Consumer Advisory Committee has been very involved in the development of all 
policies and procedures to address patient participation and protection. Discussions have taken 
place in at least two legislative sessions and consensus has been reached on the approach being 
taken in Maine for patient participation in the health information exchange. If it isn’t broken, 
why fix it? Applying a standard opt-out or opt-in approach to the claims data ignores the 
authorization agreement between subscriber and payers and will place an enormous burden on 
payers to manage which subscribers have opted in or out on an ongoing basis. Payers struggle to 
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meet the mandate to file claims data for the APCD now. To add more complexity to the mandate 
would jeopardize the completeness of the data and impact the timeliness of the filings. Unless 
MHDO intends to change the filing requirement of patient identifiers in the claims from 
encrypted to specific patient identifiers, the opt-in and opt-out requirement for claims doesn’t 
seem to fit. 
5) Recommend that requests for de-identified linked claims and clinical 
information only be granted to approved users of the information based on the 
reported uses of the data as well as ability to appropriately safeguard the 
information. ACTION: Include this  provision as a requirement under the rule and 
mechanisms to insure compliance with this requirement 
Comment: Should a government agency determine who should have access to the clinical data? 
Maine providers have a long history of working collaboratively to provide statewide databases – 
Maine was one of the first states in the country to have a voluntary statewide hospital discharge 
database. Maine led the nation with the Maine Medical Assessment Foundation (MMAF), an 
organization focused on using population-based analysis of medical and surgical rates to analyze 
physician performance across the state and to identify outliers. HIN is working with providers to 
take the same approach for access and use of the clinical data. Involvement of the providers in 
the release of the data allows those with clinical expertise, knowledge of the strengths and 
limitations of the data, and strict requirements to protect patient confidentiality, that is 
reinforced with defined financial penalties for failure to manage access to data within federal 
and state law, to play a key role in determining who should have access to the data and for what 
purposes.  MHDO, as it is now structured, is not subject to these same standards, laws and 
penalties for data protection, system audit, and breach management/notification. 
6) Accept as otherwise provided in law, protected health information (PHI) 
should continue to only be viewable for the provision of Treatment, Payment and 
Operations (TPO) as those terms are used in applicable Federal and State laws, 
and further subject to the “minimum necessary” provisions of applicable Federal 
and State laws. Recognizing that there are some uses of "minimally necessary" PHI 
that are appropriate public health imperatives that do not defile the patient and 
which can be used to improve health outcomes and quality, their determination of 
the appropriateness of the uses should include weighing the value of the use with 
appropriate consumer protections.  ACTION:  MHDO rules must comply with these 
principles and must consider and honor the circumstances that the health care 
data was submitted or exchanged under.   In addition to the APA requirements for 
submitting provisionally adopted  major substantive rules, a description of the 
analysis performed to ensure that the rules comports with these principles must 
be submitted with the provisionally adopted rules to the Health and Human 
Services legislative oversight committee.   
 
Comment: This recommendation raises the issue of a government agency having control over 
data that was collected for treatment purposes. Providers have agreed to expand the use of the 
HIE data for their operational purposes as well as allow other aggregated data to be released for 
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access by the patient through a provider based PHR. Other aggregated data may also be 
released as long as patient and provider identifiers are protected. Who is the best steward of the 
clinical data?? … the providers and the trusted HIPAA business-associate organizations they work 
with (that are subject to the same standards laws and penalties for data protection, audit, and 
breach management as the providers) or a governmental agency, who is NOT subject to these 
rules?  
7) Require that linked claims and clinical information only remain identifiable for 
the purpose of the linking process itself. Once linking is complete, the member 
information should be de-identifiable and stored in an encrypted state using the 
highest standards in available encryption technology. ACTION: The rules must 
specifically state this requirement; must include processes to ensure that this 
requirement is met; and must describe audit and enforcement mechanisms for 
compliance.      
Comment: It is unclear why the State should be the party responsible for linking the data and 
then managing the identifiers available in the clinical data. MHDO does not receive identifying 
information on the APCD – all identifiers are encrypted. This approach doesn’t make sense – why 
would MHDO be allowed to have access to patient specific identifiers for the clinical data which 
has much more revealing data about a person when they weren’t provided that type of access 
for the APCD data by the Maine State Legislature? 
8) We need to have a viable financial model(s). ACTION: Report back from 
MHDO: Conduct a review of the top three financial models for providing claims 
and clinical data to qualified requestors.  The rules should address fee models, 
including sliding-scale or subscription,  consumer education and protection, and 
rights, responsibilities, requirements, funding opportunities, and oversight.  
Endorse the use of MaineCare HIT program administrative funds, where 
appropriate to improve access to health care data and the benefits as outlined in 
the federal HITECH Act and Meaningful Use programs.   
Comment: The financial model should include an immediate estimate of the cost to collect and 
maintain the clinical data before a financial model for how the data will be released is 
developed. MHDO has a very low number of data requestors now (see above).  Who are the new 
customers for the linked data and what are the estimates for how much revenue will need to be 
generated from users as well as State funding? This approach of “build it and they will come” 
lacks specifics for who are the potential users are, the total costs to the taxpayer, and the 
revenues that will support it.  
9) There needs to be methods for ensuring accountability of the reconstituted 
MHDO Board.  ACTION: Consistent with the guidance provided by the Theme 4 
subgroup, the structure of the State agency (MHDO) should include a mechanism 
that establishes and leads ongoing multi-level advisory groups with articulated 
goals and evaluation systems.  The advisory groups should represent the broad 
spectrum of stakeholders at the organization and individual consumer levels.  The 
framework should seek to establish the MHDO as a forum for various other 
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advisory groups to report their activities to promote efficiency and meaningful 
outcomes.    
Comment: Representation is a worthwhile area for MHDO expansion but accountability and 
evaluation should be focused on the operational aspects of MHDO. Advisory groups, by 
definition, do not have the standing to enforce accountability by a Board.  They can influence the 
direction that a Board takes but can not “enforce accountability” as this recommendation 
suggests. These recommendations call for a vastly expanded MHDO operation and yet there is 
no detailed evaluation of how MHDO has improved its data management capacity and it does 
not provide a convincing proposal for how MHDO could meet the needed financial and staffing 
resources, expertise, and revenue to take on the additional governance and workgroup activities 
let alone the expanded operational activated suggested throughout this report.  
Theme 2 Recommendations: Data Protocols 
10) Support the goals of a State health care data provider to be responsive and 
timely, accurate, accessible, streamlined, and secure; 2. Support the State's health 
care data provider (MHDO) effort of building on its existing systems to take 
advantage of newer technologies better suited to meet the changing needs of the 
market, such as building a highly robust and secure data warehouse; and 3. 
Support national standards for data collection and distribution as appropriate. NO 
ACTION RECOMMENDED. 
Comment: A word of caution with this recommendation. Technology is not a cure all for old 
problems. In fact, new technologies create new problems. MHDO’s existing system will be 
undergoing a major change this year as MHDO moves from its existing vendor to a new vendor 
and its partners. The new vendor and its partners do not have any APCD processing or 
management experience, requiring a much more hands on approach by MHDO and its staff. 
Based on the complexity and volume of this new work, it is expected that MHDO will be 
stretched very thin to just transition the existing data systems and databases. Is this really the 
best time to position MHDO to take on the responsibility for a larger, more complex database 
than any of their current databases? The timing of the MHDO data has been an ongoing 
criticism. Their website still provides very limited data or not the timely data needed by users.     
Theme 3 Recommendations: Consumer Engagement 
11) Balance Consumer Privacy considerations regarding the safeguarding and 
disclosure of Protected Health Information (PHI) with the societal imperative to 
drive higher quality and more affordable health care. ACTION: Enact rules and 
policies consistent with the opt-out and opt-in described in Theme 1 Governance 
section.   
Comment: There are provisions in place that address opt-out and opt-in. What are the reasons 
for this recommendation?  Is something not working currently? Is a governmental agency the 
best place for this work?  
12) Consumers must have tools available to them to become active engaged 
consumers.  Patients must have the tools available to access their personal health 
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records in a variety of ways that build on existing sources.   Patients must be given 
opt-in and opt-out options. ACTION: The MHDO should consider ways of providing 
consumers "digital access", at no charge, to their personal health records.  This is 
critical to the "value chain" as consumers consider whether or not to allow their 
clinical data to be collected. (The digital access may be in several forms--
telephone, portal, internet--and should build on existing and emerging 
technologies and may be provided a variety of sources (health care providers, 
MHDO, HIE, or other entities.)      
Comment: Doesn’t this function contradict Theme 1, #7 recommendation? If patient identifiers 
are stored in an encrypted manner after linkage to claims, how will MHDO provide patient 
specific data via a PHR to consumers? This function would require the management of a patient 
specific file with a Master Patient index across all providers in Maine. This is a VERY different 
approach than stated throughout these recommendations. This recommendation also ignores 
the work currently underway by providers to provide patients access to their personal health 
records. HIN is working with several providers to provide all inclusive patient specific data. There 
is also a Centers for Medicare and Medicaid (CMS) Meaningful Use Program requirement that 
addresses this provision. How will this recommendation interface with that requirement? Again, 
how will the cost of providing this capability be paid for by MHDO? HIN has collected multiple 
estimates for providing a statewide PHR and they are significant. This provision by MHDO could 
also be very confusing for patients and it will most likely raise major concerns regarding 
confidentiality and security. A PHR would require the management and access to patient specific 
data with a fairly sophisticated system for linking a patient’s records and displaying them in a 
user friendly system. MHDO does not have the experience or funding to take on this type of 
responsibility.  As was stated earlier in this review document, the prospect of a state agency 
managing person identified clinical information assumes a trust framework with Maine residents 
that needs to be questioned and validated before bringing forward this recommendation that 
has significant public policy implications and a likelihood of broad and intense political 
opposition.    
Theme 4 Recommendations: Protected PHI 
13) The structure of the State agency (MHDO) should include a mechanism that 
establishes and leads ongoing multi-level advisory groups with articulated goals 
and evaluation systems.  The advisory groups should represent the broad 
spectrum of stakeholders at the organization and individual consumer levels.  The 
framework should seek to establish the MHDO as a forum for various other 
advisory groups to report their activities to promote efficiency and meaningful 
outcomes. ACTION: The legislature should require MHDO and interested 
stakeholders to develop a framework for the MHDO to become the forum for the 
advisory groups.  The framework should include specific mechanisms to measure 
the success of collaborative efforts.   
Comment: Similar recommendation as Theme 1, #9.      
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Comment # 3 on the January 8 draft report from the Maine Health Management 
Coalition  
On behalf of the Maine Health Management Coalition and its Foundation, we are submitting the 
following responses and recommendations for your consideration as you revisit the final report 
of the LD 1818 Workgroup. As you will recall, the Coalition submitted the original legislation that 
resulted in the workgroup out of growing concern and frustration about the necessity of data to 
transform care and the inability of data users to access needed data. The Coalition’s Foundation 
Board has been actively involved and have dedicated significant staff time and resources to 
participate in the workgroup and have submitted our positions to contribute to this process. We 
remain committed to the workgroup process and are submitting feedback on the proposed 
recommendations that we hope will inform decisions as they reflect carefully considered input 
from a broad multistakeholder group of large public and private employers, providers, unions 
and others. 
The Maine Health Management Coalition was founded over 19 years ago with the primary 
function ‘To assist the Members in the process of sharing and analyzing data ("Health Data"), 
related to the provision of health and related services to the Members, and their employees and 
health insurance plan participants ("Health Services")’. The Coalition now represents 65 
members with over 200,000 covered lives - nearly 40% of the commercial market in Maine. The 
Coalition and its members have been active and engaged users of data for nearly two decades 
with a membership that is knowledgeable about the current environment and challenges of  
data access and use. Coalition members recognize and appreciate the tremendous contributions 
of the Maine Health Data Organization to their work while also recognizing the dramatically 
different market and demands for data from when the MHDO was created. The Coalition 
proposes that the State build on the legacy and structure of the MHDO while not limiting us to 
the historical design and functions. Coalition members remain committed to effective use of 
data to improve the value of healthcare for all stakeholders in Maine. 
Providers need timely data to effectively manage their patient populations and to be 
accountable to and for the communities they serve. Patients need data to understand the 
variation in healthcare quality and costs and be educated and informed consumers who can 
effectively partner with their care team. Purchasers need data to ensure the care they purchase 
on behalf of their employees and their family members is of the highest quality and value. 
The Maine Health Management Coalition (MHMC) and the Maine Health Management Coalition 
Foundation proposed the following priorities and aims for the development of a statewide data 
system to support purchasers, patients and providers in the transformation of healthcare and 
improvement of healthcare value at the outset of the 1818 workgroup process: 
1. A common, shared data source of integrated clinical and claims data for all parties to use – 
with appropriate privacy, security and legal safeguards and role-based access – will serve as the 
foundation to system and payment reform. All approved users should have fair, affordable and 
equitable access to the data for the purposes of care improvement. 
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2. A publicly governed and accountable entity should maintain the functions of the MHDO. 
Public governance provides the greatest accountability and protection for data users and could 
provide fair and equal data access to all users.   
3. Timely access to all payer data is necessary to support system transformation. All payer data 
from commercial and public payers should be available at least quarterly to users. Data on a 
subset of patients is insufficient to facilitate population health management. Data that is not 
current does not allow for effective and timely interventions to change care. 
4. Patient identified data must be included but identifiable only at the patient/provider level 
to allow providers to effectively improve care for their patients. Identified data enables the 
combining of different data sources to allow a meaningful and longitudinal understanding of 
utilization, care patterns, and outcomes. 
5. Resources should be used effectively and care should be taken to avoid unnecessary 
duplication of data systems and the resources needed to support them. Data is a resource that 
is only valuable when it is accessible and used effectively. 
6. Data users- including consumers- should have input into the structure, design, and purpose 
of the state’s data systems to maximize its use for and by all stakeholders, including the public. 
7. Integrated clinical data, claims, health risk, and outcomes data is the optimal source of 
information for care improvement and high value. 
8. Information created from healthcare data should be made transparent and publically 
available in aggregate with the appropriate safeguards, processes, and criteria for reliability.  
We believe the workgroup report and recommendations largely reflect these principles and we 
are in general support. However we ask that the workgroup also consider the following items: 
1. The recommendations should consider a broader range of data sources.  
Recommendations acknowledge ‘several data repositories’ but only name two sources of data in 
the state, MHDO and HIN. Several more data sources exist including direct data from providers 
and other private clinical and claims data repositories and should be considered as possible 
partners in the Maine’s data system. The workgroup should think more broadly about options 
for data and data submissions. 
2. The recommendations should include an employer and/or plan sponsor on the 
reconstituted MHDO Board. We support the recommendation to reconstitute the MHDO Board 
but the recommendations do not acknowledge the key role of employers as data users and 
stakeholders with strong interest in a more efficient healthcare system. 
3. Linked data should be available and identifiable for multiple purposes. The recommendation 
to allow linked data only to be identifiable for linking is far too restrictive and misses the point of 
linking data to use the information for improvement. In fact, this restriction is in conflict with 
using the data for treatment, payment and operations, the recommendation directly above it, 
and in conflict with the recommendation in Theme 3 giving consumers access to their own 
information.  
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As stated in our original letter, we believe the Maine Health Data Organization’s legal status 
makes it uniquely well positioned to remain the central source of data collection and 
management. Data submissions should be received from providers, plans, and any other entity 
that collects clinical, claims, health risk and functional status data, and the MHDO or its 
successor should continue to manage the data and serve as the primary source of integrated 
clinical and claims data for the state. However, we do not believe the MHDO or the Maine 
Quality Forum in its current or proposed state should develop redundant analytic or reporting 
capabilities. The purpose of the MHDO has been and should remain collecting and managing 
data to be used as needed for approved purposes by external parties. Each entity that requests 
data may have different analytic needs and objectives. It is not desirable to have the MHDO 
and/or MQF determining the information that is generated from the MHDO data set as it is 
unlikely to reflect stakeholder and user needs, may be redundant of multiple existing efforts, 
and runs the risk of ‘politicizing’ the MHDO and jeopardizing what should be a neutral source of 
common data. Providing data and providing analyses are separate functions and we believe 
strongly that the MHDO should focus its resources on its primary mission of providing 
timely and reliable data to be used by entities as needed. 
 
Finally, in the draft report, there are repeated references to the need for data by health care 
providers to improve healthcare. While we strongly support this point, it is a far too narrow view 
of needed data uses and users. It is important that we explicitly recognize the need for other 
stakeholders- particularly consumers- to have access to data and information to improve their 
healthcare decisions. Data can and must be used for improvement and it should also be used for 
measurement, reporting, analysis, payment and other purposes by a variety of stakeholders. 
The report should reflect the need for data by multiple audiences and support for using the data 
for these purposes.  
 
Comment #4 on January 8 draft by Poppy Arford 
 
Poppy made a number of editing comments on the draft, and suggested adding this language to 
the report: 
 
It is critical that Maine provide public access to cost and quality of care health data, including 
state of the art digital access to both. This would include a much improved MHDO Health Cost 
website ( see http://gateway.maine.gov/MHDO/healthcost/ ) and patient portal access for all 
Maine residents, which ensures that patients' clinical record and individually identifiable health 
information is secure, protected, and available to the patient (see VA Blue Button  
http://www.va.gov/bluebutton/ ). Together, this health information will provide Maine people 
with the tools needed to engage fully, effectively and efficiently in improving their health and 
accelerating the attainment of the Triple Aim in Maine.  
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Comment #5 on January 8 draft by Jim Harrison 
 
Jim Harrison made detailed editing comments to the entire report. The following are some of his 
broader suggestions: 
 
 
(1) I agree that MHDO is making good progress in addressing some of the timeliness issues, 
particularly with respect to Medicare and Medicaid claims data. Commercial claims data has 
been delivered on time, refreshed quarterly, for more than two years now. 
Hospital data continues to be a problem from both a quality and timeliness standpoint. 
Onpoint is only one of a number of hospital data users but I thought our experience as a data 
user would be illustrative. In January, 2013, we are still waiting for corrected 2011 inpatient 
data (more than 6 mos overdue). The data were received in October, 2012 but contained 
quality problems that surfaced in our loading and validation process. The most recently 
available outpatient data is for 2009 (more than 30 mos overdue). 
(2) I don’t believe MHDO’s vision/goals can be realized through a new technology platform 
alone. Seldom does technology solve underlying operational problems, like those identified 
around process, data, and people in the December, 2010 Deloitte study commissioned by the 
MHDO. 
The MHDO’s approach to development of this new technology platform also introduces a 
greater level of risk when compared to alternative models. They have chosen a custom-build 
approach, which has clear benefits but also can lead to delays and cost overruns. That was 
the case with the recent MaineCare system problems. The MHDO has also selected a vendor 
that has no track record in the development of APCD systems. I am sure they are aware of 
these risks and will seek to mitigate them; I raise them here because the workgroup’s specific 
charge was around assuring timely, accurate, and cost effective structures and protocols. 
In terms of enhancements to the report, I’d suggest: 
-  Background information be provided, including the progress to date meeting the 
Deloitte recommendations 
-  Asking MHDO management to share some of the key milestones, timeline, and, 
potentially, performance standards they have put in place to ensure successful 
implementation. This seems appropriate given that this new platform is the cornerstone 
of the MHDO’s vision/goals that was presented 
 
